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Abstract
HCMV infection is usually asymptomatic in immunocompetent hosts, but serious 
disease can occur in immunocompromised individuals and in congenitally infected 
newborns. The importance of virus fitness determinations became evident in 1976, 
when it was proposed that the infecting strain of HCMV is important for clinical 
outcome, along with the intensity and duration of viral replication. HCMV strains 
exhibit different levels of virulence in vivo, depending on their passage history in cell 
culture. High and low passage HCMV strains exhibit tropism differences in vitro, 
suggesting that different tissue tropism may occur in vivo. In addition, approximately 
13 kb of novel DNA sequences located near the right edge of the unique long 
component of the genome has been identified in Toledo and clinical strains. This 
region (UL/b’) encodes several open reading frames, which are missing from the high 
passage laboratory-adapted variants of Towne and AD 169 and are thought to play 
important roles in pathogenesis.
One of the aims of this thesis was to determine the replication dynamics of different 
HCMV strains in vitro as well as compare their ability to bind to cells and mediate 
cell-to-cell spread of infection using pair-wise competition experiments in cell culture. 
AD 169 was shown to replicate better than Toledo in fibroblasts. Furthermore, 
assessment of the replication of Toledo in a different cell type, HUVEC, indicated that 
the virus replicated to higher levels in fibroblasts. Towne was found to bind to HEL 
cells with higher affinity compared to AD 169. The results showed phenotypic 
differences between high and low passaged HCMV variants and also illustrated that 
fitness differences between them are variable and highly dependent upon the status of 
the virus inoculum. To begin to understand the complex relationship between tissue 
tropism, virulence and HCMV genome composition, a DNA microarray approach was 
developed to examine host and HCMV gene expression during the productive 
infection of two distinct cell lines, fibroblasts and endothelial cells. The results showed 
that genes wiffijn the yy /b ’ fpgjpp were expressed in a cell type-specific fashion. Ip 
the context of host cell gene expression, cell type-specific host gene transcriptional 
changes were observed, reflecting different viral modulation of distinct cell type 
environments. The results provided potential insight into the function of genes 
encoded in the UL/b’ region. Of particular note was that transcriptional changes 
frequently occurred in genes associated with pathways involved in the pathology of 
HCMV in the human host.
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1.0 Human cytomegalovirus characterisation
1.1 Classification
Human cytomegalovirus (HCMV) is classified as a member of the Herpesvirinae 
family, based on virion structure and several biological characteristics, including the 
ability to establish persistent and latent infections. Herpesviruses are widespread in 
nature and to date, eight of these have been isolated from humans. They are termed 
human herpesvirus 1-8 (HHV 1-8), reflecting the order of their identification 
(Roizman and Pellett, 2001). All herpesviruses are classified into the a-, (3- and y 
herpesviruses, due to significant variation in biological properties, genome 
organisation and gene content. The human herpesviruses and the diseases they cause 
are listed in Table 1.1.
The alphaherpesviruses are rapidly growing viruses with a short replication cycle and 
a variable host range in vivo. HHV-1 (herpes simplex virus 1, HSV-1), HHV-2 
(herpes simplex virus 2, HSV-2), and HHV-3 (varicella-zoster virus VZV) belong to 
this family. HCMV (HHV-5) is classified as a betaherpesvirus due to its slow 
replication cycle in vitro, enlargement of infected cells (“cytomegalic” appearance) 
and genetic differences (McGeoch et al, 1995). Cytomegaloviruses exhibit strict 
species specificity, although the replication of baboon CMV in human fibroblasts was 
reported in 1997 (Michaels et al, 1997). Other members of the betaherpesviruses 
include HHV-6 and HHV-7. The gammaherpesviruses have restricted host range in 
vitro and can replicate in different cell types, including lymphocytes and endothelial 
cells. In lymphocytes, the major latent reservoir, these viruses can be re-activated 
from latency. The gammaherpesviruses include HHV-4 (Epstein-Barr virus, EBV) 
and HHV- 8.
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a HHV-1 Herpes-simplex virus (HSV-1) Oropharyangeal herpes 
Genital herpes
a HHV-2 Herpes-simplex virus (HSV-2) Genital herpes
a HHV-3 Varicella-Zoster virus (VZV) Varicella
Zoster
P HHV-5 Human cytomegalovirus (HCMV) CMV-mononucleosis 
CMV disease
P HHV-6 Human herpesvirus 6 Exanthem subitum
P HHV-7 Human herpesvirus 7 Exanthem subitum
y HHV-4 Epstein-Barr virus (EBV) Infectious mononucleosis 
Nasopharyngeal carcinoma 
Burkitt’s lymphoma 
Classical Hodgkin’s lymphoma
y HHV-8 Kaposi’s sarcoma-associated 
herpesvirus (KSHV)
Kaposi’s sarcoma 
Primary effusion lymphoma 
Multicentric Castleman’s disease
Table 1.1. Human herpesviruses diseases.
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1.1.1 Virion morphology
The virion of HCMV consists of a linear DNA genome, which is contained within an 
icosahedral capsid of about 100-110nm in size. The capsid is composed of 162 
pentameric and hexagonal capsomere subunits and appears similar to the HSV-1 
capsid. This, in turn, is surrounded by an amorphous tegument layer and a 
membranous envelope, the latter of which carries a large number of glycoproteins. 
The complete virion, consisting of the capsid core, the tegument and the envelope is 
about 150-200nm in size, reflecting differences in the size of the tegument (Mocarski 
and Courcelle, 1996). Figure 1.1 is a schematic representation of the CMV virion 
structure. CMV infection of cultured cells results in the production of two additional 
extracellular forms of virus particles: dense bodies and non-infectious virus particles. 
Dense bodies are composed of the tegument and viral envelope only, while the non- 
infectious virus particles lack the DNA core.
Membrane viral 
glycoproteins 
(eg gB, gH, gM)
Phospholipid 
envelope bilayer
Q P o .
Tegument Nucleocapsid 230kb linear ds  DNA
proteins
Figure 1.1. Morphology of the HCMV virion. The capsid containing the linear DNA 
genome is surrounded by the tegument layer and the envelope.
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1.1.2 Genomic arrangement
The human CMV genome has more sequence complexity than most other 
herpesviruses. It is the largest herpesvirus genome consisting of linear DNA, 230kb 
long. CMV is also the only betaherpesvirus known to contain a class E genome 
structure, comprising a genome with direct and inverted repeat elements, which can 
undergo inversion and result in four sequence isomers. The genome is divide into two 
unique components, the unique short region (US) and the unique long region (UL). 
Inversion of these regions is mediated by repeated sequences at the genomic termini 
and the UL-US junction. The inverted repeats b (TRl/IRl) and c (IRs/TRs) flank the 
unique regions of UL and US. A directly repeated a  sequence is found at the genomic 
termini and is also present in inverted orientation at the UL-US junction. Sequence 
analysis of the laboratory strain AD 169 has revealed a total of 208 predicted open 
reading frames (Chee et al, 1990), resulting in approximately 189 unique proteins, 
due to duplication and splicing events. However, AD 169 is a highly passaged 
laboratory adapted strain, therefore it may not be completely representative of the 
HCMV strains that exist in vivo. Evidence supporting this assumption appeared in 
1996 (Cha et al, 1996), when it was reported that 22 open reading frames present in 
clinical isolates and the low passaged Toledo strain, termed UL/b’ region, were not 
found in high passage laboratory strains of the virus. These novel sequences of 
Toledo, however, do not result in an increase in the size of the genome. The repeats 
flanking the Toledo UL region are ~400bp in length in contrast to AD 169 and Towne 
which have large b/b’ repeats (>10kb). This deleted region has been examined in 
Toledo, but even this low passage strain is a mutant. Re-evaluation of the HCMV 
sequence by comparison with the chimpanzee CMV sequence indicates that the virus 
encodes 164 to 167 genes (Davison et al, 2003), including 11 new ones. Figure 1.2 is 
a schematic representation of the ORFs characterised to date together with their 
genetic locus (kindly provided by Griffiths and Emery, 2002).
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U L 146. 
UL144-
US27 US28 
U S22 
US11
TRL10
UL111A 
UL11 
UL105 
UL101/102
UL100 UL99 
UL97/98 
UL94
UL16 
UL18
/  UL21.5 
'  /  UL23/24/ 
/  ^  25/26
^ UL27UL32
UL35
TRL11
HCMV
UL115
UL70 
UL72
UL73/74/75 
UL76
UL89
U185/6
UL40 
UL43 
UL44 
UL45 
UL46 
 L47/48
UL5 
U L 53 ' 
UL54 
u C sy  UL56 UL55 
UL65
UL48/49
UL49
Transactivators 
DNA replication 
Capsid & assembly 
Tegument 
Envelope 
Immune evasion 
Others
UL80A
Figure 1.2. Localisation of genes encoding HCMV proteins (kindly provided by 
Griffiths and Emery, 2002).
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1.13 Proteins
Since the sequencing of the HCMV genome, the protein nomenclature has been 
standardised such that a protein mapped to an open reading frame on the viral genome 
should be given a name that corresponds to the open reading fiame, preceeded by a 
prefix. The prefix gp denotes glycoprotein, pp phosphoprotein and p where the 
characteristics of the protein are unknown. HCMV proteins are generally grouped into 
the structural proteins that make up the virion structure and the non-structural proteins 
that are responsible for viral replication. A brief description of some major proteins 
and their functions follows.
1.13.1 Structural proteins
Capsid proteins
The capsids of herpesviruses show a high degree of structural homology and share 
closely related assembly pathways. The HCMV capsid consists of at least four 
predominant proteins: the major capsid protein (pUL86, MCP, 153kD), the minor 
capsid protein (pUL85, 34kD), the minor capsid binding protein (pUL46, 33kD), and 
the smallest capsid protein (pUL48/49, SCP, 8.5kD) (Irmiere and Gibson, 1985, 
Gibson et al, 1996). The major capsid protein shows low imunogenicity in humans 
and a high degree of homology to the VP5 protein of HSV (Jahn and Mach, 1990), the 
smallest capsid protein is essential for the assembly of infectious virus in HCMV- 
infected cells (Borst et al, 2001). It has been recently documented that the MCP and 
SCP interact in the cytoplasm of transfected cells through two linear sequences in the 
SCP (Lai and Britt, 2003).
Tegument proteins
The tegument is situated between the capsid and the envelope and comprises mostly 
phosphoproteins. Although it occupies a large part of the HCMV virion (-40% total 
mass) (Irmiere and Gibson, 1983), there is little knowledge about its function. 
Comparison with other herpesviruses predicts that it may be essential for viral gene 
regulation and envelopment. The most abundant tegument proteins are pp65 (ppUL83
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or lower matrix protein) and ppl50 (ppUL32 or basic phosphoprotein), both able to 
produce a dominant immunologic response in humans. pp65 can be detected HCMV- 
infected cells in culture within 24 hours post-infection (Revello et al, 1992) and is 
also present in the peripheral blood of immunocompromised patients with active 
HCMV infection (Grefte et al, 1995). This protein constitutes a major target for the 
cytotoxic T cell immune (CTL) response in humans (He et al, 1995, Akiyama et al, 
2002, Allart et al, 2003). Other tegument proteins include pp71 (ppUL82 or upper 
matrix protein), pp28 (UL99) and ppl30 (UL56). The upper matrix protein is highly 
homologous to pp65 but less abundant. It is a transactivator of gene expression along 
with pUL69 (Ishov et al, 2002). It facilitates viral genome deposition and 
transcription at nuclear domains 10 (ND10), possibly preparing the virus for more 
efficient productive infection. pp28 is highly immunogenic and ppl30 is involved in 
virion maturation.
Envelope proteins
The HCMV envelope contains viral proteins and cellular lipids that are derived from 
either the nuclear or cytoplasmic membrane. Sequence analysis has shown that many 
of the viral proteins (-55) are glycoproteins (Chee et al, 1990). Of these, only two 
have been characterised CMV glycoprotein B (gB or gpUL55) and glycoprotein H 
(gH or gpUL75). gB is the most abundant glycoprotein and shares sequence 
homology with related proteins in HSV, VZV, HHV-6 and HHV-7. It is a 
transmembrane protein, containing two components, which are linked together by 
disulphide bonds. It is the major target for neutralising antibody responses in humans 
and is also the target for CD4+ and CD8+ T cell responses, making it a good candidate 
for use in subunit vaccines (Britt and Vugler, 1990, Riddell et al, 1991, Temperton et 
al, 2002). Glycoprotein B has been implicated in cell penetration, fusion of infected 
cells, cell to cell transmission and the alteration of cellular transcription early during 
infection (Tugizov et al, 1994, Simmen et al, 2001). In epithelial cells, the cytosolic 
domain of gB is responsible for internalisation from the cell surface into clathrin- 
coated vesicles, mediating HCMV entry in the endocytic pathway (Tugizov et al, 
1999).
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Glycoprotein H is less abundant than gB but has been shown to elicit -30% of the 
total neutralising activity in human sera. It was reported in 1994 that antibodies to gH 
in AIDS patients were essential for limiting retinitis (Rasmussen et al, 1994). Some 
other glycoproteins that have been mapped to viral open reading frames include gL 
(gpULl 15), gO and the gcll complex. These proteins along with gH have been shown 
to play roles in virion attachment to the cell, fusion and penetration (Kari and Gehrz, 
1992, 1993). Finally, the gM glycoprotein associates with gN to form a complex that 
induces a neutralising antibody response in the host (Mach et al, 2000, Pignatelli et al, 
2001).
1.1.3.2 Homologues of cellular proteins
HCMV encodes a number of proteins that are homologous to cellular proteins. UL33, 
UL78, US27 and US28 are homologous to the G-coupled receptor proteins 
(Rawlinson et al, 1996) and are involved in the interaction between the virus and a 
variety of different cell types during infection. US28 encodes a C-C chemokine 
receptor that binds RANTES and the monocyte chemoattractant protein 1. This 
binding increases calcium levels in the cells and provides a favourable environment 
for viral gene expression (Neote et al, 1993). The HCMV UL146 and UL147 ORFs 
encode a  chemokine homologues (Penfold et al, 1999), suggesting they may interfere 
with neutrophil activity during HCMV. Additionally, UL144 has been shown to be 
homologous to members of the tumour necrosis factor receptor (TNFR) superfamily 
(Benedict et al, 1999, Lurain et al, 1999). It was found that the UL144 protein was 
expressed early after infection and was retained in an intracellular compartment. This 
gene product is important because of its possible role in HCMV pathogenesis as a 
growth factor decoy that facilitates evasion of the immune response by the virus. 
HCMV also encodes MHC class I homologues, UL18 and UL142 (Beck and Barrel, 
1988, Tomasec, 2000, Wills et al, unpublished data). The expression of these genes 
may contribute to immune evasion. HCMV also contains a gene, which is 
homologous to the R1 subunit of ribonucleotide reductase (RNR). RNR is a cellular 
gene with an essential role in deoxyribonucleotide synthesis, consisting of an R1 and 
an R2 subunit. The host enzyme is expressed in proliferating cells. M45 protein of 
murine CMV exhibits sequence homology to R1 RNR, but lacks some amino acids
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believed to be critical for enzymatic function. Experiments using a polyclonal 
antibody against a recombinant M45 protein showed that the protein was expressed at 
12 hours after infection of mouse fibroblasts, was associated with the virion particle 
and was not a functional equivalent of a RNR R1 subunit. Mutant viruses containing 
an inactivated M45 gene displayed a reduced growth in vitro, failed to replicate in 
organs of Balb/c mice and did not cause any mortality. These data suggest that M45 is 
indispensable for virus replication in vivo (Lembo et al, unpublished data). Some 
herpesviruses encode proteins with FcyR activity (Costa et al, 1978, Baucke et al, 
1979). In murine CMV an FcyR protein is encoded by the early gene m l38 (Thale et 
al, 1994), which has no homologue in the HCMV AD 169 sequence. The deletion of 
this gene resulted in an attenuated phenotype in vivo (Cmkovic-Mertens et al, 1998). 
Recently, however, two glycoproteins in ADI69, named UL119-118 and gpTRLll, 
were found to be homologous to and share functional properties with FcyR (Atalay et 
al, 2002). Lastly, homology between the HCMV UL1 protein and the CEA/PSG 
human protein family has been documented (Holzerlandt et al, 2002). CEA family 
members are involved in cell adhesion, signal transduction and innate immunity 
(Hammarstrom, 1999). PSGs, a CEA family subgroup, are expressed in the placenta 
and possibly regulate immune system responses. The homology between UL1 and 
PSGs could contribute to the pathology of HCMV during pregnancy.
1.2 Entry of HCMV into host cells
One of the factors required for successful viral replication is the ability to gain access 
into a susceptible cell. CMV infection begins by the low affinity attachment of the 
virus on the cell, followed by high affinity attachment, fusion of the viral envelope 
with the cell membrane, uncoating of the nucleic acid and transport of the viral DNA 
to the cell nucleus. The initial low affinity attachment is mediated by an interaction 
between cell surface heparan sulphate (Compton et al, 1993) and viral glycoproteins, 
most probably gB and gcll complex (Kari et al, 1992, 1993) and followed by high 
affinity binding, which is heparin resistant, which may be regulated by CD 13, an 
aminopeptidase (Soderberg et al, 1993). Studies have shown that CMV infection and 
binding of virions to cells, can be inhibited by antibodies directed against CD13. The 
viral ligand involved in this high affinity binding is not known yet.
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Findings suggest that annexin II, a 30kD member of the lipocortin family, is the 
principal CMV receptor involved in virus binding to cells and cell to cell spread 
(Wright et al, 1994, Bold et al, 1996). However, another group using a different cell 
type, demonstrated that neutralisation of cell surface annexin II was inconsequential 
for direct cell to cell spread of the virus (Pietropaolo and Compton, 1999). It is 
therefore possible that the role of annexin II in HCMV entry, as well as the entry 
mechanism itself, differs from cell type to cell type. MHC (major histocompatibility 
complex) class I molecules have also been suggested as possible receptors for 
HCMV. However, none of the interactions of the virus with these receptors has been 
linked to HCMV-induced signalling and entry. Only recently, it was revealed that the 
EGFR (epidermal growth factor receptor) is a necessary receptor for HCMV (Wang et 
al, 2003). Wang et al showed that HCMV infects cells through interaction of viral gB 
with EGFR, triggering an intracellular signalling cascade.
Following the attachment of HCMV to the cell surface, virus penetration occurs by 
pH independent fusion of the viral envelope with the cell membrane. It has been 
demonstrated that gB and gH are essential in this process. Antibodies against gB have 
been shown to interfere with HCMV penetration and cell to cell spread of infection 
(Navarro et al, 1993), while similar observations were made with antibodies directed 
against gH. Entry of HCMV in endothelial and retinal pigment epithelial cells occurs 
through endocytosis (Bodaghi et al, 1999). Finally, the nucleocapsid is released into 
the cytoplasm, allowing the launch of virus replication after entry in the nucleus.
13 HCMV replication
After the nucleocapsid is released into the cell cytoplasm it enters the nucleus, capsid 
proteins are removed followed by DNA genome circularisation and the onset of 
replication. Differential gene expression during viral replication plays a crucial role in 
determining whether the resulting infection will be productive, abortive or latent. 
Therefore, the extent of genome expression in any given cell type shapes the pattern 
of the virus-host interaction.
Hie expression of HCMV genes during productive replication is temporally regulated. 
The full replication cycle of HCMV in vitro takes approximately three days, however
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it has been estimated from studies in vivo that this does not reflect the replication time 
in host cells in vivo. Through such modelling studies the in vivo doubling time of 
HCMV can be assessed as one day (Emery et al, 1999, 2002). During HCMV lytic 
replication viral genes are expressed sequentially in three phases, termed immediate 
early (IE or a), early (E or p) and late (L or y), according to the timing of transcription 
(Table 1.2).
Class Time of
expression
after
infection
(hr)
Definition
Immediate-early, a 1 Expression requires no prior viral protein synthesis.
Early , pi 4-8 Expression is independent of virus DNA synthesis.
Delayed early , p2 8-24
Late , y 48-72 Expression requires virus DNA synthesis.
Table 1.2. Regulatory classes of herpesvirus genes expressed during lytic replication 
after infection, a , p and y in this case, refer to the gene expression classes rather than 
the viral subfamily.
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The first genes (immediate early, IE genes) are expressed within an hour of infection 
and their expression is independent of any viral de novo protein synthesis. The 
expression of the IE genes is confined to discrete regions of the viral genome, 
although the main site of IE transcription is in the UL component (Mocarski and 
Courcelle, 1996). Their products are non-structural proteins, essential for switching 
on early gene expression. The IE 1 and 2 proteins are known transcription factors, 
which regulate the expression of viral and cellular genes (Caswell et al, 1996). 
Several studies have uncovered similarities between the functions of HCMV IE 
proteins and IE equivalents encoded by adenovirus, such as the targeting of 
retinoblastoma and p53 families and the induction of S-phase in resting cells. Despite 
this, HCMV encodes several other IE proteins that act early in infection to prevent 
host DNA replication and apoptosis (Castillo et al, 2002).
The next set of genes (early, E genes) are expressed in two phases, name early or p i, 
with transcription occurring at 4-8 hours after infection, and delayed early p2, with 
transcription occurring at 8-24 hours after infection. They encode products that are 
involved in DNA replication, DNA repair, and other non-structural proteins. Viral 
DNA synthesis is initiated from the origin of replication (orijyt) and proceeds in both 
directions to form a rolling circle, yielding “head to tail” concatameric DNA.
The last set of genes, (late, L genes) are expressed after the onset of viral DNA 
replication, at about 48-72 hours post infection in vitro. These encode mainly 
structural proteins such as capsid, tegument and envelope proteins. Additionally, 
some of these proteins may play an important role in regulating transcription, viral 
assembly, as well as altering host cell proteins. The expression of HCMV proteins can 
be inhibited at several stages with the use of metabolic inhibitors, as illustrated in 
Figure 1.3.
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Figure 1.3. HCMV gene expression. This diagram also shows the stages at which 
metabolic inhibitors can be employed to manipulate the cascade. Cyclohexamide is an 
early protein synthesis inhibitor; actinomycin is a transcriptional inhibitor; GCV is a 
late protein synthesis inhibitor. GCV=ganciclovir.
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During the synthesis of virion components and late DNA replication, virus particles 
begin to assemble in the nucleus. DNA is packaged into the mature capsid, followed 
by the assembly of tegument, which is thought to occur when the nucleocapsids bud 
through the nuclear membrane, where initial envelopment may take place. It has been 
recently reported that UL97 is required for nucleocapsid nuclear egress (Krosky et al, 
2003). Although it is still unclear whether the final virus envelope is derived from the 
nuclear or the cytoplamic cell membrane, it has been shown recently that the final 
envelopment of HCMV particles takes place mainly in a Golgi-derived secretory 
vacuole (Homman-Loudiyi et al, 2003), which may act to release new infectious 
particles by fusion with the plasma membrane. Viral glycoprotein insertion and virus 
egress of the mature virion are thought to occur in the endosomal compartment of the 
cell (Tooze et al, 1993). Once produced, the virus can be released to the extracellular 
body fluid or may infect neighbouring cells via cell-to-cell spread. Figure 1.4 
illustrates the different steps in the life cycle of HCMV.
1.4 The strains of HCMV and identification of the UL/b’ region
AD 169, Towne and Toledo are HCMV strains commonly used in the laboratory 
environment. Clinical data have demonstrated that HCMV strains exhibit different 
levels of virulence depending on their passage history in cell culture. AD 169 and 
Towne were developed as potential live, attenuated vaccine candidates by serial 
passage of a clinical isolate in fibroblast cultures. AD 169 was passaged over 50 times 
in fibroblasts after being isolated from the adenoids of a 7-year-old girl undergoing 
tonsillectomy-adenoidectomy (Elek and Stem, 1974). Towne was isolated from the 
urine of a congenitally infected 2-month-old infant and was passaged over 128 times 
in fibroblasts (Plotkin et al, 1984). Both strains were tested in controlled human trials 
and shown to be avirulent in HCMV seronegative volunteers. In contrast, a low 
passaged strain, Toledo, has produced clinical disease when administered to healthy 
adult volunteers (Quinnan et al, 1984). Toledo was derived as a challenge virus 
during development of the Towne vaccine and was passaged for only five times on 
fibroblasts. It has also been shown that Toledo is more vimlent that both AD 169 and 
Towne when inoculated into SCID-hu (thymus plus liver) mice (Brown et al, 1995). It 
has been speculated that Toledo contains genes important for tropism/replication
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efficiency, which have been lost by other strains upon extensive passage in fibroblast 
cell culture.
Immediate
early
Nucleus
Figure 1.4. A schematic representation o f  the life cycle o f HCMV. After virus adsorption, the 
nucleocapsid is released into the cell cytoplasm and enters the nucleus. Capsid proteins are removed 
followed by the onset o f replication. During HCMV lytic replication viral genes are expressed 
sequentially in three phases (IE, E, L). At the late stage o f  DNA replication, virus particles begin to 
assemble in the nucleus, DNA is packaged into the mature capsid, followed by the assembly o f  
tegument and nucleocapsid budding through the nuclear membrane. Once produced, the virus can be 
released to the extracellular body fluid or may infect neighbouring cells via cell-to-cell spread.
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An extensive comparison of the restriction enzyme profiles of Toledo and a highly 
passaged variant of Towne combined with genome sequencing revealed an additional 
region of unique DNA at the right edge of the Toledo UL component, which was not 
present in AD 169 (Cha et al, 1996). This region was termed UL/b’ and was found to 
span 13kb encoding 19 potential ORFs, designated UL133-UL151. In addition to the 
19 genes missing in ADI69 and Towne, Towne contains 3 extra ORFs (not present in 
AD169): UL152, UL153 and UL154. It was concluded that AD169 and Towne 
contained segments homologous to the UL/b’ region that were lost upon extensive 
passage of these viruses in culture. Hybridisation showed that a portion of the variants 
in the Towne stock from the ATCC contained sequences highly homologous to the 
sequences of the Toledo UL/b’ region (Duke et al, unpublished data), a finding that 
supported this conclusion. Figure 1.5 shows the predicted genome structure in the 
UL/b’ region of Toledo.
Overall, the UL/b’ region is thought to contain a total of 22 additional genes which 
are present in clinical isolates but absent in highly passaged laboratory strains. 
Although these genes are not essential for replication in vitro, they are likely to be 
essential in vivo. The maintenance of these ORFs in clinical isolates suggests that the 
encoded gene products are also important for HCMV pathogenesis in vivo.
The functions of products encoded by 5 of these genes has been investigated to date. 
UL141, UL142, UL144, UL146 and UL147. Recent studies on UL141 and UL142 
have suggested a role in natural killer (NK) cell evasion. The expression of both genes 
in fibroblasts was shown to protect the infected cells from NK lysis (Wilkinson et al, 
Wills et al, unpublished data). The UL146 and UL147 ORFs encode a  chemokine 
homologues (Penfold et al, 1999). The UL146 gene from clinical isolates from AIDS 
patients is one of the most variable genes within the entire HCMV genome. The 
nucleotide sequence variability is less than 70% for UL146, resulting in a high level 
of variation at the amino acid level. The primary amino acid sequence from a clinical 
isolate was only 37% identical to Toledo UL146, resulting into different functional 
outcomes in clinical isolates (Sparer et al, unpublished data). This sequence 
divergence is highly unusual, since there is a >95% nucleotide sequence conservation 
for the rest of the HCMV genome. The expression of UL146 has been documented in
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many clinical isolates. In vitro experiments using a recombinant virus showed that 
this gene product is present in cells lysates, with a heavily glycosylated form secreted 
in the media. Function studies indicated that the protein could induce calcium 
mobilisation and neutrophil chemotaxis. The nucleotide and amino acid sequence of 
UL147 are also highly variable within clinical isolates. UL146 and UL147 may 
interfere with neutrophil activity during HCMV infection and consequently the loss of 
the UL/b’ region could contribute to the attenuation of AD 169.
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Figure 1.5. Illustration showing the layout of genes at the right end of UL in Toledo 
(Figure taken from Davison et al, 2003).
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UL144 is conserved in more than 45 low passage clinical isolates (Lurain et al, 1999), 
but shows sequence hypervariability. Therefore, clinical isolates cluster into three 
major groups, based on UL144 sequence. Looking at UL144 sequence in isolates 
derived from the same person illustrated that UL144 remains unchanged within an 
individual. The predicted amino acid sequence contains elements of a type I 
transmembrane protein and UL144 was shown to be homologous to HVEM 
(herpesvirus entry mediator), and other members of the tumour necrosis factor 
receptor (TNFR) superfamily (Benedict et al, 1999, Lurain et al, 1999). HVEM is 
required for HSV-1 entry into T cells (Mauri et al, 1998). UL144 protein is expressed 
early after infection and retained in an intracellular compartment, showing no cell 
surface expression (Benedict et al, 1999). Furthermore, it does not interact with any of 
the known TNF-related ligands, suggesting that this protein lacks a functional ligand- 
binding domain. UL144 is important because of its possible role in HCMV 
pathogenesis as a growth factor decoy that facilitates evasion of the immune response 
by the virus.
Additional differences between the low and high passaged HCMV strains exist 
outside the UL/b’ region. Different variants of ADI 69 have a 929bp deletion near 
UL42-UL43, compared to Toledo (Dargan et al, 1997, Mocarski et al, 1997). The 
coding region of UL36 gene of Towne has a deletion of several hundred nucleotides 
relative to the one in Toledo (Goldmacher et al, unpublished data). Additionally, the 
origin of lytic phase replication in Towne contains repeat sequences, which are 
missing from Toledo viral DNA (Anders et al, 1992, Masse et al, 1992, Kemble et al,
1996).
HCMV replication in a particular cell type is also dependent on the virus strain used. 
In vitro studies have shown that endothelial cells are not generally permissive for 
infection with high passage strains of HCMV (Friedman et al, 1981). However, these 
cells are permissive for infection with some low passage HCMV isolates (Ho et al, 
1984, Waldman et al, 1989). Monocyte-derived immature dendritic cells were shown 
to only support the full replication cycle of endothelial cell tropic strains of HCMV in 
vitro, resulting in the expression of IE, E and L viral genes and production of 
infectious virus (Riegler et al, 2000). It has been suggested that low passage strains of 
HCMV contain a number of endothelial cell tropic variants within a mixed population
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of strains that are lost after extended passage in fibroblasts, rather than 
deletion/mutation of existing genomes accounting for the observed effects 
(MacCormac and Grundy, 1999).
1.5 Cell tropism of HCMV and determinants of replication
Although HCMV receptors are found on a variety of cell types in vitro, entry of virus 
does not always result in the establishment of permissive infection in culture. The 
extent of HCMV infection ranges from lytic infection, to low-level persistent 
infection, to abortive infection, and finally, to latency, suggesting that host cell factors 
play a significant role in controlling replication of the virus.
Blood monocytes appear to be abortively in vitro. However, they become permissive 
once they have differentiated to macrophages following phorbol ester treatment 
(Weinshenker et al, 1988). HCMV replication can also be stimulated in some 
endothelial and epithelial cells after they have been treated with factors that promote 
cellular differentiation, such as sodium butyrate (Tanaka et al, 1991, Wu et al, 1994). 
In addition, the induction of cell differentiation by retinoic acid in teratocarcinoma 
cells, which are otherwise non-permissive for HCMV infection, promotes productive 
infection (Gonczol et al, 1984).
Most of the above in vitro studies have been performed using strains of HCMV that 
have been passaged in fibroblasts many times, which can affect the tropism for other 
cell types. The importance of the infecting strain of HCMV for clinical outcome has 
been the subject of speculation since it was first recognised that all epidemiologically 
unrelated clinical isolates have a unique genetic profile (Huang et al, 1976). Although 
they have a high level of sequence homology, they can be readily differentiated by 
restriction enzyme analysis of full-length genomic DNA and immunologic assays 
(Waner et al, 1978). Different HCMV strains also display biological differences, the 
genetic basis for which is still being investigated. Studies have shown that low 
passage clinical isolates can readily infect human endothelial cells and 
polymorphonuclear leukocytes isolated from human blood (Waldman et al, 1991, 
Grundy et al, 1998, Sinzger et al, 1999). Additionally, while the AD 169 strain was 
found to infect fibroblasts efficiently, it showed a low infectivity profile to smooth
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muscle cells, whereas a low passage clinical isolate exhibited comparable infectivity 
characteristics on both cell lines (Woodroffe et al, 1997). These tropism differences 
between high and low passage strains suggest that different tissue tropism may occur 
in vivo. Indeed, differences in the distribution of CMV infection in leukocytes from 
tissues of patients have been demonstrated (Sinzger et al, 1996). Another study 
showed that different clinical isolates obtained ffom transplant patients had specific 
tropism for different cells (Torok-Storb et al, 1993) and therefore it was proposed that 
the variation in tropism might account for differences in pathogenicity. The 
association between different gB genotypes and different tissue distribution of the 
virus in subsequent studies strengthen this statement (Rasmussen et al, 1997, Meyer- 
Konig, 1998). Variability in gene sequence of low passage isolates has also been 
reported for UL11 (Hitomi et al, 1997) and exon 3 of the IE gene (Hebart et al, 1997). 
However, there is contradictory data on the association between gB genotypes and 
clinical outcome. Several studies have shown no correlation was between the gB 
genotype and the development of CMV disease following liver or kidney 
transplantation (Sarcinella et al, 2002, Pacsa et al, 2003).
HCMV Towne lacks two biological properties that are present in clinical isolates: 
endothelial cell tropism and polymorphonuclear leukocyte tropism. It has been shown 
however, that Towne can reacquire tropism for both cell types after its adaptation to 
growth in endothelial cells. Leukotropism was reacquired 10-20 passages later than 
reversion to endothelial cell tropism, implying that these two biological activities are 
distinct (Gema et al, 2002). Furthermore, AD 169 was also shown to reacquire both 
properties in vitro (Gema et al, 2003). Recently, the genome region that determines 
leukocyte and endothelial cell tropism has been mapped to the UL131-UL128 locus. 
Transcript mapping data showed that UL128 and UL131A genes are spliced, and they 
flank UL130, which is unspliced (Davison et al, 2003). All three genes are expressed 
at late times after infection. Sequence analysis suggests that UL128 encodes a p 
chemokine (Akter et al, 2003). Compared with two HCMV isolates analysed directly 
ffom infected human tissues, each of eight isolates that were passaged in fibroblasts 
contained a mutation in one of these genes. Additionally, AD 169 had a ffameshift in 
UL131A and Towne in UL130. In Toledo, UL128 is dismpted by an inversion of part 
of the genome. An alternative approach by Hahn et al used a wild type virus strain
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with endothelial and leukocyte cell tropism and cloned it as a bacterial artificial 
chromosome (BAC) in E.Coli (Hahn et al, unpublished data). Virus mutants with a 
deletion in either individual genes UL128, UL130, UL131 or the entire UL131- 
UL128 region lost HCMV tropism for both endothelial cells and leukocytes. In 
contrast, deletion of the UL/b’ region did not alter tropism. In addition, leukocyte but 
not endothelial cell tropism could be restored in knock-out mutants by trans- 
complementation in fibroblasts expressing the UL131-UL128 locus. The UL131- 
UL128 region is thought to encode 5 proteins with chemokine homology, namely 
UL131, UL131xl, UL128xl, UL128 and UL130. Baldanti et al also showed that loss 
of tropism for endothelial cells is associated with mutations in this region, by 
sequencing UL131-UL128 in tropism deficient HCMV variants and then adapted 
them to grow in endothelial cells, which led to recovery of endothelial and leukocyte 
cell tropism, along with a back-mutation in the UL131-UL128 region. However, 
again, only leukocyte tropism could be complemented in trans in fibroblasts 
expressing the wild type UL131-UL128. These results indicate that the UL131- 
UL128 products are sufficient for endothelial cell spread, as well as for the attraction 
of monocytes and subsequent viral transfer. However, additional chemotactic factors 
appear to be required for full expression of leukocyte tropism. The combined data 
from studies on the UL131-UL128 region suggest that it is intimately involved in 
determining tropism.
HCMV replication is also regulated at the level of viral entry. It has been shown 
recently that while HCMV enters both fibroblast and endothelial cells within five 
minutes of contact, entry into endothelial cells occurs via endocytosis, while entry 
into fibroblasts occurs via fusion (Bodaghi et al, 1999). Therefore, the sequestration 
and degradation of incoming particles in endocytic vacuoles in endothelial cells could 
account for the low level of infection seen in this cell type. It has also been shown that 
AD 169 appears to be defective in its ability to translocate viral nucleic acid to the 
nucleus of human umbilical vein endothelial cells (HUVEC) following entry of the 
virus into the cell (Slobbe-van Drunen et al, 1998, Sinzger et al, 2000).
Histopathological analyses of autopsy material from HCMV-infected individuals have 
demonstrated the presence of HCMV in virtually all the organs of the body. The 
major sites of viral replication include the salivary glands, liver, kidney, brain, heart,
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eye, GI tract, placenta and peripheral blood (Egbert et al, 1980, Wreghitt et al, 1988, 
Schmidt et al, 1993, Sinzger et al, 1995). Fibroblasts seem to be the major cell type 
infected in the lungs, intestine and the placenta (Sinzger et al, 1993). This is 
reassuring, since it provides a degree of relevance for the in vitro studies in 
fibroblasts. Apart ffom fibroblasts, the virus replicates in many different cells within 
the infected host, such as macrophages, smooth muscle, neurons, trophoblasts, 
hepatocytes, epithelial and endothelial cells (Ibanez et al, 1991, Sinzger et al, 1996, 
Gabrielli et al, 2001).
It is thought that haematopoietic cells and their progenitors play important roles in 
HCMV latency and replication (Hahn et al, 1998), with evidence suggesting that 
monocytes are the key site of latency in vivo (Soderberg-Naucler et al, 1997). During 
active HCMV infection, viral DNA can be detected in monocytes, polymorphonuclear 
cells (PMNLs), B cells and T cells of immunocompromised patients (Gema et al, 
1992, Boivin et al, 1998). Although PMNLs contribute the greatest to the overall viral 
load in blood (~105 genomes per ml of blood), monocytes have the highest viral 
burden than any other leukocyte population (1 genome per 2 cells) (Hassan-Walker et 
al, 2001), illustrating the importance of this cell type the carriage of HCMV during 
viremic episodes. Detection of HCMV transcripts in leukocytes in vivo though, has 
produced conflicting results. In the bloodstream of healthy carriers, viral gene 
expression in monocytes is limited to immediate early genes (Dankner et al, 1990, 
Taylor-Wiedeman et al, 1991, Larsson et al, 1998). In contrast, the presence of IE and 
L viral transcripts, was demonstrated in all leukocyte populations by other groups 
(Von Laer et al, 1995, Hassan-Walker et al, 2001). It is widely accepted however, that 
tissue macrophages support full replication of the virus, with detection of early and 
late antigens (Sinzger et al, 1996). Additionally, it has been shown that HCMV can be 
transmitted by blood transfusion, where leukocyte depletion is associated with a 
reduction in the rate of HCMV transmission, indicating that infectious vims is 
predominantly cell associated. During latency the vims genome exists in a circular 
episomal conformation (Bolovan-Fritts et al, 1999). A model has been proposed 
where HCMV establishes a latent infection in monocytes, and is able to reactivate and 
generate a productive infection upon their differentiation into tissue macrophages. 
The reactivation of HCMV in vivo is a frequent phenomenon that occurs in both 
healthy carriers and immunosuppressed individuals (Soderberg-Naucler et al, 1997,
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Prosch et al, 1999). HCMV is reactivated under conditions of allogeneic stimulation, 
for example after transplantation or blood transfusion. In vitro evidence has also 
suggested a role for the proinflammatory cytokine tumor necrosis alpha (TNF-a) in 
virus reactivation probably via the stimulation of IE genes (Hahn et al, 1998, Prosch 
etal, 1999).
1.6 Spread within the host
In vivo, the epithelial cells of the GI, genitourinary tract and respiratory tracts are the 
first to be infected by the virus. HCMV then gains access to the peripheral blood by 
an unknown mechanism and can further infect fibroblasts, epithelial cells and 
endothelial cells coating the blood vessels. The endothelial cells in turn, due to their 
crucial localisation at the interface between the organ tissues and peripheral blood, 
can pass the virus on to monocytes circulating in the blood. The virus replicates in 
these cells without causing cell lysis, by localising in endocytic vacuoles (Fish et al, 
1995). This event makes monocytes a good vector for HCMV transfer to remote 
locations within the body.
During HCMV replication in vivo, the viral DNA is also detected in 
polymorphonuclear leukocytes (PMNLs), particularly neutrophils (Dankner et al, 
1990). Additionally, the co-cultivation of neutrophils with endothelial cells infected 
with a low passage HCMV clinical isolate resulted in neutrophil acquisition of 
infectious virus (Grundy et al, 1998). Recently, HCMV was shown to encode a 
protein homologous to an a  chemokine, capable of mediating neutrophil chemotaxis 
(Penfold et al, 1999). Therefore, apart from monocytes, endothelial cells could attract 
neutrophils to the site of infection and spread the virus, enabling viral dissemination 
within the body.
Finally, the infected endothelial cells could detach from the vessel wall, and enter the 
blood circulation. Indeed, the presence of infected cytomegalic cells in the blood of 
individuals with active HCMV infection was reported in 1995 (Sinzger et al, 1995). 
These circulating infected endothelial cells themselves could then transmit the virus to 
capillary endothelial cells and initiate organ infection.
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1.7 Epidemiology
HCMV is distributed in human populations universally, with prevalence depending on 
socio-economic status and geographical location. It is acquired earlier in life in 
developing countries, infecting >90%, while infecting -60% of individuals in the 
developed world (Wentworth and Alexander, 1971). Although in general HCMV 
infection rates are higher in nonwhites than whites, this variation probably reflects 
differences in socio-economic status rather than differences in racial orientation. 
Transmission can occur either vertically or horizontally.
HCMV can be spread ffom the mother to the baby either during gestation, birth or 
breastfeeding (Numazaki, 1997). The virus is the most common cause for congenital 
infections, infecting 0.25% to 2.5% of infants (Ahlfors et al, 1984, Griffiths et al, 
1991, Murph et al, 1998). Infections of the fetus during gestation usually occur in 
women who were infected before conception as well as in those who have primary 
HCMV infection during pregnancy. Primary infection has a foetal transmission rate of 
50% compared to less than 2% for recurrent infection. Additionally, it is quite rare for 
infants to develop clinically apparent HCMV disease when the mothers have pre­
existing immunity to the virus (Fowler et al, 1992). Therefore, pre-existing immunity 
plays a role in the control of HCMV disease. The developmental stage of the fetus at 
the time of maternal primary infection is important, with infection occurring during 
the first trimester accounting for almost all the symptomatic cases (Stagno et al, 
1986). Transmission of HCMV during birth depends on local shedding of the virus. 
Genital tract shedding is more common in women under 30 years of age. If the virus 
is being shed at the time of delivery, there is a 50% chance of transmission to the 
newborn (Reynolds et al, 1973). The most common route for transfer of the virus 
from the mother to the baby is during breastfeeding, with a strong relationship 
between the presence of viral DNA in milk and transmission (Vochem et al, 1998, 
Hamprecht et al, 2001). Although viral transmission during delivery and 
breastfeeding occurs more frequently than during gestation, it is not associated with 
the morbidity seen in congenital HCMV infection. However, asymptomatic infants 
shed the virus for a long period, contributing to the horizontal spread of HCMV in the 
community.
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Although primary HCMV infection in the immunocompetent host is usually clinically 
silent, it can sometimes result in mononucleosis, which has similar clinical 
manifestations to EBV-induced mononucleosis (Pannuti et al, 1985). Some of the 
symptoms include fever, malaise, fatigue, elevated hepatic transaminases and 
pharyngitis. Following infection with HCMV, the virus can be detected in saliva, 
semen, tears and cervical secretions and remain latent in CD 14 monocytes and other 
bone marrow progenitors. The horizontal transmission of HCMV requires direct 
contact with infectious material. The main routes of horizontal transmission are 
through sexual intercourse and person-to-person contact. Indeed, day care centres are 
major sites of risk for infection in pregnant women from children shedding virus in 
urine and saliva due to asymptomatic infection (Hutto et al, 1985, Pass et ah 1986, 
Shen et al, 1993, Kashiwagi et al, 2001).
HCMV can also be acquired via blood transfusion, although the use of screened blood 
products from seronegative donors has reduced the risk of infection (Bowden et al, 
1986). This, however, limits the availability of donors. The use of procedures that 
remove the leukocytes (major cell type carrying HCMV in blood) from blood have 
been shown to decrease the risk of virus transmission. Finally, the transplantation of 
an organ from an infected individual can also result in HCMV transmission within the 
population.
1.8 Host immune response to HCMV
1.8.1 Innate immune response
HCMV establishes a life-long association with its host. The virus remains in a latent 
form within a healthy individual, but can cause severe disease when the immune 
system is impaired. This highlights the immune system’s crucial role in controlling 
viral replication. The immune response to any invading organism consists of two 
branches, the innate response and the adaptive response. The first occurs immediately 
after infection and is mediated mainly by macrophages (Janeway et al, 1996). 
Macrophages function at the front line of immune defences against incoming 
pathogens. The invading organism is phagocytosed by macrophages, broken down 
and presented to the cells constituting the adaptive immune response. Macrophages
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can inhibit virus replication in adjacent cells themselves, by secreting a , p and y 
interferons (Gessani et al, 1998). They also secrete TNF-a and interleukins, which 
attract neutrophils and natural killer (NK) cells (Wewers et al, 1997), leading to 
elimination of foreign pathogen. Natural killer cells function as both effector cells and 
as a source of cytokines. They can lyse transformed cells and virus-infected cells, 
becoming functional in the absence of MHC class I antigens on target cells. Their 
importance is emphasized in patients devoid of NK cells but with an otherwise normal 
T cell and antibody response, who exhibit increased susceptibility to HCMV (Biron et 
al, 1989). A number of other correlations between NK cell function and sensitivity to 
CMV infection have been reported in vivo (Cauda et al, 1987). For example the 
ability of bone marrow transplant patients to develop an NK cell response correlated 
with recovery from HCMV infection (Quinnan et al, 1982). Studies have shown that 
mice genetically deficient in functional NK cells have an increased susceptibility to 
murine CMV (Shellam et al, 1981). Additionally, in mice with severe combined 
immunodeficiency, NK cells could decrease levels of HCMV replication, without 
being able to completely inhibit infection, suggesting that T and B cell responses are 
also required for the eradication of infection (Welsh et al, 1994). Therefore, NK cells 
represent a bridge between innate and adaptive immune response, by inhibiting the 
spread of infection until specific immune responses are developed (Biron et al, 1989, 
Kos etal, 1996).
There are two types of interferons (IFNs), IFN type I (IFN-a and IFN-p) and IFN 
type II (IFN-y). Mammalian cells respond to infection by generating an intracellular 
antiviral state, characterised in many cases by the synthesis and secretion of type I 
interferons. There are at least 20 types of IFN-a, produced mainly by infected 
monocytes and macrophages. Fibroblasts also produce some type I IFNs. Most of the 
viruses studied, including HCMV, show evidence of inducing an IFN-based antiviral 
response through the induction of IFN-a, IRFs and STAT-1 (Zhu et al, 1997). In the 
case of HCMV, this induction is principally mediated by the interaction of gB with a 
receptor on the surface of the target cell (Boyle et al, 1999). Type I IFNs are produced 
within 24 hours after infection, and bind to receptors on neighbouring cells. They then 
activate intracellular signalling pathways that lead to the binding of transcription 
complexes to IFN-responsive elememts (ISRE) for IFNs, activating transcription of
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IFN stimulated genes (ISGs) and inducing an antiviral state. In addition, they up- 
regulate MHC class I expression on neighbouring uninfected cells and activate NK 
cells, causing enhanced killing of virus-infected cells.
1.8.2 Adaptive immune response
The innate response is not successful and some infectious agents, including HCMV, 
can persist or replicate in macrophages. It is at this point where the cellular and 
humoral immune responses become essential in host control of HCMV infection.
Cellular immune response
The cellular immune response is essential for restraining CMV infection. This is 
demonstrated by the fact that acute disease is seen in people who have severely 
impaired cell-mediated immunity, such as patients who have AIDS or undergo bone 
marrow transplantation. CD8+ cytotoxic T-lymphocytes (CTLs) are the major cell- 
mediated immune response to HCMV. They recognize a specific antigen only when 
presented by MHC class I antigen on the target cell and eliminate it. The induction of 
a CTL response is dependent on recognition of specific T-cell epitopes by the immune 
system. Several different HCMV antigens have been identified to generate a cytotoxic 
T cell response but the protein responsible for the majority of the response is pp65 
(ppUL183) (Boppana and Britt, 1996, Wills et al, 1996). Many pp65-derived peptides 
are targets for CTLs, however one HLA-A2 restricted peptide seems to be 
immunodominant (Solache et al, 1999). ppl50, another tegument protein, is also 
recognised by CTLs (Li et al, 1997). The fact that the majority of the CTL response is 
directed against structural virion proteins ensures that the virus is presented to the 
immune system prior to the initiation of its replication, allowing it to be eliminated 
before producing virus progeny. Unfortunately in cells that reactivate latent virus, 
pp65 and ppl50 cannot be processed until after the onset of viral replication, 
rendering these cells relatively resistant to elimination by pp65- and pp 150-specific 
CTLs (Khattab et al, 1997). Some IE proteins also act as T cell epitopes. Recently, the 
presence and functional capacity of CMV-specific CD8+ T cells was monitored in 
organ transplant patients and healthy donors with latent CMV infection. The study 
showed that although the CMV-specific T cell numbers were similar in both groups,
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the CD8+ T cells in immunosuppressed patients exhibited a reduced functional 
response (Engstrand et al, 2003). These findings indicate impaired activation of 
cytotoxic T cells controlling latent infection in immunosuppressed individuals.
The murine CMV-infected mouse model has provided a large amount of information 
on immune responses to infection. Early studies showed that the suppression of T cell 
function led to reactivation and dissemination of natural infection (Gardner et al, 
1974). Another study using mice immunosuppressed with irradiation, showed an 
increased virus growth rate and mortality, compared to non-irradiated mine 
(Reddehase et al, 1985). Recently it has also been shown that the adoptive transfer of 
CD8+ T cells in murine bone marrow recipients can prevent lethal CMV disease 
(Steffens et al, 1998). Finally, the adoptive transfer of murine CMV-immune lymph 
node cells in T-cell depleted mice can prevent the development of retinitis (Lu et al, 
1997).
Adoptive transfer of HCMV-specific T cell clones has been used as a therapeutic 
strategy in bone marrow transplant patients, after observing an association between 
CMV-specific CTL recovery and recovery from HCMV pneumonia. The transfer of 
CTL clones prevented the development of HCMV viraemia and disease and the 
persistence of CD8+ T cells required HCMV-specific CD4+ T helper cell function 
(Walter et al, 1995). CD4+ T lymphocytes recognize a specific antigen only when 
presented by MHC class II antigen on the antigen-presenting cell. Unlike MHC class I 
antigens, which are present on all cell types, MHC class II antigens only exist on B 
cells, dendritic cells and macrophages. In humans with HCMV infection the presence 
of CD4+ helper T lymphocyte responses and their protective role has been 
demonstrated. In response to CMV infection these cells are able to release cytokines 
to promote viral clearance. Lymphocytes from healthy seropositive volunteers could 
mediate the lysis of HCMV-infected monocytes, suggesting a direct antiviral effect 
(Lindsley et al, 1986). Additionally, they have been shown to be essential for the 
CD8+ cytotoxic response (Hayward et al, 1984).
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Humoral immune response
The major impact of the humoral immune response is the eventual clearance of virus 
ffom the body. Effective antibody responses comprise the induction of neutralising 
antibodies and antibodies that can mediate antibody-dependent cytotoxicity. There is 
evidence that humoral immunity to CMV is crucial for the prevention of disease in the 
host. Data have shown that in immunosuppressed mice infected with murine CMV, 
dissemination was reduced significantly by administering CMV-specific antibodies 
(Shanley et al, 1981). Furthermore, in the guinea pig model, immunisation of 
pregnant dams with CMV-specific antibodies resulted in a decrease in the rate of 
foetal infection after CMV challenge (Harrison et al, 1995). In humans, the protective 
role of humoral immunity has been clearly demonstrated during pregnancy, where the 
presence of maternal antibody to HCMV before conception was shown to provide 
significant protection against HCMV disease in the infant (Fowler et al, 1992). 
Numerous studies have provided evidence that serum antibodies to HCMV obtained 
before transplantation are protective against severe HCMV disease (Alberola et al, 
2000). Renal transplant patients receiving pretransplant immunisation exhibited a 
reduced severity of HCMV disease (Plotkin et al, 1984). Additionally, passive 
immunisation of seronegative renal transplant patients using hyperimmune y-globulin 
has also provided a degree of protection against HCMV disease in controlled trials, 
with a reduced incidence of CMV associated fever, and mortality (Snydman et al, 
1987, Weimar et al, 1990). Antibodies to a wide variety of immunogenic HCMV 
proteins can be detected in sera from seropositive humans (Landini et al, 1988). 
Nearly all the immune human sera have antibodies to envelope glycoproteins gB and 
gH, and to the tegument phosphoprotein ppl50 (Schoppel et al, 1998). However, 
neutralising antibody is directed mainly against gB and gH (Kniess et al, 1991).
1.83 Immune escape mechanisms
The success of HCMV as a long-term parasite is in part due to its ability to interfere 
with the immune response. The virus has evolved multiple strategies for immune 
escape at different times of its replication cycle. There are two classes of viral 
proteins mediating immune regulation. The first class comprises proteins encoded by
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genes with sequence homology to cellular genes. This suggests that the virus has 
“stolen” genes from the host that were subsequently modified through mutation or 
selection to benefit the virus. The second class contains proteins encoded by viral 
genes without sequence similarity to host genes. These may represent an example of 
co-evolution and might possess properties required for interaction with the cellular 
machineries. An overview of mechanisms that HCMV uses to evade the immune 
response follows.
Modulation o f  MHC molecules
One HCMV antiviral strategy involves the modulation of MHC class I molecules, 
resulting in inhibition of antigen presentation and so clearance by CD8+ CTLs. 
HCMV down-regulates MHC class I on the surface of infected cells (Barnes and 
Grundy, 1992), which has been shown to correlate with increased resistance to lysis 
by CTLs (Beersma et al, 1993, Warren et al, 1994). A series of elegant studies in vitro 
has shown that the viral genes mediating this effect are US2, US3, US6 and US 11 
(Jones et al, 1995). US3, an IE gene, prevents MHC class I cell surface expression by 
retaining the fhmicroglobulin-associated heavy chain in the endoplasmic reticulum 
(ER) immediately after infection (Jones et al, 1996). US2 causes decreased levels of 
the class I heavy chain, by binding to it and transporting it to the proteasome for 
degradation (Jones et al, 1997). US6 inhibits peptide transport to the ER lumen by 
binding to TAP 1/2 system, which are essential for antigen translocation (Ahn et al,
1997). US 11 acts in a similar manner to US2 (Wiertz et al, 1996), but probably 
targeting a different class I allele. The region responsible for MHC class I degradation 
is located at the transmembrane part of the protein (Tomazin et al, 1999). HCMV also 
inhibits class I presentation at a different stage, via the tegument protein pp65. pp65 
phosphorylates the CMV IE proteins, disrupting their processing by the proteasome 
and their presentation to CTLs (Gilbert et al, 1996). Recently, an additional viral gene 
with a role in MHC class I regulation was identified. The HCMV UL82 gene product, 
termed pp71, is a tegument phosphoprotein that localises at nuclear domain 10 
(ND10) structures and is required for viral gene transcription. Pp71 has been shown to 
increase infectivity of viral DNA and degrades hypophosphorylated forms of 
retinoblastoma (Rb) proteins. Cell surface MHC class I levels were significantly
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decreased by 48 hours after infection with adenovirus expressing pp71, whereas total 
cellular levels were similar in infected and uninfected cells (Miller et al, 2002).
HCMV can also modulate cell surface expression of MHC class II antigens. Infection 
of macrophages with HCMV resulted in a down-regulation of cell surface MHC class 
II expression. Furthermore, the virus was shown to prevent induction of MHC class II 
on infected endothelial cells (Knight et al, 1997). More recently, it was reported that 
HCMV infection of glioblastoma cells stably transfected with the major class II 
transcriptional regulator (CUTA), resulted in a decrease in cells surface MHC class II 
levels (Cebulla et al, 2002). This effect was not due to a decrease in biosynthesis of 
MHC class II complex components, or due to their degradation by a proteasome- 
dependent mechanism (Colleen et al, unpublished data). The loss of MHC class II 
expression correlated with a restricted perinuclear localisation of MHC class II 
molecules and a disruption of actin and microtubule networks. Furthermore, 
transfection of cells with cosmids spanning the genome suggested that the UL131 to 
US25 region also led to decreased accumulation of MHC class II at the cell surface. 
These data imply that the HCMV could alter the localisation and transport of MHC-II 
complexes to perinuclear endosomal/lysosomal compartments, leading to down- 
regulation of CD4+ T cell responses.
There are a number of contradictory in vitro studies, showing an increased MHC class 
I expression after CMV infection of fibroblasts (Grundy et al, 1988), endothelial 
(Tuder et al, 1994), epithelial (Van Dorp et al, 1993) and smooth muscle cells 
(Hosenpud et al, 1991). This up-regulation of MHC class I molecules on the surface 
of infected cells requires the binding of HCMV particles to cell surface heparan 
sulphate proteoglycans (Song et al, 2001). In vivo studies also suggest that CMV 
infection increases the expression of class II molecules on infected cells. This was 
seen in tubular and endothelial cells of human renal allograft recipients with an active 
CMV infection (Von Willebrand et al, 1986). The same effect was observed on 
endothelial cells in the kidney and liver (Ustinov et al, 1994) in adult rats. 
Interestingly, the increased expression of MHC molecules on infected cells could 
elicit CD4+ and CD4+ cell activation, contributing to allograft rejection. Indeed, 
increased class I expression was observed on hepatocytes, epithelial and endothelial 
cells during liver allograft failure (Gouw et al, 1988) and increased class II expression
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is associate with acute rejection in kidney transplant recipients (Von Willebrand et al, 
1993).
Induction o f  FcyR
HCMV induces the expression of Fey receptors on infected cells (Litwin et al, 1990). 
These receptors can bind nonvirus-specific antibodies, inhibiting the attachment of 
specific IgG to the cell, and so protecting infected cells from antibody-mediated 
destruction (Adler et al, 1978). HCMV induces such a receptor soon after infection, 
which could allow the virus to evade the immune response (Keller et al, 1976, 
Sakuma et al, 1977). Additionally, HCMV induces an Fey receptor in fibroblasts and 
endothelial cells that is distinct from the human cellular Fey receptors (MacCormac 
and Grundy, 1996). The increased expression of the FcyR could also lead to 
deposition of immune complexes on the infected cell, a process which could 
contribute to the initial lesions seen in the development of atherosclerotic plaques 
(Raines and Ross, 1993) or tissue injury (Oldstone et al, 1975).
Escape from NK cell lysis
Although the downregulation of MHC class I expression prevents CD8+ CTL 
recognition, virally infected cells that downregulate these molecules are susceptible to 
lysis by NK cells (Leong et al, 1998). NK cells have receptors for certain MHC 
molecules. Some of these receptors silence the NK cytolytic machinery and act as 
killer cell inhibitory receptors (KIR). Other receptors, named leukocyte 
immunoglobulin-like receptors (LIR), are expressed mainly on monocytes and B 
cells. Studies have shown that HCMV may protect cells from NK cell elimination. 
Evidence supporting this came from the observation that HCMV-infected endothelial 
cells with reduced MHC class I expression were resistant to NK lysis (Waldman et al,
1998). In 1988, it was demonstrated that HCMV encodes a MHC class I homologue, 
named UL18 (Beck and Barrell, 1988). There is contradictory data about the function 
of UL18. It was initially thought to block NK cell activity through binding with the 
killer inhibitory receptor on NK cells (Reybum et al, 1997), but was later discovered 
that UL18 did not appear to bind this inhibitoiy receptor (Leong et al, 1998). The role
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of UL18 in NK evasion is still unclear. Recently, however, it was demonstrated that 
UL18 was required for the induction of T cell unresponsiveness and for the growth 
inhibition of leukaemic T cell lines. These data suggest that this protein may 
participate in the silencing of T cells, leading to subversion of the immune system 
(Odeberg et al, unpublished data).
In 2000, Tomasec et al identified an MHC-I-like region of nine amino acids in 
another viral protein, UL40 (Tomasec et al, 2000), which was conserved in multiple 
isolates of CMV. This protein was able to up-regulate HLA-E cell surface expression 
by binding to inhibitory receptors on the surface of NK cells, providing a mechanism 
for immune evasion. This effect was solely mediated by the MHC-I-like, nine amino 
acid region of UL40. The role of UL40 in NK cell evasion was confirmed in 2002, 
where AD 169 was shown to abolish the cytotoxicity of NK cells, while this effect was 
inhibited when using an AD 169, UL40 deletion mutant (Wang et al, 2002).
However, clinical isolates of HCMV confer a much stronger NK resistance than the 
laboratory strains tested so far, and the resistance was not related to MHC-I 
expression (Cerboni et al, 2000). This raised the question whether any proteins from 
the UL/b’ region of clinical strains could function as ligands for NK receptors. A 
program for prediction of protein function identified UL142 as a UL18 / MHC class I 
homologue. mRNA expression analysis in infected fibroblasts classified UL142 as a 
late gene (Wills et al, unpublished data). By 72 hours, fibroblasts infected with 
Toledo were resistant to NK lysis, while fibroblasts infected with AD 169 were lysed 
even when the level of MHC class I down-regulation was comparable. Further 
experiments showed that fibroblasts infected with a UL142 knockout virus were more 
susceptible to polyclonal NK lysis. Therefore, UL142 represents another viral protein 
that can inhibit the lytic activity of some NK clones. UL141 is another UL/b’ region 
gene, expressed by 24 hours after infection of fibroblasts with HCMV and retained 
within the cell. Studies have shown that UL141 is a robust inhibitor of NK cell 
function by an unknown mechanism. These data suggest that the loss of the UL/b’ 
region after serial propagation of clinical isolates in culture, could be associated with 
the loss of NK-specific functions.
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HCMV UL16 is another gene that interferes with NK cell function. It was described 
in 1992 as a late gene, dispensable for viral growth and replication. Its gene product is 
soluble and has been shown to bind some of the ligands recognised by an activating 
receptor on NK cells, named NKG2D (Bauer et al, 1999). These ligands include UL- 
16 binding proteins (ULBP) 1 and 2 and MICB (Cosman et al, 2001). Cell surface 
expression of these ligands after HCMV infection is reduced (Rolle et al, unpublished 
data) and correlated with an increased dependency on NKG2D for recognition, with 
the overall NK sensitivity remaining the same. Infection with a UL16 deletion mutant 
however, resulted in an entirely NKG2D-dependent increase in NK cell sensitivity. 
Consequently, a new model of immune evasion for HCMV has been proposed. 
Following viral infection, the host cell initiates ULBP expression in order to increase 
its susceptibility to NKG2D-mediated NK recognition. This antiviral response is 
however limited by UL16, which interferes with ULBP1 and 2 expression, leading to 
escape from NK cells.
In murine CMV, it has been shown that the product of M l57 gene serves as a ligand 
for an activating NK cell receptor, Ly49H (Arase et al, 2002, Smith et al, 2002). The 
significance of this protein for NK cell-mediated virus control was also tested in vivo, 
using deletion mutants on both Ly49H positive and negative mouse strains (Bubic et 
al, unpublished data).
CMV -encoded homologues o f IL-10, TNF R, chemokines and chemokine receptors
Cytokines play a key role in the initiation and regulation of the innate and adaptive 
immune response, and viruses have learned evolved strategies to modulate cytokine 
production, and signal transduction (Miskin et al, 1998). Interleukin 10 is a cellular 
cytokine that down-regulates MHC class I and II expression and inflammatory 
cytokine production (Fumeaux and Pugin, 2002, Haddad et al, 2003). HCMV encodes 
a viral protein expressed in fibroblasts, which shows 27% sequence homology to IL- 
10, termed vIL-10 (UL111a) (Kotenko et al, 2000). Despite this low level homology, 
cmvIL-10 was found to compete for binding to the cellular IL-10 and so could 
contribute to the immunosuppression observed during HCMV infection. The viral IL- 
10 also suppressed the maturation and cytokine production of DCs, preventing the 
polarisation of naive CD4+ T cells to IFN-producing T helper cells. Further studies
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have shown that the presence of vIL-10 during stimulation of immature DCs with 
LPS strongly inhibited their maturation and secretion of pro-inflammatory cytokines 
such as IL-12 (Chang et al, unpublished data). These data are consistent with a role 
for vIL-10 in reducing tissue inflammation and DC migration to lymph nodes. 
Furthermore, mature DCs treated with vIL-10 failed to induce MHC class II 
expression compared to untreated mature DCs. These data suggest that HCMV can 
attenuate the ability of DCs to induce immune responses, leading to the establishment 
of persistent infection. Additionally, infection of fully permissive astrocytes with 
HCMV resulted in vIL-10 mRNA expression (Cheeran et al, 2003). Medium from the 
infected astrocytes inhibited virus-induced IL-10 production from microglial cells 
through the IL-10 receptor, suggesting another mechanism employed by HCMV to 
avoid elimination by the immune system.
Chemokines are small cytokines that mediate recruitment of leukocytes to sites of 
infection and inflammation (Baggiolini et al, 1997, Greaves and Schall, 2000). A 
number of DNA viruses have been shown to encode a  (CXC) and p (CC) chemokines 
and chemokine receptors, resulting in immune modulation (McFadden et al, 1998). 
HCMV encodes US28, a protein with homology to a p (CC) chemokine receptor (Gao 
and Murphy, 1994), which enters infected cells through clathrin-mediated endocytosis 
(Fraile-Ramos et al, 2003). US28 mRNA is detected before gB and pp65 transcripts 
and is present in permissive, semi-permissive and non-permissive cell types (Zipeto et 
al, 1999). The protein was shown to bind RANTES and the monocyte chemoattractant 
protein 1 (Kuhn et al, 1995, Vieira et al, 1998). This binding could lead to increased 
calcium levels in the cells and provide a favourable environment for viral gene 
expression (Neote et al, 1993). In 1999, it was shown that US28 was required for the 
migration of HCMV-infected smooth muscle cells. More recent studies indicated that 
US28 promotes cellular migration through the activation of a focal adhesion kinase 
(FAK) signalling complex and promotes a mechanism by which HCMV contributes 
to the development of vascular disease (Streblow et al, 1999).
HCMV encodes two a  chemokine homologues, UL146 and UL147 (Penfold et al, 
1999), which are conserved in clinical isolates. UL146 was shown to induce calcium 
mobilisation and neutrophil chemotaxis and degranulation. Although the function of
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this protein has not been elucidated, it could contribute to the disruption of normal 
leukocyte migration and to viral dissemination by infecting neutrophils. Additionally, 
HCMV UL144 has been shown to be homologous to members of the tumour necrosis 
factor receptor (TNFR) superfamily (Benedict et al, 1999, Lurain et al, 1999). UL144 
was expressed early after infection and was retained in an intracellular compartment. 
This gene product is important because of its possible role in HCMV pathogenesis as 
a growth factor decoy that facilitates evasion of the immune response by the virus. 
Sequence analysis of guinea pig CMV predicted an ORF of 101 amino acids with 
homology to the CC chemokines (Haggerty and Schleiss, 2002). This ORF had the 
strongest sequence identity to the macrophage inflammatory protein (MIP) 
subfamily, and was named GPCMV-MIP. Using recombinant GPCMV-MIP, specific 
signalling was observed with the CCR1 receptor and further cell migration assays 
indicated that this protein could induce chemotaxis in CCR1 cells. Finally, a 
GPCMV-MIP deletion mutant replicated normally in cell culture, but was attenuated 
compared to wild type virus after inoculation in guinea pigs at early time points post­
infection.
Interferon modulation
The key role of IFN type I and II as one of the first lines in the anti-viral defence 
system is highlighted by the fact that viruses employ a variety of anti-IFN strategies 
(Goodboum et al, 2000). Viruses can block IFN-induced transcriptional responses and 
the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) 
signal transduction pathways. Additionally, viruses inhibit IFN effector pathways that 
induce an antiviral state in the cell and reduce virus replication. HCMV has been 
shown to inhibit the JAK/STAT pathway by reducing levels of JAK1 and p48 
(Goodboum et al, 2000). Experiments with mouse CMV indicate that the gene M27 
interferes with IFN signalling. Isolated expression of M27 prevented the nuclear 
accumulation of STAT2 in infected cells and resulted in a rapid proteasome- 
dependent degradation of STAT2 only. M27 was also found to have a more drastic 
effect on IFN gamma mediated antiviral activities, which was dependent on STAT2 
along with IFN alpha/betaRl expression (Zimmermann et al, unpublished data). 
These data support a model of crosstalk between IFN gamma and IFN alpha/beta 
signalling components, which requires the presence of STAT2.
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Modulation o f cell adhesion molecules
Alterations to cell adhesion molecules have been associated with leukocyte 
extravasation during graft rejection and atherosclerosis (Hayry et al, 1992). Several 
studies have suggested that increased expression of cell adhesion molecules may 
result in prolonged inflammatory reactions in the allograft after HCMV infection 
(Eriksson et al, 2001). Indeed, in heart transplant patients there is an increase of 
ICAM-1 and VCAM-1 levels on endothelial cells, associated with T cell infiltration 
during allograft rejection (Briscoe et al, 1991). Another adhesion molecule, E- 
selectin, is also up-regulated in heart transplant patients with CMV viremia 
(Koskinen, 1993). Additionally, the levels of vascular adhesion protein-1 (VAP-1) 
were increased in acute rejection liver allografts in RCMV-infected rats (Martelius et 
al, 2000). Using the same model, a prolonged expression of ICAM-1 and VCAM-1 in 
the CMV infected grafts was associated with accelerated chronic allograft 
nephropathy (Kloover et al, 2000). Up-regulation of E-selectin, ICAM-1 and VCAM- 
1 was also observed on HCMV-infected endothelial cells in vitro (Span et al, 1991, 
Shahgasempour et al, 1997, Altannavch et al, 2002), while increased levels of ICAM- 
1 and LFA-3 have been demonstrated on CMV-infected fibroblasts in vitro (Grundy 
and Downes, 1993). Other in vitro data using endothelial cells however, have failed to 
confirm the alterations in levels of cell adhesion molecules (Sedmak et al, 1994). 
Further studies are required in order to provide a clear picture of the functional 
consequences of the expression of adhesion molecules on the surface of endothelial 
cells after HCMV infection.
Inhibition o f  apoptosis and complement-mediated lysis
Apoptosis, or programmed cell death, can be triggered by TNF ligands, cell cycle 
inhibitors and viruses. Among other functions apoptosis acts as an innate cellular 
response to limit viral propagation and viruses encode proteins that can inhibit 
apoptosis (Smith et al, 1997, Tortorella et al, 2000). HCMV also uses this strategy to 
prolong the lifespan of infected cells and therefore maximises the chance to spread the 
infection. It has been shown that infection of fibroblasts with HCMV inhibited death 
receptor-induced apoptosis. CMV UL37, localised in mitochondria, was identified as 
the viral gene mediating this effect (Goldmacher et al, 1999). Additionally, the IE1
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and IE2 HCMV genes have been shown to interfere with TNF-induced apoptosis 
(Hengel et al, 1998, Kalvakolanu, 1999). Another viral anti-apoptotic mechanism is 
targeting the cellular proteins implicated in the control of apoptosis. Some examples 
include inhibition of cascade activation, encoding homlogues of cellular anti- 
apoptotic protein Bcl-2 and inactivation of p53 (Macen et al, 1998, Wang et al, 2001). 
HCMV also contains two genes, UL36, UL37, which encode proteins with anti- 
apoptotic functions, named vICA and vMIA, respectively (Skaletskaya et al 2001, 
McCormick et al 2003).
The complement system is also major innate host defence mechanism (Kotwal, 2000). 
Viruses encode homologues of complement regulatory proteins that block 
complement activation and neutralisation of virus particles. HCMV employs a clever 
tactic in order to avoid complement attack. HCMV actively acquires cellular CD59, a 
complement inhibitor, and incorporates it into the viral envelope (Hengel et al, 1998). 
CD46 is another complement inhibitor, expressed in cells, protecting them from 
homologous complement lysis. Infection of these cells with murine CMV resulted in 
increased expression of CD46 mRNA and protein levels (Nomura et al, 2002). This 
represents another strategy by which murine CMV can circumvent host complement 
attack. Table 1.3 summarises the strategies by which HCMV evades immune 
recognition.
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Function Gene / Protein Proposed mechanism
Inhibition of MHC class I 
antigen presentation
ppUL183 
US2, US 11 
US3 
US6
UL82
Blocks IE-1 peptide presentation
Dislocate class I to cytosol
Retains class I in the ER
Inhibits TAP-dependent peptide 
translocation
Unknown
Inhibition of apoptosis UL122, UL123 
UL37
Inhibit TNF-induced apoptosis
Inhibition of membrane 
attack complex (MAC) 
formation
Host CD59 
Host CD46
Host protein incorporated into 
envelope
Increased protein levels on the 
surface of infected cells
Inhibition of JAK / ST AT 
pathway
Unknown Decrease in the levels of JAK1 and 
p48; proteasome involvement
TNF receptor UL144 TNF R homologue
P chemokine receptor US28 Mediates migration of smooth 
muscle cells and decreases local 
concentration of RANTES
a  chemokines UL146, UL147 Chemoattractants for neutrophils
IL-10 UL111 IL-10 activity 
Immunosuppressive
Effect on NK cells UL18,UL40,
UL142
UL16
UL141
MHC class I homologues 
Inhibit NK-mediated cell lysis
Interferes with cell surface 
expression of ligands that bind an 
NK activation receptor
unknown
Inhibition of apoptosis UL36
UL37
Inhibits caspase 8 activation 
Disrupts mitochondrial fission
Table 13. The inhibition of immune responses by HCMV.
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1.9 Pathology and treatment of HCMV disease
1.9.1 Factors in disease production
The pathogenesis of HCMV infection is complex and is determined by a variety of 
factors, mainly the type of infection, the level of viremia, the virus load and patient 
group.
Type o f infection
The type of HCMV infection, namely primary infection, reinfection or reactivation, 
are important in determining the severity of HCMV disease. Infection in an 
immunologically naive individual represents the greatest risk of disease in pregnant 
women. Primary infection of the mother has a foetal transmission rate of 50% 
compared to less than 2% for recurrent infection. Additionally, it is quite rare for 
infants to develop clinically apparent HCMV disease when the mothers have pre­
existing immunity to the virus (Fowler et al, 1992). In bone marrow transplant 
patients, reactivation is the major source of HCMV disease (Winston et al, 1985) 
while in solid organ transplant patients, reinfection of seropositive individuals 
represents more of a risk for disease than reactivation of latent virus (Grundy et al, 
1988).
Viremia
The detection of HCMV in the blood (viremia) as a marker of disease is more 
predictive that the detection of HCMV in saliva or urine (Gema et al, 1991, Kidd et 
al, 1993). Additionally, a recent study looking at allogeneic peripheral blood stem cell 
transplant patients showed that reconstitution of total lymphocytes was associated 
with recovery from viremia and no progression to HCMV disease (Gutierrez et al, 
2003). Viremia is an indicator of overwhelming virus replication at local sites of 
infection, resulting from an imbalance between the rate of HCMV production at sites 
of infection and the immune clearance rate, which permits HCMV to spread to 
multiple organs (Rubin, 1991). The detection of plasma HCMV DNA (cell-free 
viremia) in seroconverting blood donors may explain the low residual risk of CMV
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transmission by both CMV seronegative and leukodepleted seropositive blood (Drew 
et al, 2003).
Virus load
The advent of PCR has enabled greater sensitivity of HCMV detection and 
quantitation of HCMV load. The association between the quantity of virus load in the 
urine of congenitally infected infants and disease was first established in 1975 (Stagno 
et al, 1975). The results from this study showed a significant association between 
disease and virus load in the urine at birth of congenitally infected infants compared 
to asymptomatic infected infants. Additional studies have also found a direct 
relationship between elevated virus load and disease in a variety of 
immunocompromised patient groups (Fox et al, 1995, Bowen et al, 1996, Cope et al, 
1997, Emery et al, 1999, Hassan-Walker et al, 1999, Smith et al, 1999, Spector et al, 
1999, Emery et al, 2000, Nokta et al, 2002, Boeckh et al, 2003).
1.9.2 T ransplant patients
Solid organ transplantation
In the absence of prophylaxis, the onset of HCMV infection in transplant recipients of 
organs such as kidney, liver, lung, and heart, usually occurs within the first three 
months after transplantation, as indicated by detection of virus in blood or virus 
shedding (Falagas and Snydman, 1995, Ducloux et al, 1997). The onset and 
establishment of disease can vary, depending on the degree of immunosuppression, 
initiation of antiviral treatment, allograft source, HLA mismatching, receipt of 
infected blood products and donor seropositivity. Additionally, symptomatic disease 
usually results from primary infection rather than reactivation (Ho et al, 1975, Betts et 
al, 1977). There is a lower risk of HCMV disease resulting from virus reinfection, 
which is associated with the transplantation of an organ from a seropositive donor to a 
seropositive recipient, suggesting that pre-existing immunity in the recipient is 
beneficial, leading to a reduction in the incidence of HCMV disease. This observation 
is consistent with the reduced growth rate, basic reproductive number and peak virus 
load in solid organ transplant patients who are D+R+ (Emery et al, 2002). HCMV 
seropositive blood products, which may be given as part of the transplantation
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program, are also an important source of virus transmission for HCMV seronegative 
transplant recipients. Multiple transfusions have been associated with HCMV 
infection (Chou et al, 1987, Landaw et al, 1996) and procedures that limit the quantity 
of leukocytes in transfused blood limit the incidence of HCMV infection following 
transfusion, suggesting that leukocytes are responsible for transfusion-associated 
HCMV infections in transplant recipients (Gunter, 1995). Patients that received high 
doses of cytotoxic drugs showed increased morbidity from HCMV infection (Hayry et 
al, 1992). In the case of renal transplant recipients, the degree of HLA mismatch 
increases the risk for HCMV infection (Boland et al, 1993, Keever-Taylor et al, 
2001).
The most common manifestations of HCMV disease are fever, leukopenia, 
thrombocytopenia, malaise and macular rash. Some patients however may develop 
life-threatening diseases like pneumonitis, GI (gastrointestinal) tract ulceration, 
hepatic dysfunction, and fungal and bacterial infections (Duncan et al, 1994). Host 
versus graft rejection together with an active HCMV infection is also associated with 
severe disease and poor prognosis (Goral and Helderman, 1994, Martelius et al, 
1997). HCMV infection has been consistently associated with poor graft survival, 
although the mechanism underlying the rejection process is not well understood. A 
potential mechanism is the upregulation of MHC molecules in the organ, leading to 
increased immunogenicity. Retinitis in transplant recipients is very rare.
Bone marrow transplantation
The greatest risk of HCMV disease in seropositive bone marrow transplant recipients 
is associated with reactivation of endogenous HCMV rather than re-infection of 
exogenous virus (Winston et al, 1985). Additionally, patients receiving bone marrow 
from seropositive donors show a lower incidence of HCMV disease (Grob et al, 1987, 
Lin et al, 2002). These findings indicate that instead of marrow representing a high 
risk for virus transmission, it may actually provide immunity to the recipient. 
Furthermore, the use of screened, seronegative blood products has also decreased the 
occurrence of primary infection or re-infection in these patients (Bowden et al, 1991).
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Pneumonitis is the major life-threatening presentation of HCMV in bone marrow 
(BM) transplantation, with an 85% mortality rate if left untreated (Meyers et al, 
1986). For allogeneic transplants, about 0% to 15% of seronegative recipients of 
marrow from a positive donor and 6% to 36% of seropositive patients develop 
pneumonitis (Boeckh and Bowden, 1995). This complication is much less common in 
autologous transplant patients, consistent with the supposed immunopathologic nature 
of the disease process (Grundy et al, 1987). While HCMV excretion is common after 
autologous or identical twin marrow transplant, HCMV disease is not. Furthermore, 
graft-versus-host disease (GVHD) occurs more frequently in the case of donor- 
recipient histoincompatibility. In 1996, a multivariate analysis of risk factors for 
HCMV disease was performed, showing that GVDH was the most significant risk 
factor for pneumonitis and mortality (Ljungman, 1996). The induction of GVDH by 
HCMV could either result from uncontrolled virus replication in the lung or from an 
immunopathological reaction triggered by HCMV infection (Greenberg, 1991). 
Despite the proven associations between HCMV infection and GVDH, the actual 
mechanism by which HCMV mediates GVDH remains unclear. Studies using the 
murine CMV model support the hypothesis that the pneumonitis resulting from 
GVHD is immune-mediated (Grundy et al, 1987). Experiments looking at 
pneumonitis after bone marrow transplantation in mice showed that while there was 
no histopathological evidence of the disease, the virus could still replicate in the lungs 
of these mice (Shanley, 1991) and disease resulted after altering the immune response. 
In another model, pneumonitis only developed in mice infected with murine CMV 
and given a graft-versus-host challenge (Grundy et al, 1985). Therefore in the mice, 
GVHD represents a risk factor for pneumonitis. Additionally, the infiltration of T 
cells in mice contributes to the pathology of CMV disease. Other, less common, 
diseases in bone marrow transplant recipients include GI tract disease, hepatitis, 
encephalitis and retinitis. Retinitis however has become more common since more 
matched unrelated donor transplants have occurred, probably due to a delayed 
immune reconstitution compared to sibling transplants (Larsson et al, 2002).
In the case of BM transplant patients, the amount of HCMV in blood (whole blood or 
peripheral blood leukocytes) and bronchoalveolar lavage fluid is a strong predictor of 
disease (Weinberg et al, 2002). Successful management of HCMV infection in these 
patients requires pre-transplant donor and recipient screening, prevention of HCMV
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transmission through blood products, virological and clinical screening for HCMV 
infection after transplantation, and the correct use of antiviral therapy.
1.93 HIV patients
HCMV infection is an important pathogen in HIV positive individuals (Drew, 2003). 
Clinical disease due to HCMV has been reported in up to 40% of patients with 
advanced human immunodeficiency virus (HTV) disease (Cheung and Teich, 1999). 
The risk of HCMV increases with decreased immune function, and symptomatic 
HCMV disease is most frequently associated with a low CD4+ T cell count (<50 cells 
per mm3) (Gallant et al, 1992, Pertel et al, 1992). The majority of homosexual men 
are seropositive for HCMV (Collier et al, 1987), suggesting that disease in these 
patients is most likely due to reactivation of endogenous virus. Re-infection with new 
HCMV strains though may also play a role in HCMV pathogenesis, since many AIDS 
patients are infected by more than one HCMV strain (Drew and Mintz, 1984, Collier 
etal, 1989).
HCMV disease has been classified as an AIDS defining illness according to the 
Centre for Disease control in Atlanta, USA. It has also been suggested as a cofactor in 
the development of AIDS, because clinical and molecular studies have linked CMV 
and the progression of HIV-1 infection (Webster et al, 1989, 1992, Mocroft et al,
1999). Epidemiological studies have shown that the progression to AIDS occurs much 
faster in patients infected with both viruses (Detels et al, 1994). In vitro evidence also 
indicate that HCMV can enhance HIV-1 replication or reactivation from infected 
cells. Syncytiotrophoblasts, for example, are restrictive for HIV-1 replication, 
however when these cells are co-infected with HIV-1 and HCMV, there is a 1500-fold 
increase in HIV-1 replication (Toth et al, 1995). In monocyte-derived macrophages, 
HCMV also enhances HIV replication (Lathey et al, 1994). HCMV can enhance HIV- 
1 replication through a number of mechanisms, including the induction of a Fey 
receptor expression (McKeating et al, 1990), transactivation of the promoter in the 
HIV-1 long terminal repeat region (Barry et al, 1990) and production of 
proinflammatory cytokines (Ostrowski et al, 1998).
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Unlike the clinical manifestations in the transplant patients, the most common 
symptom in AIDS patients is chorioretinitis, which is seen in 20% to 45% of 
individuals (Jacobson et al, 1988). This condition often leads to blindness due to 
necrotising damage to the retina. HCMV can also cause encephalitis, characterised 
either by damaging of the cortex of the brain or by damaging the cranial nerves 
(Kalayjian et al, 1993), leading to delirium and rapid progression to death. Apart from 
the central nervous system (CNS), HCMV disease can also affect the peripheral 
nervous system, causing polyradiculopathy as a result of virus infection of the spinal 
cord (Whitley et al, 1998). GI tract disorders, characterised by ulcerations or 
epithelial lining perforations, are the second most common clinical syndrome, 
occurring in 5% to 12% of HIV infected individuals (Williams et al, 1992). 
Symptoms include oesophagitis, gastritis and enterocolitis. Endothelial, epithelial and 
smooth muscle cells are the major cell types infected (Sinzger et al, 1995). The GI 
tract damage is thought to result from direct viral cytopathogenicity, since the 
symptoms are resolved after anti-viral treatment (Dieterich et al, 1988). Other 
syndromes caused by HCMV include fever, hepatitis and polyradiculopathy (Bell,
1998). HCMV pneumonitis is less common in AIDS patients than in transplant 
recipients, suggesting that the pathogenesis of HCMV infection in the lung differs in 
these two patient groups (Bower et al, 1990, Millar et al, 1990).
The introduction of new combination treatment protocols to control HIV infection 
(highly active antiretroviral therapy or HAART) has led to improved immune 
functions (Deeks et al, 1997). The use of nucleoside analogues and protease inhibitors 
as part of the new treatment regimen has limited HIV viral load and enhanced CD4+ T 
cell count.
1.9.4 Congenital infection
HCMV infection is the most common viral congenital infection in humans. It is an 
important medical and public health problem because it causes damage to the central 
nervous system. HCMV can be acquired by the fetus either during pregnancy via 
intrauterine transmission of the virus or perinatally during birth or breastfeeding. The 
first mode of transmission is associated with more severe complications (Fowler et al,
1992). Other significant risk factors for the development of HCMV disease include
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the serostatus of the mother, gestational age at the time of transmission, viral load and 
the particular HCMV strain. Although symptomatic congenital infection and central 
nervous system (CNS) injury have been reported after recurrent maternal infection, 
primary maternal infection is more likely to result in symptomatic congenital 
infection and significant central nervous system implications in infants. Both 
symptomatic and asymptomatic neonates excrete high titres of virus for long periods 
of time in the urine and saliva, making them an important reservoir of virus for 
primary infection in pregnant women. Therefore, day care centres pose a significant 
risk setting for acquiring primary infection, with virus spread occurring through oral 
and respiratory routes (Pass and Kinney, 1985, Shen et al, 1996). Other important 
routes of virus transmission include sexual contact and blood transfusion (Demmler et 
al, 1986, Soderberg-Naucler et al, 1997). Gestational age is important for the 
pathogenesis of HCMV infection. Acquisition of virus within the first trimester is 
associated with more severe sequelae in congenitally infected infants (Anderson et al, 
1996). In vitro studies have implied a role for viral load and type of HCMV strain in 
the pathogenesis of congenital HCMV infection (Lazzarotto et al, 2003). Increased 
viral load leads to a poorer prognosis in the guinea pig, while different murine CMV 
isolates exhibit different in vivo behaviours (Reynolds 1993, Harrison et al, 1995). A 
comparison of virus loads in various body fluids of the infected infant has shown that 
detection of HCMV DNA in the cerebrospinal fluid is the most predominant factor for 
the risk of developing symptoms (Halwachs-Baumann et al, 2002).
While 90% of newborns congenitally infected with HCMV are asymptomatic at 
delivery, 10% will have a variety of symptoms. Abnormalities include 
thrombocytopenia, haemolytic anemia, elevated hepatic transaminases and 
cerebrospinal fluid protein, low birth weight, lethargy, hypotonia, periventricular 
calcification and cortical atrophy (Pass et al, 1980). Although some of the symptoms 
will resolve spontaneously within a few weeks of birth, newborn disease can be 
severe. Infected infants could develop microcephaly, hearing loss, vision impairment 
and mental retardation (Ramsay et al, 1991, Bale et al, 1996, Boppana et al, 1996). 
Unfortunately, between 5% to 17% of infected infants who were asymptomatic at 
birth will go on to develop hearing loss within the first two years of life (Hanshaw et 
al, 1976).
61
In conclusion, HCMV is a major pathogen in the immunocompromised host, infecting 
multiple organs. The pathology in these organs can be caused either directly as a 
result of viral cytotoxicity or by indirect tissue damage caused by the host immune 
system, or by both mechanisms (see section 1.9.2). Additionally, HCMV can cause 
disease in the immunocompetent host (see section 1.9.5).
1.9.5 HCMV and atherosclerosis
Atherosclerosis is a disease of large and medium-sized arteries, characterised by the 
thickening of the inner portion of the artery wall in association with lipid deposits 
(Ross et al, 1990). Advanced lesions of atherosclerosis can inhibit blood flow, 
particularly to crucial blood vessels supplying the heart and the brain, and therefore 
contribute to the pathogenesis of myocardial and cerebral infraction. All blood vessels 
consist of three layers (tunics), the tunica intima, tunica media and tunica adventitia. 
The tunica intima is the innermost layer and comprises endothelial cells. The tunica 
media consists mainly of smooth muscle cells and interspersed proteoglycans, while 
the tunica adventitia is formed by connective tissue containing elastic and collagenous 
fibres. The adherence of leukocytes to the endothelium is the first step in the 
development of atherosclerosis (Masuda and Ross, 1990). The adhered leukocytes 
then migrate to the subendothelial space and they become filled with lipids, forming 
activated lipid-filled macrophages, called “foam” cells. The accumulation of “foam” 
cells leads to the creation of the fatty streak, the first lesion of atherosclerosis. The 
leukocytes start producing inflammatory cytokines and matrix-degrading enzymes 
that initiate smooth muscle cell migration. Continued inflammation results in 
increased numbers of leukocytes migrating from the blood to the lesion, resulting in 
the formation of fibrous tissue, which further enhances the lesion. The fibrous plaques 
increase in size and by protruding into the arterial wall they may restrict blood flow. 
Atherosclerosis is considered to be an inflammatory disease, since its lesions are the 
result of a continued inflammatory reaction (Ross, 1999).
Epidemiologic data and pathologic studies suggest a link between HCMV infection 
and atherosclerosis. The search for a viral aetiological agent was initiated after 
discovering that Marek’s disease virus could induce the development of arterial 
vascular lesions in chickens, similar to those seen in human atherosclerosis (Fabricant
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et al, 1978, 1978). The mechanics of atherosclerosis also suggest that an infectious 
agent, such as a herpesvirus, could lead to endothelial cell injury, exposing the 
underlying smooth muscle cells and triggering the onset of atherosclerosis (Ross,
1999). In 1987, the first study that implicated a role for HCMV in the development of 
atherosclerosis took place. Blood samples were analysed from two groups of people; 
patients who underwent surgery for atherosclerotic vessel disease and a matched 
control group of patients with high cholesterol levels but no evidence of 
atherosclerotic disease. The study showed that that 70% of patients undergoing 
surgery for vascular disease had high levels of HCMV antibodies compared with only 
40% of control patients (Adam et al, 1987). Two studies in heart transplant patients 
reported that HCMV infection was significantly associated with the development of 
post-transplant coronary artery restenosis and graft rejection (Grattan et al, 1989, 
McDonald et al, 1989). In vitro experiments have shown that CMV infection in the rat 
model leads to increased smooth muscle cell proliferation even when there was no 
detectable virus in the vessel wall, suggesting a general proinflammatory effect 
(Lemstrom et al, 1993). All of the above data suggest a possible association between 
CMV infection and atherosclerosis. However, some other studies show that HCMV is 
not a major risk factor for the development of atherosclerosis (Hendrix et al, 1991, 
Gulizia et al, 1995, Adler et al, 1998). Although the role of HCMV remains unclear, it 
is obvious that the virus is neither necessary nor sufficient for the development of 
atherosclerosis. Atherosclerosis is a multifactorial disease process and other factors 
contributing to its development are age, gender and hypercholesterolemia. HCMV 
could contribute to vascular damage and enhancement of the inflammatory response.
1.9.6 Antiviral therapy
HCMV is an important pathogen and as such, has been and continues to be a target 
for antiviral therapy. There are three ways in which antiviral therapy can be 
administered to patients: prophylactically, before the onset of disease, pre-emptively 
upon virus detection, but prior to the onset of symptoms, or for the treatment of 
clinically apparent HCMV disease. The most cost effective and ideal administration 
of antivirals is pre-emptively, avoiding unnecessary exposure to the toxic effects of 
the drugs. During the last few years, the introduction of sensitive viral detection 
methods such as PCR and antigenemia assays, have allowed the use of pre-emptive 
treatment. The antiviral agents currently used for the management of HCMV disease
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include the nucleoside analogue ganciclovir (GCV), the pyrophosphate analogue 
foscamet and the nucleotide analogue cidofovir. All these drugs have a common 
target: the viral DNA polymerase. Ganciclovir’s mechanism of action relies on its 
phosphorylation by UL97 viral kinase (Littler et al, 1992, Sullivan et al, 1992). GCV 
undergoes further phosphorylation by cellular kinases to its triphosphate form, which 
acts as a competitive inhibitor of the viral DNA polymerase. There are also many new 
compounds which are at various stages of development, including tomeglovir and 
benzamidavir, which act as inhibitors of the viral terminase complex that is involved 
in cleavage and packaging of viral DNA into capsids (Emery and Hassan-Walker, 
2002).
The use of ganciclovir, foscamet and cidofovir has been proved to be effective in 
treating GI tract disease and retinitis in AIDS patients (Bowen et al, 1996, Spector, 
1996, Spector et al, 1996, Lalezari 1997, Lalezari et al, 1997). However, in the pre- 
HAART era AIDS patients never regained a fully competent immune system, so long­
term therapy was required in order to prevent re-appearance of the original symptoms. 
This in turn, has led to the development of ganciclovir- and foscamet-resistant HCMV 
strains in this patient group (Balfour, 1992, Drew, 1996, Baldanti, 1998). Treatment 
of solid organ transplant recipients has also been effective in limiting HCMV disease 
(Cooper, 1991, Duncan and Cook, 1991, Jordan, 1992). More recently, the use of pre­
emptive oral ganciclovir therapy in renal transplant recipients during the first twelve 
weeks post-transplantation, effectively prevented HCMV disease during this time 
period, and did not result in late onset CMV disease (Sagedal et al, unpublished data). 
In contrast, treatment of bone marrow transplant recipients with HCMV disease, 
especially pneumonitis, has not been as successful. When used prophylactically, 
ganciclovir could reduce the incidence of HCMV disease after transplantation, but did 
not provide a benefit for long-term survival (Goodrich et al, 1993, Winston et al,
1993). This mortality was caused by non-viral superinfections that resulted from the 
ganciclovir-induced neutropenia. Pre-emptive treatment has been more effective in 
reducing the occurrence of HCMV disease in transplant recipients (Egan et al, 1998). 
Despite reducing HCMV levels, antiviral treatment with ganciclovir only, cannot 
clear HCMV pneumonitis in bone marrow transplant recipients (Schmidt, 1991). The 
combined use of ganciclovir and HCMV immune globulins has produced better 
results (Reed et al, 1988), although more recent studies have shown that a range of
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complications occur later in this patient group due to non-viral superinfections 
(Reusser, 1996).
1.10 DNA array technology
1.10.1 Genomics and beyond
The form and function of an organism is determined by the expression of genome 
content. Genome analysis can provide a quantitative measure of gene copy number, as 
well as the presence of single base differences in the primary DNA sequence. Genome 
analysis therefore provides a detailed picture of the genetic potential of an organism 
by defining the precise nucleotide sequence of all the genes and gene regulatory 
regions. Based on this, a tremendous amount of effort has been directed towards 
obtaining entire genomic sequences for a number of organisms. Phi X I74 
bacteriophage was the first organism to have its genome completely sequenced in 
1977, bringing virology into the post-genomic era (Sanger et al, 1977). Since then, 
public and private efforts have resulted in complete genome sequences for over 900 
species, (Galibert et al, 1996, Goffeau et al, 1996, The C. Elegans Sequencing 
Consortium, 1998). Additionally, the completion of the draft sequence of the human 
genome has been recently announced, predicting 30,000 to 40,000 genes (Lander et 
al, 2001, Venter et al, 2001).
Genomic analysis at the DNA level, however, does not provide a measure of gene 
behaviour and function, as the genome is a relatively static repository of the 
organism’s genetic potential. Therefore, genome sequencing raises the essential task 
of assigning the role of each gene and deciphering the interactions between genes in 
that genome. In terms of understanding gene function, knowing the level and timing 
of gene expression is essential to understanding the biological activity of its encoded 
protein. Therefore, the collection of genes that are transcribed from genomic DNA 
(expression profile or “transcriptome”) is a major determinant of cellular phenotype, 
function and ultimately disease. However, transcript levels do not necessarily predict 
protein function. Nevertheless, proteins can not synthesised without an mRNA and 
therefore dissecting an expression profile can provide an insight into what type of 
information a genome is using at any stage. mRNA levels can be very informative
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about cell state and activity of the genes, and for most genes, changes in mRNA 
amount mirror changes in protein levels.
To correctly quantify and interpret the transcriptome, the combination of molecular 
and computational biology is required. There are a variety of methods used for 
measuring mRNA abundance, including northern blots, RT-PCR, nuclease protection, 
cDNA sequencing, cDNA fingerprinting (Ivanova and Belyavsky, 1995, Shimkets et 
al, 1999), subtractive hybridisation (Bonaldo et al, 1996, Carulli et al, 1998), 
differential display (Liang and Pardee, 1992), serial analysis of gene expression 
(SAGE) (Velculescu et al, 1995, 2000), rapid analysis of gene expression (RAGE) 
(Wang et al, 1999) and DNA arrays. Although some of these techniques have been 
employed to measure mRNA levels on a genomic scale (Zhu et al, 1997), the DNA 
array technique has been the most widely used technique for large-scale gene 
expression studies. HCMV is a complex virus infecting many different cell types, 
each with its own complex function, resulting in complex disease pathology. 
Therefore, we need to use post genomic technology to investigate and integrate such 
complexity. However, in order to interpret the biology systems investigated, they need 
to be well defined. The post genomic studies need to be forward and hypothesis 
orientated to aid interpretation. One of the most advanced methods is transcriptome 
study using DNA microarrays.
Protein synthesis (translation) is the second step in gene expression, and assessing 
protein activity is also essential for understanding genomic function. The importance 
of protein-based methods relies on the fact that they measure the final expression 
product of a gene rather than an intermediate. In some instances, they can also detect 
post-translational protein modifications and provide information on protein 
localisation. Protein-based methods include western lots, two-dimensional gels, 
chromatographic separation and mass spectrometry (O’Farrell, 1975, Gygi et al, 1999, 
Mann, 1999, Oda et al, 1999). More recently, protein arrays have been constructed for 
the measurement of the total protein complement of the cell (proteome) (Lueking et 
al, 1999, Haab et al, 2001). However, protein-based approaches are generally more 
difficult, less accurate quantitatively and have a lower throughput than RNA-based 
ones. DNA microarrays and proteomics are complementary technologies, and since 
biology in this millennium will focus on the study of complex biological phenomena,
66
only their integration will enable us to understand the great complexity lying beneath 
biological processes.
1.10.2 DNA arrays
DNA arrays are the current development of Southern Blot technology (Southern, 
1975). The transition from Southern blots to arrays was made possible by advances in 
two fields; robotics, which give the ability to automate array construction with 
reproducibility and accuracy at a microscopic scale, and the use of personal 
computers that allow safe and accessible storage of vast amounts of data. Like 
Southern Blots, the principle on which DNA arrays are based is the ability of nucleic 
acids to hybridise to complementary strands even when present in a complex mixture, 
forming sequence-specific duplexes. There are 4 main types of array: membrane (or 
nylon) arrays, Aflymetrix GeneChips, Agilent arrays and DNA microarrays (Table 
1.4). All DNA arrays consist of DNA sequences (probes) positioned on defined places 
on a solid support. A solution containing thousands of labelled nucleic acid targets, 
most often labelled cDNA, is incubated with the array and each immobilised probe 
specifically hybridises to complementary sequences present in the nucleic acid mix. 
The intensity of the label at each probe location relates to the abundance of that 
sequence in the target mixture. In this way, the relative abundance of many specific 
mRNA species in total cellular mRNA can be measured. Oligonucleotide arrays have 
been shown to correlate well with SAGE and Northern blots (Harkin et al, 1999, Lee 
et al, 1999, Murakami et al, 2000). Furthermore, changes in mRNA levels measured 
by cDNA and PCR product microarrays have also been validated by Northern blots 
and RT-PCR (Heller et al, 1997, Iyer et al, 1999).
Array types
Membrane arrays and microarrays are produced by spotting gene-specific PCR- 
amplified or oligonucleotide DNA onto nylon membrane or glass slides respectively, 
using robotic deposition. The number of different genes spotted on microarrays 
varies, but the maximum achieved with current robotic technology is around 39,000 
(Cuadras et al, 2002). Glass has unique advantages compared to nylon for the 
production of microarrays. First, glass is non-porous, allowing the use of very small
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hybridisation volumes, thus reducing reagent consumption and cost. Biochemical 
reactions also benefit tremendously from non-porous glass surfaces (Cheung et al,
1999). Being impermeable and smooth, it allows rapid diffusion during hybridisation 
and washing (Southern et al, 1999). Second, it is a durable material that can withstand 
high temperatures and stringent washes. Third, glass can be made optically flat which 
coupled with its transparency and low fluorescence improve image acquisition and 
analysis. Finally, two different target nucleic acids can be incubated with the 
microarray in a single reaction, while nylon arrays are limited to serial or parallel 
hybridisations. For Asymetrix GeneChips, oligonucleotides are synthesised directly 
on glass supports (in situ) using photolithography. A mercury lamp is used to 
illuminate through a photolithographic mask on to the surface of the chip, selectively 
removing photo-labile groups from the growing oligonucleotide chain in a stepwise 
fashion to create oligonucleotides (Fodor et al, 1991, 1993). Current human 
Affymetrix arrays each contain oligonucleotide probes constituting around 17,000 
genes. Each gene is represented by 16-20 different 25-mer oligonucleotides and 
contains a corresponding mismatch control (with one mismatch relative to the gene 
sequence) that is used for background subtraction (Lockhart et al, 1996). The Agilent 
system also synthesises oligonucleotides on glass supports, but uses ink-jet 
technology to deposit reaction components on each spot location (Okamoto et al,
2000).
Filter Array Agilent Affymetrix Microarray
Solid Support Nylon Glass Glass Glass
Probe PCR product or 
oligonucleotide
Oligonucleotide Oligonucleotide PCR product or 
oligonucleotide
Synthesis
Label
Robotic deposition
3 3 p
In situ by inkjet 
nucleotide 
deposition 
Cy3 and Cy5
In situ by 
photolithography
Fluorescein
Robotic deposition 
Cy3 and Cy5
Labelling
method
Scanning
Reverse 
transcription or 
end-labelling 
Phosphor imager
Reverse 
transcription or 
amino-allyl ligation 
Fluorescent scanner
Reverse transcription 
or biotinylation
Affymetrix scanner
Reverse 
transcription or 
amino-allyl ligation 
Fluorescent scanner
Table 1.4. Different types of DNA arrays.
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Sample labelling and array hybridisation
The nucleic acid mixture hybridised with the array can be derived from cell culture or 
from tissue and must be of high quality. Sometimes however, the quantity of RNA 
available is limiting and in vitro transcription is employed in order to generate 
sufficient amounts (amplified RNA or aRNA) (Van Gelder et al, 1990, Baugh et al,
2001). After obtaining purified total RNA, messenger RNA (mRNA), or aRNA, the 
sample has to be labelled. This is usually achieved by a single round of reverse 
transcription, where the RNA of interest is converted to cDNA, with the simultaneous 
incorporation of labelled nucleotides. The primers used for this are either poly(dT), 
which primes from the poly(A)-tail of mature mRNA, random primers, or a pool of 
sequence specific primers. The sample of interest is labelled either radioactively or 
fluorescently. Fluorescent labels can be detected with either a charge coupled device 
(CCD) camera or photomultiplier tube (PMT) scanner. Unlike membrane arrays and 
Affymetrix GeneChips that can analyse one sample at a time, two samples can be 
hybridised to a microarray or an Agilent array. In two-colour microarrays, sample 
mRNA is converted to cDNA and is simultaneously labelled with a fluorescent dye. 
mRNA from a reference RNA source is also labelled with a different dye, the two 
labelled samples are mixed and hybridised to the array. The most common 
fluorophores used are Cy3 and Cy5. cDNA can also be labelled after synthesis. Cy3 
and Cy5 fluorophores can be coupled to the cDNA through amino-allyl-modified 
nucleotides. When using Affymetrix GeneChips, RNA can be labelled using a 
psoralen-biotin derivative or by ligation to an RNA molecule carrying biotin 
(Wodicka et al, 1997). The biotinylated RNA is subsequently labelled by staining 
with a fluorescent streptavidin construct. Molecules from each sample will bind 
competitively to the complementary DNA present on the array and this can be 
measured using a scanner sensitive for the label (Figure 1.6). The outcome of such 
analyses will be a ratio between the Cy5 and Cy3 signal, representing the relative 
amounts of each sequence between the two samples. By using a common reference 
mRNA for a series of microarrays, it is possible to cross-compare all the different 
gene expression values by comparing the ratio of sample hybridisation signal to 
reference hybridisation signal across all the arrays.
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Figure 1.6. Schematic representation of a competitive microarray hybridisation. One 
RNA sample is labelled with Cy3 (green) and the other with Cy5 (red). These are 
mixed and hybridised to an array of PCR products or oligonucleotides printed (or 
synthesised in situ) on a glass slide. The hybridised array is scanned with a 
fluorescent scanner at two wavelengths and an image is generated. The colour of each 
array element corresponds to the ratio of that sequence between the two samples.
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1.11 Microarray data analysis
1.11.1 Analysis of differential gene expression
One of the early steps in analysing expression data is to determine the quality of the 
entire array and the individual spots on the array. Spots that flawed (ie part of a 
scratch or badly misshapen) are identified and removed before conducting any further 
analysis. The fluorescence intensities in each of the two channels are subsequently 
measured by laser scanning and image recognition software. Several statistical 
algorithms have been developed to control quality issues in microarray data (Ideker et 
al, 2000, Zhou and Abagyan, 2003). When comparing two samples, for example 
virus-infected cells and uninfected cells, these are labelled with different fluorophores 
and are either hybridised on two arrays (when using Affymetrix GeneChips or nylon 
mambrane) or on the same microarray. Expression ratios are then calculated for each 
gene and natural log transformed to produce a normal distribution. Differentially 
expressed genes can then be identified (i) by choosing arbitrary log(2) fold changes 
(cut-off values), (ii) as outliers in a scatter plot or MA plot (M as the y-axis and A as 
the x-axis, where M=log ratios and A=average intensities) (Dudoit et al, 2001), or (iii) 
other more complex statistical models (Newton et al, 2001). The importance of 
replicates in array experiments has been emphasised recently, mainly for confirming 
results, increasing the precision of estimated quantities (Kerr and Churchill, 2001, 
Yang and Speed, 2002) and allowing estimation of the statistical significance of 
expression ratios (Thomas et al, 2001, Wolfinger et al, 2001). Additionally, dye-swap 
experiments should be performed when using glass microarrays, to account for any 
biases introduced by dye variation (Jin et al, 2001, Tseng et al, 2001).
Usually however, the comparison of more than two samples is required. For example, 
during a time-course experiment, transcript abundance is monitored over time in 
response to a stimulus. In this case, the samples are hybridised against RNA from 
untreated cells or mixed reference (Iyer et al, 1999). When transcriptional 
programmes in a number of independent samples are investigated, such as comparing 
different cellular responses to a common virus, a common reference RNA can be used 
(Perou et al, 1999). The reference RNA is usually a collection of RNAs derived from 
the samples to be analysed or from related samples that exist in abundance, such as
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cell lines. The task of the common reference is to bind to as many of the array 
elements as possible, in order to obtain expression ratios for all the genes expressed in 
the samples of interest. Additionally, its use allows minimisation of variations that 
exist between printed arrays. The experimental sample is usually labelled with Cy5 
and the reference sample with Cy3, which are mixed and hybridised onto the arrays. 
Scanning of the microarray results in the generation of expression ratios for each gene 
(Cy5/Cy3), which represents the gene expression level in the sample relative to the 
reference. To make data cross-comparable and remove the reference effect, the data is 
transformed so that the median expression ratio for each gene across all samples 
equals 0 (median centering). This data processing enables the expression of each gene 
in each sample, relative to its median expression level in all samples to be assigned. A 
number of methods have been suggested for the identification of differentially genes 
in such experiments. These include methods based on statistical models such as the 
analysis of variance (ANOVA) model (Wemisch et al, 2003) and the mixed effects 
model (Kerr et al, 2000, Wolfinger et al, 2001, Park et al, 2003). More recently, an 
associative model has been developed for the identification of differentially expressed 
genes. This model associates gene expressions presented as residuals in regression 
analysis against control averaged expressions to a common standard (Dozmorov and 
Centola, 2003).
1.11.2 Data normalisation
After image processing and before applying the proposed models for analysis, it is 
necessary to normalise the relative fluorescent intensities in each of the two scanned 
channels. This is necessary to adjust for differences in labelling and detection 
efficiencies for the fluorescent labels and for differences in the quantity of starting 
mRNA from the two samples examined. There are three widely used techniques that 
can be used to normalise gene expression data, all of which make certain assumptions 
about the data. These methods are based on the principle that within the data for each 
experimental array set there is a non-varying set of genes that has the absolute level of 
gene expression in each sample. This can be a set of genes whose expression levels 
co-vary across the experimental set (“housekeeping genes” with basic cellular 
functions whose expression remains constant over different experimental conditions). 
This method is usually employed for normalisation of data derived from membrane
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and Affymetrix arrays (DeRisi et al, 1996, Heller et al, 1997, Chambers et al, 1999). 
However, this method is potentially flawed in that some studies have shown that for a 
given subset of “housekeeping genes” their expression level varies in different 
conditions and cell types (Jenner et al, 2001). Alternatively, data can be normalised 
by adding a group of RNAs to each sample at a defined level for each array (spiked 
RNAs). For microarrays though, the most common method for normalising the data is 
“global normalisation”, which applies a factor that adjusts the average or median 
expression ratio to 1. This approach assumes that the majority of genes on the array 
do not change their expression levels when comparing two mRNA samples (linear 
regression analysis). It also assumes that the expression ratio is independent of signal 
intensity. For some microarray experiments the fluorescent intensities however are 
nonlinear, and local regression techniques are used for normalisation, such as 
LOWESS (locally weighted scatterplot smoothing) (Yang et al, 2002). In any 
normalisation method, care must be taken in handling genes expressed at low levels, 
since they can introduce a degree of variation in the system. In fact, the majority of 
genes with large standard deviation in the level of gene expression occur at low signal 
intensity. Typically, the final analysis only includes spots where the intensities in the 
two channels are considerably above background.
1.113 Cluster analysis
Once a dataset is normalised, it is important to determine which sets of genes exhibit 
similar patterns of expression, since generally, genes with similar expression patterns 
have similar functions. Several distance matrices exist that quantify whether two 
expression profiles are similar to each other. One is the Pearson correlation, which is a 
measure of the directions similarity in which two expression vectors point (Heyer et 
al, 1999). A second one is the Euclidean distance, which measures the absolute 
distance between tw o points in space. Other measures used include squared Pearson 
correlation, Spearman rank correlation and mutual information (Butte and Kohane,
2000). Various clustering techniques have been applied to the identification of 
patterns in gene expression data. Clustering techniques can be classified as 
agglomerative or divisive, supervised or unsupervised. A description of the various 
clustering methods follows.
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Hierarchical clustering
Hierarchical clustering has become one of the most widely used techniques for the 
analysis of gene expression data, since it has the advantage that it is simple and the 
result can be easily visualised. There are various hierarchical clustering algorithms 
that can be applied to microarray data analysis, including single-, average- and 
complete-linkage clustering and weighted pair-group average (Michaels et al, 1998). 
Hierarchical clustering is an agglomerative approach, in which single expression 
profiles are joined together to form groups, which are further joined until the process 
is complete, forming a single tree (Figure 1.7). The branch lengths of this tree reflect 
the degree of similarity between items (genes) (Hartigan, 1975, Eisen et al, 1998), so 
shorter branches connecting two genes or samples are indicative of more similar 
expression patterns. The process of hierarchical clustering starts by converting the 
data into log(2) expression ratios, with each row representing a single array element 
(gene) and each column the results from one array (sample). The pair-wise distance 
matrix for all the genes to be clustered is then calculated and the matrix is searched 
for the most similar genes or clusters joining them by a node. The distances are 
calculated between this new cluster and all other clusters, and joining is repeated until 
all objects are in one cluster. This approach results in the grouping of genes or 
samples with similar expression patterns. Expression levels are depicted as a colour 
scale with green representing negative and red positive log(2) expression values. After 
applying hierarchical clustering, genes with similar function or samples from similar 
sources usually group together (Perou et al, 1999, Ross et al, 2000), allowing the 
assignment of functions for new uncharacterised genes, based on the functions of the 
genes with which they cluster.
Nevertheless, hierarchical clustering can lead to artefacts. One potential problem is 
that as clusters grow in size, the expression vector that represents the cluster might not 
represent any of the genes in this cluster (Quackenbush, 2001). Additionally, if a bad 
placement is made early in the process, it cannot be corrected (Tamayo et al, 1999). 
Therefore, as the clustering progresses, the gene expression patterns become less 
relevant. An alternative is to use divisive clustering methods, such as K-means
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clustering or self-organising maps, to segregate data into groups that have similar 
expression patterns (Kohonen, 1991, Tavazoie et al, 1999).
f t
*
Figure 1.7. Average-linkage hierarchical clustering of gene expression data, during 
KSHV latency and lytic replication in a B cell lymphoma cell line. Each column 
represents one array and each row one array element (gene probe). Relative gene 
expression level is represented as a pseudo-colored representation of log(2) 
expression ratio with red being above and green below the row/column median level 
of expression. Groups of genes with related functions cluster together. Figure taken 
from Jenner et al, (2001).
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K-means clustering and self-organising maps
While agglomerative techniques usually start with single-member clusters and 
gradually fuse them together, the divisive methods begin with elements in one large 
cluster that is broken down into smaller clusters. In K-means clustering, objects are 
isolated into a fixed number of clusters (k ), so  that the data is more related within a 
cluster group than between clusters; there is no production of dendrograms (Tavazoie 
et al, 1999). A disadvantage of k-means clustering is that the user needs to decide on 
the number of divisions in the data. Principal component analysis (PCA or singular 
value decomposition), is a technique which can be used in combination with K-means 
clustering to provide visual estimation of the number of clusters represented in the 
data. This method reduces high-dimensional data space to two or three dimensions 
that can be visualised and the axes of the dimensions (x, y, z) are the principal 
components (Raychaudhuri et al, 2000). Another method, which shares features with 
both agglomerative clustering and K-means had the ability to remove ill-fitting genes 
from clusters, which led to its use in studying yeast sporulation data (Zhu and Zhang, 
2000).
A self-organising map (SOM) is a neural-network-based divisive clustering algorithm 
that assigns genes to a series of clusters in 2-dimensional space, on the basis of the 
similarity of their expression vectors to reference vectors that are defined for each 
division. The nodes represent the most prominent patterns in the data and similar 
patterns occur as neighbouring nodes. This method is more structured than K-means in 
that the cluster centers are located on a grid. It places genes with similar, but not 
identical profiles, in neighbouring groups, creating a smooth transition of related 
profiles. SOMs can be used to order the clusters produced by hierarchical clustering 
(Chu et al, 1998, Eisen et al, 1998, Herrero and Dopazo, 2002). As with k-means 
clustering, the user can use PCA in order to determine the number of clusters that best 
represents the available data. Overall, the SOM algorithm is an excellent tool for the 
analysis and visualization of gene expression patterns (Toronen et al, 1999).
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Supervised clustering
The techniques discussed so far are all unsupervised methods for identifying patterns 
of gene expression. Supervised methods represent a robust alternative that can be 
applied if there is existing information about which genes are expected to group 
together. One example is the support vector machine (SVM) (Brown et al, 2000), 
which finds variables that are most related with a division that can then be used to 
order a training dataset into known classes. In this way, SVMs can identify genes in 
the training set that are outliers or that have been previously assigned to the incorrect 
class, or use biological information to determine expression features that are 
characteristic of a group. SVMs can also be used for the classification of samples 
(Furey et al, 2000). If gene expression patterns are measured from different patients 
for whom there is disease-stage classification data, the microarray can be used to 
create an algorithm, which will be able to categorise other uncharacterised samples. 
This could lead to the classification of disease, based on molecular expression 
“fingerprinting”. Among others, tree harvesting is another supervised clustering 
method, which consists of first generating numerous candidate groups by 
unsupervised hierarchical clustering, and then models the outcome variable as a sum 
of the average expression profiles of chosen clusters and their products (Hastie et al, 
2001, Dettling and Buhlmann, 2002). Recently, a tool has been developed which 
allows the comparison of the results derived using different clustering methods (Stum 
et al, 2002).
1.12 Applications of arrays
Arrays have found applications in just about every aspect of molecular biology. One 
of the larger areas of array use is the investigation of pathogen and the integrated host 
response to the pathogen.
1.12.1 Microbial transcription programmes
One of the main areas for array application is the simultaneous monitoring of 
thousands of transcripts in different biological settings, leading to identification of 
new gene networks and an understanding of gene expression patterns. The first
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microarray ever, consisted of probes for the model plant Arabidopsis (Schena et al, 
1995). The analysis revealed gene expression differences between root and leaves, 
implying that this method can be used to evaluate gene expression between two 
samples. In 1997 it became obvious that the array technology could also help assign 
functions to uncharacterised genes, since in general, genes with similar expression 
patterns have similar functions. This conclusion came from work on the yeast 
Saccharomyces cerevisiae, whose entire transcriptional programme was measured 
using genome-scale arrays (DeRisi et al, 1997). More studies have been performed on 
Saccharomyces cerevisiae using different experimental conditions and yeast mutants 
(Cho et al, 1998, Chu et al, 1998, Gasch et al, 2000, Hughes et al, 2000), showing 
that the time at which a gene is expressed, is associated with its function or cellular 
response. Since then, the expression of a large number of pathogens has been 
documented using arrays. Some of these pathogens include E. Coli (Richmond et al, 
1999, Tao et al, 1999), Mycobacterium tuberculosis (Wilson et al, 1999), 
Streptococcus pneumoniae (De Saizieu et al, 2000), Listeria monocytogenes (Cohen 
et al, 2000), Salmonella typhimurium (Eckmann et al, 2000, Rosenberger et al, 2000) 
and Plasmodium falciparum (Rathod et al, 2002). These studies confirm that the 
physiologic state of bacteria can be inferred from gene expression data. Because 
genes with similar expression patterns may be regulated by the same regulatory genes, 
microarray technology can also be used to identify regulatory elements that control 
the expression network (De Saizieu et al, 2000). Gene expression studies may also 
reveal key regulatory differences that lead to differing virulence between closely 
related pathogen strains. For example, variations in virulence of Listeria 
monocytogenes serotypes have been correlated with differential transcription profiles 
of virulence-associated genes (Bohne et al, 1996, Sokolovic et al, 1996).
1.12.2 Viral transcription programmes
The microarray technology is ideal for studying gene expression of DNA virus 
genomes. Arrays for a large number of viruses have been constructed, such as human 
cytomegalovirus (Chambers et al, 1999), herpes simplex virus-1 (Stingley et al,
2000), MHV-68 (Ahn et al, 2002) and KSHV (Jenner et al, 2001, Paulose-Murphy et 
al, 2001).
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For herpesviruses it is widely accepted that the relative time at which the expression 
of a gene is detected correlates with the stage of the life cycle in which it is thought to 
act, therefore knowing a gene’s kinetic class can help us determine its function. 
Herpesviral genes are expressed sequentially in three phases, termed immediate early 
(IE or a), early (E or P) and late (L or y), according to the timing of transcription (see 
section 1.3). The expression of the IE genes is independent of any viral de novo 
protein synthesis. Their products are non-structural proteins, essential for switching 
on early gene expression. The next set of genes (E genes) encodes products that are 
involved in DNA replication, DNA repair, and other non-structural proteins. The last 
genes (L genes) encode mainly structural proteins like capsid, tegument and envelope 
proteins. Therefore, the study of the whole virus genome can give a coordinated view 
of the virus’s gene expression programme.
The first array analysis for the identification of the kinetic classes of viral genes took 
place in 1999 by Chambers et al, for HCMV (Chambers et al, 1999). Before this 
study, the expression of only one third of the HCMV genome had been documented. 
Additionally, the results showed 90% agreement with published studies. This analysis 
allowed the assignment of functions for uncharacterised genes and the search for 
common promoter elements that may be responsible for the timing of expression. 
Since then, the genes of HSV-1, KSHV and MHV-68 have also been categorised 
(Stingley et al, 2000, Jenner et al, 2001, Ahn et al, 2002). In the case of HSV-1, the 
studies were extended to monitoring viral gene expression patterns in more than one 
cell type. Additionally, the use of cloned HSV-1 genomes with gene deletions 
revealed that the immediate-early HSV-1 gene ICP27 is necessary for the expression 
of a sub-set of early and late genes. Therefore, array technology can help determine 
the effects of viral genes on the expression o f all other viral genes and compare viral 
gene expression of wild type and mutant viruses. Furthermore, the effects of novel 
anti-viral drugs on gene expression has been monitored using arrays. DNA array 
analysis also led to the discoveiy of viral RNAs on the HCMV capsid, an unexpected 
finding (Bresnahan and Shenk, 2000).
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1.12.3 Understanding of disease
During the last seven years, a number of articles have been published, illustrating the 
power of microarray analysis in identifying alterations in gene expression levels in 
human disease. Importantly, gene experession data from array experiments have 
helped in better understanding of cancer. Among the first microarray studies directly 
relevant to cancer biology were those of Schena et al and DeRisi et al (DeRisi et al, 
1996, Schena et al, 1996). Determination of cancer type and stage is often crucial to 
the assignment of appropriate treatment. One of the first attempts to classify cancer 
cell lines using microarrays was reported in 1998 (Khan et al, 1998). A year later it 
was shown by another group, that cancer could be classified according to gene 
expression profile, when comparing two types of leukaemia (Golub et al, 1999). This 
classification was critical, since each cancer type responds differentially to 
chemotherapy. Since then, classification between multiple cancer classes has been 
achieved by a number of groups (Perou et al, 2000, Khanna et al, 2001, Ramaswamy 
et al, 2001, Pomeroy et al, 2002). Array analysis has also revealed novel class 
divisions in B-cell tumour types (Alizadeh et al, 2000). There was no general 
approach for identifying new cancer classes before arrays. Supervised learning has 
been used to find genes able to predict clinical outcome for a number of cancer types, 
including embryonal tumours of the CNS, prostate cancer and breast cancer (Pomeroy 
et al, 2002, Singh et al, 2002, V an ’t Veer et al, 2002). Arrays can also be employed 
to profile drug side effects and correlate gene expression to the sensitivity of tumour 
cell lines to anti-cancer agents in an attempt to find the targets (Grever et al, 1992). 
Recently, the first report to show global gene expression changes during 
chemotherapy in a human solid tumor has been documented (Buchholz et al, 2002). 
Microarrays are a useful tool for investigating the mechanisms of drug action. The 
gene expression signature for the immunosuppressive drug FK506 was studied in S. 
Cerevisiae (Marton et al, 1998), revealing new promising targets for the drug. 
Similarly, microarrays were used to determine the gene expression signature of M. 
tuberculosis exposed to isoniazid (Wilson et al, 1999). Analysis of array data 
identified the induction of the efpA  gene. This was an attractive drug target, since the 
gene is only present in pathogenic members of the mycobacterial genus. The analysis 
of gene expression data can also predict harmful effects. For example, if the
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expression profile engendered by a drug candidate is similar to that induced by a 
known toxic agent, it can be assumed that the drug candidate would also be toxic, a 
fact that has been confirmed in vitro (Braxton and Bedilion, 1998).
Arrays have been utilized to analyse human atherosclerotic lesions from arteria carotis 
sampled from patients undergoing surgery (McCaffrey et al, 2000). One important 
finding was a strong up-regulation of the early growth response gene Egr-1, a DNA- 
binding protein that influences the transcription of genes encoding growth factors, 
cytokines and proteins involved in coagulation. This finding was confirmed by animal 
experiments and identified Egr-1 as a possible target for therapeutic intervention.
1.12.4 Clinical diagnostics
Arrays have the potential to become an important tool for clinical diagnostics. Once 
fabrication costs decrease and validated targeted arrays are developed, it will be 
possible to use them for detection of pathogens in clinical material. Some groups have 
started investigating the role of microarrays in blood testing and prenatal diagnosis 
(Dobrowolski et al, 1999, Petrik, 2001). More recently, a protein array has been 
developed for the detection o f Toxoplasma gondii, rubella virus, HSV types 1 and 2 
and cytomegalovirus (Mezzasoma et al, 2002), which could be optimised for clinical 
use.
1.13 Host and pathogen arrays
Viruses are obligate intracellular parasites and as such their relationship with the host 
plays a key role in their survival. Regulation of infection and in vivo pathogenesis 
involves multiple points of interaction between viral and host factors. Therefore 
unfolding the cellular and molecular mechanisms underlying these interactions will 
contribute to our understanding of the processes by which viruses cause disease and 
provide the underpinning for the development of novel therapeutic strategies.
DNA array technology has the potential to offer an unparalleled view of the 
transcription changes that underlie the host response to pathogens. Much work has 
been carried out in this field, monitoring host gene expression upon infection by
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viruses of all families except for the ssDNA viruses. The majority of these studies 
followed host responses after in vitro infection either at a selected time point or as a 
time-course. Zhu et al. (Zhu et al, 1998) have reported one of the first analyses of the 
interaction of a human pathogen with a host cell using microarrays. They catalogued 
258 genes whose expression levels varied 4-fold early in the HCMV replication cycle, 
up to 24 hours post infection. Some of these were further confirmed by northern 
blotting. Since then it has been shown that infection with a variety of viruses 
dramatically alters host gene expression, modulating the transcription of many genes 
across a variety of functional groups. (Khodarev et al, 1999, Browne et al, 2001, 
Geiss et al, 2001, Simmen et al, 2001, Cuadras et al, 2002, Moses et al, 2002). During 
these time-course experiments, the number of differentially regulated transcripts has 
been shown to increase with time, probably reflecting increasing numbers of virus 
genes. The identification o f cellular genes, which change in response to infection, 
may provide essential clues into the pathogenesis of viral infection.
Unfortunately, it is a difficult task to cross-compare results from array experiments in 
order to identify common patterns of gene expression, due to the use of different cell 
types and array methods. This however is likely to change, especially after the 
establishment of MIAME (Minimum standards for the Annotation of Microarray 
Experiments), a framework for defining the type of data that should be databased and 
dividing the large amount of data types into defined groups for database operation. 
This allows microarray labs to design their own databases, which will be compatible 
with ArrayExpress, the proposed international microarray database. Despite the 
several issues associated with cross-comparing viral microarray data, some common 
patterns are apparent, including expression changes in host genes of certain functional 
groups such as interferon response, cell cycle, protein synthesis and inflammation. 
These will be discussed in further detail in Chapters 5 and 6.
Microarrays have been used to compare the effects of inactivated viruses with their 
active counterparts on host gene expression. This analysis can identify differential 
host responses, dependent on virus gene expression and has been performed for 
HCMV, influenza virus and HSV-1 (Browne et al, 2001, Geiss et al, 2001, Mossman 
et al, 2001). The effects of individual virus genes on host gene expression has also 
been measured by microarrays (Hobbs and DeLuca, 1999, Stingley et al, 2000). Some
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of these proteins include HCMV IE86 and gB (Simmen et al, 2001, Song and Stinski
2002), HIV-1 Tat (De La Fuente et al, 2002) and Nef (Simmons et al, 2001, 
Shaheduzzaman et al, 2002). DNA arrays have also monitored host gene expression 
in latently infected cells (Chang and Laimins, 2000, Mikovits et al, 2001, Carter et al, 
2002, Moses et al, 2002) and responses to herpesvirus reactivation from latency in 
vitro (Jenner et al, 2001, Paulose-Murphy et al, 2001, Poole et al, 2002). Apart from 
in vitro experiments, gene expression patterns have also been documented after 
infection in vivo (Taylor et al, 2000, Bigger et al, 2001, Domachowske et al, 2002). 
Additionally, herpesvirus reactivation from latency ex vivo (Hill et al, 2001, 
Tsavachidou et al, 2001) has been analysed using the gene arrays. Table 1.5 shows 
human herpesviruses whose effects on host gene expression have been assessed using 
DNA arrays.
The identification of differentially expressed genes may pinpoint targets for the 
development of novel therapeutic strategies. HCMV infection of fibroblasts leads to 
cox-2 up-regulation and prostaglandin E2 release (Zhu et al, 1998). When the effect 
of various cox-2 inhibitors was studied in culture, a dose-dependent inhibition of 
HCMV growth was observed, suggesting that the virus needs its pathway for its 
replication (Speir et al, 1998, Zhu et al, 2002). Since cox-2 inhibitors are already in 
clinical use, it is possible to test whether they can improve HCMV disease. Also, 
microarray analysis of KSHV infected DMVECs (Ciufo et al, 2001), revealed over- 
expression of the proto-oncogene c-kit. This up-regulation is essential for KSHV- 
mediated transformation and a c-kit inhibitor can block proliferation of KSHV- 
infected cells. Since inhibitors of c-kit signalling are already in clinical use, they 
could be evaluated for the treatment of Kaposi’s sarcoma. The results from these 
studies suggest that the discovery of potential new targets for treatments can be 
rapidly achieved using microarray technology.
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Family Species Array type Reference(s)
Human
Herpesvirus
HSV-1 Membrane (Khodarev et a l, 1999)
Membrane (Hobbs and DeLuca, 1999)
Microarray (Stingley et al., 2000)
Microarray (Mossman et a l, 2001)
Membrane (Hill et a l, 2001)
Human
cytomegalovirus
(HCMV)
Membrane
Asymetrix
Asymetrix
(Tsavachidou et al., 2001) 
(Zhu et a l, 1998)
(Browne et a l,  2001)
HHV-6
Microarray
Membrane
(Simmen et al., 2001) 
(Mayne et al., 2001)
EBV Membrane (Carter et a l, 2002)
KSHV Membrane (Mikovits et a l, 2001)
Microarray (Moses et a l,  2002)
Membrane (Poole et al., 2002)
Microarray
Table 1.5. Human herpesviruses whose effects on host gene expression have been 
assessed using DNA arrays.
84
HCMV effects on host cells as revealed by array analysis
Infection of fibroblasts by HCMV leads to increased expression of interferon- 
stimulated genes (Zhu et al, 1998), which indicates the activation of the cellular anti­
viral response. The number of interferon-responsive genes up-regulated by UV- 
inactivated HCMV though, is greater than for transcriptionally active virus (Browne 
et al, 2001), suggesting that structural components of the virion trigger the response. 
Indeed, when cells were treated with purified HCMV gB, most of the cellular genes 
induced or repressed were also induced or repressed by HCMV infection as well 
(Simmen et al, 2001). This suggested that gB binding is responsible for this up- 
regulation. HCMV also leads to increased expression of various cytokine mRNAs, 
such as IL-6 and RANTES. This induction is strengthened by virus inactivation, 
suggesting that HCMV encodes proteins that block this response (Browne et al,
2001). Therefore, as with interferon-responsive genes, cytokine expression can vaiy 
according to virus type and the genes expressed. Infection of fibroblasts with HCMV 
results in the induction of genes involved in the synthesis of prostaglandin E2, such as 
cyclooxygenase-2 (cox-2) which may act to trigger an immune response against the 
virus (Zhu et al, 1998, Browne et al, 2001). HCMV also induces stress-response 
genes and genes involved in protein synthesis. HCMV affects transcription of a 
number of cyclins, resulting in inhibition of cell cycle progression. It also changes 
transcription levels of genes involved in oncogenesis, apoptosis and complement- 
mediated lysis. These effects will be discussed more extensively in Chapters 5 and 6.
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AIMS OF THIS THESIS
The combination of detailed molecular and cellular virology with global views of host 
and pathogen biological processes by functional genomics, represents an exciting 
opportunity to delve deeper into the biology of host-pathogen interactions. This PhD 
therefore aims to use such investigational methods in the context of HCMV. HCMV 
strains differ in genome content, exhibit different levels of virulence, infect different 
cell types and different pathologies occur associated with the immune state of the 
host. To understand HCMV disease we need to start to integrate our knowledge, 
therefore this thesis aims to.
1. To compare the ability of HCMV strains AD 169 and Towne to bind to cells, 
replicate and mediate cell-to-cell spread of infection, using pair-wise competition 
experiments in cell culture.
2. To construct a DNA array to examine expression of host and the 19 ORFs found in 
clinical isolates and low passaged HCMV strains.
3 . To describe the transcription program of the 19 ORFs encoded by the UL/b’ region 
during Toledo infection of fibroblasts and endothelial cells.
4. To study the interplay between host and viral gene expression during:
(i) Toledo infection of fibroblasts and endothelial cells
(ii) Infection of fibroblasts with AD 169 and Toledo
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Chapter 2 
Materials and Methods
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2.1 Cell Culture
2.1.1 Cell culture media
Fibroblast growth medium
Minimal essential medium (MEM) (Gibco Life Technologies) with Earle's salts was 
supplemented with 200mM L-glutamine, 10,000U penicillin and lOmg streptomycin 
(Sigma). For the propagation of human embryonic lung fibroblasts, the medium was 
supplemented with 10% heat-inactivated foetal calf serum (FCS) (Labtech). For the 
maintenance of cells following virus infection, MEM was supplemented with 3% 
FCS.
Endothelial cell growth medium
Endothelial cell basal medium was supplemented with 0.5ml human recombinant 
epidermal growth factor, 2ml human fibroblast growth medium, 0.5ml vascular 
endothelial growth factor, 0.5ml ascorbic acid, 0.2ml hydrocortisone, 0.5ml human 
recombinant insulin-like growth factor, 0.5ml heparin, 10ml foetal bovine serum, 
0.5ml gentamicin, amphotercin (all from Clonetics).
2.1.2 Cell lines
All cell lines were grown under standard cell culture conditions in a 5%CC>2, 37°C 
incubator and tested for mycoplasma infection, as described in section 2.15.
Human embryonic lung fibroblasts
Human embryonic lung (HEL) fibroblasts were derived from the lung material of 
terminated pregnancies. HEL fibroblasts were isolated from lungs of eight to twelve 
week gestation foetuses. The lung tissue was dissected into small pieces using a 
scalpel, and digested with 0.1% trypsin / EDTA (Gibco Life Technologies) solution 
for 30 minutes at 37°C. The universal containing the tissue was then agitated, 
allowing the large tissue pieces to settle and digestion was repeated. The tissue was
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disaggregated with a Pasteur pipette and the cells were centrifuged at 700rpm for 10 
minutes and seeded into a 75cm2 culture flask in MEM supplemented with 10% FCS. 
The cells were cultured at 37°C in a humidified atmosphere containing 5% C 02. 
Unless stated otherwise in the text, HEL fibroblasts were used in all experiments.
MRC-5 fibroblasts
MRC-5 fibroblasts are established from normal lung tissue of a 14 week-old male 
foetus. They were obtained from the ECACC (European collection of cell cultures) 
collection at passage number 14, maintained in MEM, 10% FCS and passaged in cell 
culture. They were used for experiments between passage 20 and 30.
Human umbilical vein endothelial cells (HUVEC)
The human umbilical cord was collected in phosphate buffer saline (PBS) and 
processed within 12 hours. The cord was wiped and cut off from one side to identify 
the vein. The vein was cannulated and rinsed 3 times by passing PBS through two 
syringes attached to the cannulae. The cells were then detached from the vein by 
collagenase digestion. Veins were filled with PBS containing 200U/ml collagenase 
(Boehringer Mannheim) and incubated for 20 minutes at 37°C. The vein was flushed 
with 2% FCS in PBS and the collagenase solution collected into a universal. The cells 
were collected by centrifuging at l,500rpm for 5 minutes. The cells were re- 
suspended in growth medium and seeded into a 25cm tissue culture flask that had 
been coated with 2% gelatine for 1 hour at 37°C. The flask was incubated overnight 
and fresh growth medium was added. The cells were re-fed every 2 days and 
passaged when confluent. The endothelial cell growth medium consisted of Iscove's 
modified Dulbecco's medium (Gibco Life Technologies) supplemented with 20% 
FCS, 50pg/ml endothelial cell growth factor (Sigma) and 20U/ml heparin. These 
endothelial cells were used for adaptation and titration of Toledo at passage 2-4. 
Human umbilical vein endothelial cells used for virus infections, were obtained from 
Clonetics. These cells were thawed and passaged in culture, using endothelial cell 
growth medium (Clonetics) and 0.025% trypsin/ 0.01% EDTA solution.
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2.1.3 Thawing of cells
Cells were taken from liquid nitrogen and thawed rapidly at 37°C. Cells were re- 
suspended gently and added to 30 ml of growth medium. The cells were then pelleted 
at 700rpm for 10 minutes, re-suspended in 30ml of pre-warmed growth media and 
added to a 75cm2 tissue culture flask for overnight incubation at 37°C.
2.1.4 Cryopreservation of cells
The cells were trypsinised, re-suspended in MEM, 10% FCS and centrifuged at 
700rpm for 10 minutes. The medium was discarded and the cell pellet was re- 
suspended in 1ml freezing medium. 1ml aliquots were placed into cryovials (Nunc, 
USA), insulated with tissue, and stored at -70% overnight before being finally 
transferred to liquid nitrogen.
Freezing medium for fibroblasts: 10%DMSO, 90% FCS
Freezing medium for HUVEC : 10% DMSO, 10% FCS, 80% growth medium
2.1.5 Mycoplasma testing
Cells and virus stocks were negative when tested for mycoplasma. The method used 
was a nested PCR, with primer sets directed against a highly conserved section of 
mycoplasma ribosomal DNA, located in the 16S and 23 S rRNA genes and the spacer 
region between (Pruckler and Ades, 1995). The primers used were the following:
5’ ACT CCT ACG GGA GGC AGC AGT A 3’ GPOl
5’ TGC ACC ATC TGT CAC TCT GTT AAC CTC 3’ MGSO
First round 
primers
5’ CTT AAA GGA ATT GAC GGG AAC CCG 3’ GP02
5’ TGC ACC ATC TGT CAC TCT GTT AAC CTC 3’ MGSO
Nested
primers
The PCR reaction mix was initially prepared. For 5 samples, the mix contained the 
following ingredients: 156.5pl H2O, 25pi lOxPCR buffer, 25pl 2.5mM MgCl2, 16pl 
dNTPs, lpl of each primer (1 nanomole/pl), and 0.5 pi Taq DNA polymerase
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(AmpliTaq Gold). 45jil of the reaction mix were aliquoted into 0.75ml PCR tubes and 
overlaid with mineral oil. 5pl of sample (either virus stock or trypsinised cells) were 
added to the PCR reaction mixture and PCR cycling was performed. Subsequently, 
5pi of the PCR product were added to a PCR mix (prepared as before) for a second 
round of amplification.
The following cycling conditions were performed:
Round 1 Round 2
Temperature Duration Duration N° cycles
(°C)
95 12min 12min 1
94 30sec 15 sec
55 60sec 40sec 40
72 60sec 15 sec
72 lOmin lOmin 1
The PCR products were analysed by electrophoresis on 3% agarose gels. The 
expected size of the first round product is approximately 720bp and the second is 
145bp.
2.1.6 Viral stocks
The AD 169, Towne, ToledoF (fibroblast-adapted) and ToledoE (endothelial cell- 
adapted) laboratory strains of human cytomegalovirus were a kind gift from Dr. Jane 
Grundy, Royal Free and University College Medical School, London, UK 
(MacCormac LP and Grundy JE, 1999). AD 169, Towne and ToledoF were 
propagated by the serial inoculation of cell-free virus on uninfected fibroblasts for 1 
hour at 37°C in 5% CO2 , after which the supernatant was removed and the fibroblasts 
were maintained in medium containing 4% FCS. To prepare the virus-free inoculum, 
each strain was harvested from the supernatant fluids of infected fibroblasts at days 4 
to 7 post infection, clarified by centrifugation at 800g for 20 minutes and stored at - 
80°C until use. ToledoE (to maintain consistency we called it ToledoE, although it is 
likely that it is not the prototype Toledo strain) was propagated by the serial 
inoculation of cell-free virus on uninfected human umbilical vein endothelial cells, by
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centrifugation at l,500g for 1 hour and subsequent incubation at 37 °C in 5% C 02. 
Virus-free inoculum was prepared in the same manner for the other strains. AD 169, 
Towne, ToledoF had been highly passaged in fibroblasts for many years, while 
ToledoE had been initially passaged in fibroblasts and then adapted for growth in 
endothelial cells.
2.1.7 Viral infection of cell monolayers
35mm dishes or 25cm2 flasks were seeded with 5xl05 or 106 cells (p4 HUVEC or p27 
MRC-5), respectively. These were left in a 5%C02, 37°C incubator overnight. The 
media was removed and the cells washed three times with PBS. The cells were 
infected with virus diluted in cell culture medium. The flasks were incubated for 1 
hour, the inoculum removed and the cells washed three times with PBS. Finally, cell 
culture medium was added and the cells were harvested at several time-points post 
infection.
2.1.8 Titration of infectious dose
The virus stock titre was evaluated in slides by DEAFF (detection of early antigen 
fluorescent foci) test for immediate early/early antigen (IEA/EA) 24 hours post 
infection. HEL fibroblasts were cultured in 8-well glass slides. The monolayer was 
infected in duplicate with 250pl of the appropriate virus, in 2-fold dilutions from 10'1 
to 10"4. The slides were incubated for 1 hour in a 37°C 5% C 02 incubator. The 
inoculum was removed and the wells were washed once with medium supplemented 
with maintenance media. After 24 hours, the culture medium was removed and the 
monolayer was fixed with 80% cold acetone for 10 minutes at room temperature. The 
slides were air-dried and tested for IEA/EA positive cells by incubating them with the 
primary antibody for 30 minutes at 37°C. The slides were washed, air-dried, FITC- 
labelled goat anti-mouse Ig was added, and incubated for a further 30 minutes at 
37°C. After the cells were washed and air-dried, they were mounted with 30% 
glycerol/PBS solution (Citifluor). The number of antigen forming units (AFU) per ml 
of each virus stock was calculated, based on the number of IE/E antigen positive cells 
in two wells. For the experiments described in Chapter 3, virus stocks were titrated by 
quantitative competitive PCR (QC-PCR) (see section 2.2.1.2).
92
2.2 Viral fitness experiments
2.2.1 Time-courses of infection
In 1992, a quantitative assay was developed for the detection of HCMV nucleic acid 
in clinical samples, by using a modified polymerase chain reaction. This technique 
involved the construction of a control PCR target sequence by PCR mutagenesis to 
allow the post-amplification quantification of HCMV DNA. The control region was 
identical to a sequence within the gB coding part of the virus genome, except that a 
unique restriction site allowed post-amplification differentiation of control/non­
control target amplified product (Fox et al, 1992).
Viral DNA in culture supernatant relates to viral particle presence. To assess the 
comparative levels of DNA in cell culture, a time-course experiment using different 
multiplicities of infection of AD 169 on HEL cells at time points 0, 6, 12, 24, 48, 72 
and 96 hours was set up. A time-course was also performed using ToledoE in HEL 
cells and HUVEC. 35mm2 tissue culture plates were seeded with 5xl05 cells. 
Triplicate plates were grown overnight at 37°C in 5% CO2 . The media was removed 
and the cell sheet washed three times with PBS. Virus was added to the cells and 
incubated at 37°C in 5% CO2 for 1 hour. The viral inoculum was removed (time point 
Oh) and the cells washed three times with PBS, maintenance media was replaced and 
incubated for the appropriate time period. The cells were harvested for each time 
point and DNA was extracted. QC-PCR was used to quantitate the levels of HCMV 
DNA in infected cells.
2.2.1.1 DNA extraction
DNA extraction was performed using the Puregene extraction kit (Flowgen). The 
media was removed from the cell monolayer and 600pl of the cell lysis solution were 
added with vigorous pipetting, to ensure complete cell lysis. The lysate was 
transferred to a 1.5ml Eppendorf tube, 3 pi of RNAse were added, the tube was 
inverted several times and incubated at 37°C for 15 minutes. The lysate was allowed 
to cool at room temperature, 200pl of protein precipitation solution were added, 
vortexed vigorously and centrifuged at 13,000g for 3 minutes, leaving the DNA in the
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supernatant. This was precipitated with 600pl of 100% isopropanol in a new 1.5ml 
eppendorf tube by inverting the tube and centrifuged at 13,000g for 1 minute. The 
DNA was washed twice with 600pl of 70% ethanol, re-suspended in distilled water 
and stored at -70°C.
2.2.1.2 Quantitative competitive PCR
The PCR reaction mix was initially prepared. For 1 sample (including an extra sample 
to allow accurate aliquoting), the mix contained the following ingredients: 75.8pl 
H2O, lOpl lOxPCR buffer, 2pl 25mM MgCh (2mM final), 3 pi dNTPs, lpl gBl 
forward primer (lOOng/pl), lpl gB2 reverse primer (lOOng/pl), and 0.2pl Taq DNA 
polymerase (5U/pl). 93pi of the reaction mix were aliquoted to 0.75ml PCR tubes and 
overlaid with 4 drops of mineral oil. The following primers were used:
QCgbl 5’ GAG GAC AAC GAA ATC CTG TTG GGC A 3’ (nt 81683-81707) 
QCgb2 5’ GTC GAC GGT GGA GAT ACT GCT GAG 3 3’ (nt 81580-81558)
5pi of sample DNA were added to the PCR reaction mixture. The control plasmid 
(stock: 108 copies/2pl) was diluted with water to 5xl03, 103 and 102copies/2pl. Each 
control plasmid dilution was then vortexed for ~45 seconds before adding the 2pl of 
the appropriate dilution to the PCR reaction mixtures. In the samples, positive and 
negative controls were included. The tubes were placed in the thermocycler-Hybaid 
omnigene machine.
Cycling conditions consisted of:
Temperature Duration N° cycles
(°C)
95 15min 1
94 30sec
60 30sec 40
72 30sec
72 lOmin 1
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Agarose gel electrophoresis
A 2% agarose gel was prepared by adding 2g of agarose to 100ml of lxTBE in a 
200ml glass bottle. The agarose solution was boiled in a microwave to dissolve the 
agarose and 3 pi of lOmg/ml ethidium bromide were added to 100ml of the solution. 
The solution was then allowed to cool to ~50°C. The gel was poured and allowed to 
set. 3jjl1 of DNA loading dye were added to the wells in a microtitre plate to which 
I O j j l I  of the PCR reaction would be added. The gel was electrophoresed in lxTBE 
buffer at 80mA, visualized under UV light and photographed using Polaroid film.
Restriction enzyme digestion o f  PCR products
The reaction mixture (for 1 sample) consisted of: 7.5pl H2O, 2pl lOxbuffer and 0.5pi 
Hpal. 10(4,1 of the reaction mix were added to lOpl PCR reaction in a 1.5ml 
microcentrifuge tube, and incubated at 37°C for 2 hours.
Polyacrylamide gel electrophoresis
A 12% acrylamide gel was prepared using the following recipe: 6ml H2O, 3ml 40% 
acrylamide solution, 1ml lOxTBE, 75pl 10% APS and 7.5pi TEMED. Each sample 
was loaded onto the gel and run at 40mA. An ethidium bromide solution was prepared 
by adding 1.5pl of lOmg/ml EtBr to 100ml of lxTBE. The gel was placed in solution, 
stained for 5 minutes and photographed.
lOxTBE buffer: 432gr Tris base (Sigma)
220gr Boric acid (Sigma)
37.2gr EDTA (Sigma) —1
Diluted in water
2.2.2 Co-infection experiments
Virus stocks were mixed together in known ratios to infect HEL fibroblasts (all 
experiments performed in triplicate). Cells and supernatants were harvested at several
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time-points after absorption and DNA was extracted from cells as described in section 
2 .2 . 1. 1.
2.2.2.1 Qualitative PCR
PCR was used to amplify a 583-586bp (size difference due to sequence variability 
between the strains) segment of the CMV gB gene flanking the gp55 cleavage site 
(Chou et al, 1992, 1992). The following primers were used:
5 ’ CTG GGA AGC CTC GGA ACG 3 ’ gB 1
5’ ACC CAT GAA ACG CGC GGC 3’ gB2
Sequences of the gBl and gB2 primers correspond to nucleotides 1200-1217 and 
1765-1782, respectively. The PCR reaction mix was initially prepared. For 1 sample, 
the mix contained the following ingredients: 77.8pl H2O, lOpl lOxPCR buffer, 2pi 
25mM MgCb (2mM final), 3pi dNTPs, lpl gBl forward primer (lOOng/pl), lpl gB2 
reverse primer (lOOng/pl), and 0.2pl Taq DNA polymerase (5U/pl). 95pl of the 
reaction mix were aliquoted to 0.75ml PCR tubes and overlaid with 4 drops of 
mineral oil. 5pl of sample DNA were added to the PCR reaction mixture. The tubes 
were placed in the thermocycler-Hybaid omnigene machine, and the following 
cycling conditions were applied:
Temperature Duration N° cycles
(°C)
95 15min 1
94 60sec
60 60sec 39
72 2min
72 lOmin 1
The PCR products were checked on agarose gels. When no products were derived 
from the first round of amplification, a nested PCR was performed. 2pl of the product 
were added to a PCR reaction mixture (as before) and the same cycling conditions 
were performed, this time using 20 cycles.
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22.2.2 Restriction fragment length polymorphism
For restriction endonuclease digest analysis, 9[il of PCR product were incubated with 
lpl of Maelll (Boehringer Mannheim) at 55°C for 2 hours. The resulting DNA 
fragments were separated on 3% agarose gels and visualized by EtBr staining. The 
number of DNA base pairs in each fragment for Towne was expected to be 281, 153, 
and 152; for AD 169 was 188, 153, 152, and 90. The ratios of the two viral DNA 
quantities within cells and cell culture supernatants were estimated using NIH image 
software (http://rsb.info.nih.gov/nih-image/, Kidd et al, 2000).
2.2.2.3 Calculation of viral fitness
The relative fitness (replication rate) differences between the two HCMV variants was 
calculated according to the formula:
S=l/t ln[q(t)p(0)]/[p(t)q(0)],
where q is the proportion of the more fit variant at time 0 and time t, whilst p is the 
proportion of the less fit variant at time 0 and time t (Goudsmit et al, 1996).
2.3 Creation of array probes
2.3.1 PCR amplification
DNA was purified from HEL fibroblasts infected with ToledoE using the Puregene 
extraction kit, as described in section 2.2.1.1 The concentration of the purified DNA 
was calculated from the UV absorbance at 260 nm using a UV spectrophotometer.
Primers were designed for the selected HCMV genes (Table 2.1) and PCR was 
performed for each pair of these primers using a thermal cycler. PCR conditions, such 
as primer concentration and annealing temperature, were optimised for each primer 
set.
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The PCR reaction mix was initially prepared. For 1 sample, the mix contained the 
following ingredients. 80.8pi distilled water, lOpl lOxPCR buffer, 2pl 25mM MgCb 
(2mM final), 3pl dNTPs, lpl of each primer (lOOng/pl or 200ng/pl) and 0.2pl Taq 
DNA polymerase (5U/pl). 98pl of the reaction mix were aliquoted to 0.75ml PCR 
tubes and overlaid with mineral oil. 2pl of sample DNA were added to the PCR 
reaction mixture.
The following cycling conditions were used:
Temperature
(°C)
Duration N° cycles
95 15min 1
94 30sec
55 or 60 30sec 40
72 30sec
72 lOmin 1
Primer Design Criteria (For Table 2.1): 20-22 bases long
-50% GC content 
End in C or G 
Avoid AAA... TTT repeats 
300-3 5Obp fragment amplified
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Gene PCR
product
bp
Primer sequences Primer
ng/pl
UL18 197 a t a g c g a g c c t c a a t g
g t t a g c t g t c g g g t g a t c a g g g
100
gB 149 c t g g g a a g c c tc g g a a c g
a c c c a t g a a a c g c g c g g c
100
UL130 350 t g c g g c t t c t g c t t c g t c a c
g t t g c g a c c g c t c a g a t a c c
200
UL 132 276 t t c a t a g c g g t a c t g a t c g c
g a t g a c g t t c t c a g g a t c a t
100
UL 133 330 a t g g g t t g c g a c g t g c a c g a
g t a a c a c g c tg a a c a g c a g c
200
UL 134 342 a c c a g g g a a g c c a g t c c g g t a
c c a t g c c g c a g a t g c c a c c c
200
UL 135 334 g a g a t tc c a a g c a g g a g a g a
t a t c g g c a g a c c a t c c t c t c
100
UL 136 336 a t g t c a g t c a a g g g c g t g g a g
c t c g g g a t a a t g a c a g c c g c a a
100
UL 137 260 t t c a g c g g c a g a t c g t c c a t
c a c t g c t g c c a g a a t g g a t g
100
UL 138 278 c t c g t g c t g a t c g t g g c c a t
c a a c g g a c c a a g a t c t c g t c
200
UL 139 295 c c a c t a c a g g t a c c a g c t c t a
g g t a a c g t t g c g t c g g a a g a
100
UL 140 289 c g c t c a g a c t a a c g c g a c t a
c g t a c g a t g a c a c g c t g t t a
200
UL 141 258 g c a t g c g t c t c t g t g a a a a a
a g g a g t g t g t c a t g a c c g t g
200
UL 142 325 c g g t c a t t a t c c a t c g t t a c c
c g c a a g t g t g a t t c t c t t g c a g
100
UL 143 211 g a c g a t t c g g a t t c a a c a c a
a a g c t g a t g g a c g t t g g t t g
200
UL 144 331 a t g a a g c c t c t g a t a a t g c t c
g a t g t t g g a c g c c t g g a g t g
100
UL 145 241 c c a t c a t g c g t c g t a t c a c g
c a t c g a g g a g t c a t c g t c g c t
200
UL 146 190 t a t t g g c t t c a t c g c g a t c c
g t c t c g g t c c t g g t g a t t t c
100
UL 147 247 g c a a t c g t c a g g a a g t g c t g g
c a g c g c a g t c t g a a g t g g t g
200
UL 148 244 a g a t g g c c t t a c a g g t g g a g
a g c a a t g t g t t g a g g t a c t g
100
UL 149 193 g g t g g a t c a g t g t t g c t a t c
g t a c g c g t g a g t c t c t g t t c
100
UL 150 296 g c g a c a t g t t g c t t c g t c t a
t c c t t g a a c g t c t g t g g t t g
200
UL 151 303 t g c t g t g g c g t a t t g t t c t c
c t a t c a g a a c c g c c g c t a t t
100
Table 2.1. Sequences and concentrations of primers used to construct the HCMV- 
human microarray.
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2.3.2 PCR product purification
The PCR products (80pl) were analysed on 1% Nusieve low-melting agarose gel at 
100V for 1 hour. The gel was placed under UV light, the DNA bands were excised 
and put in 1.5ml eppendorf tubes. 3 volumes of Buffer QG (Guanidine thiocyanate, 
Qiagen) were added to 1 volume of gel and incubated at 50°C for 10 minutes. 1 
volume of isopropanol was added and the samples were mixed, applied to a QIAquick 
column and spun at 13,000rpm for 1 minute. The flow-through was discarded and the 
column was placed back in the collection tube. 0.5ml of Buffer QG was added to the 
column and centrifuged again for 1 minute. The flow-through was discarded, 0.75ml 
of Buffer PE (50% ethanol, lOmM Tris-HCl pH=8.5) was added, the column was left 
to stand for 5 minutes and centrifuged for 1 minute. The flow-through was discarded 
and centrifugation was repeated. The column was placed into a clean 1.5ml eppendorf 
tube and 50pl of RNase-free water were added to the centre of the membrane. The 
column was allowed to stand for lmin, centrifuged twice and discarded. The samples 
were stored at -20°C. 5 pi of the purified PCR products were run on 3% agarose gel.
2.3.3 Cloning
PCR products were cloned into pGEM-T Easy (Promega). A description of the 
cloning procedure follows.
Optimisation of insert:vector molar ratios
The insert to vector molar ratios were optimised for each product to be ligated, using 
the following formula:
50ng vector x v kb insert x 3 = z ng insert 
3 kb vector
Ligations
The vector and control insert DNA tubes were briefly centrifuged and the ligation 
reactions were set-up according to the following table:
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Materials Reaction
Oil)
Positive control
M )
Background 
control (pi)
2x rapid ligation 
buffer
5 5 5
Vector (50ng) 1 1 1
PCR product X - -
Control insert 
DNA
- 2 -
T4 DNA ligase 1 1 1
dH20  (lOpl final 
volume)
y 1 3
The reactions were mixed by pipetting and incubated at 4°C overnight. 
Transformations
The tubes containing the ligation reactions were briefly centrifuged and 2pi were
o
added to a sterile 1.5ml eppendorf tube on ice. JM109 competent cells (10 cfu/pg 
DNA) were thawed on ice for 5 minutes. 50pl of cells were transferred to each tube 
containing the ligation reactions and left on ice for 20 minutes. The cells were heat- 
shocked at 42°C for 45 seconds and returned to ice for 2 minutes. 950pl of room 
temperature LB broth (20gr LB base/litre dH20 ) were added to the transformed cells 
and incubated at 37°C (shaking) for 1.5 hours. Two LB agar plates were prepared for 
each ligation reaction, as follows:
15gr agar/lt LB broth
640pl of 50mg/ml X-Gal (5-bromo-4-chloro-3-indolyl-i-D-galactoside)
2ml of lOOmM IPTG (isopropylthiogalactoside)
400pl of 50mg/ml ampicillin
lOOpl of each reaction were plated and incubated at 37°C overnight. Bacterial 
colonies containing the PCR product were identified by their white colour due to 
disruption of the LacZ ORF and therefore the ability to convert X-Gal to its blue 
colour. They were picked from each plate, added to 5ml of LB broth with ampicillin 
and incubated at 37°C (shaking) overnight.
Glycerol stocks
850pl of the overnight culture were mixed with 150pl of glycerol and stored at -70°C.
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2.3.4 Plasmid DNA purification
1.5ml of overnight culture were transferred to 1.5ml eppendorf tubes and centrifuged 
at 13,000rpm for 5 minutes. The cells were re-suspended in 250pl of Buffer PI 
(50mM glucose, 25mM Tris-HCl pH=^, lOmM EDTA pH=8, lOOpg/ml RNaseA). 
250pl of Buffer P2 (0.2N NaOH, 1% SDS) were added and the tubes were inverted 4- 
6 fimes (Qiagen plasmid DNA preps kit). 350pl of Buffer N3 (3M Guanidine-HCl 
pI04.8) were added, inversion was repeated and the tubes were centrifuged for 10 
minutes. The supernatants were applied to a column, centrifuged for 1 minute and the 
flow-through was discarded. 0.5ml of Buffer PB (Guanidine hydrochloride and 
isopropanol) was added and the flow-through was discarded by centrifugation. 0.75ml
of Buffer PE (50% ethanol, lOmM Tris-HCl pH=7) was added, the columns were
/
centrifuged for 1 minute, the flow-through was discarded and centrifugation was 
repeated for 1 minute. The columns were placed in clean tubes, 50pl of RNase-free 
water were added and the purified DNA was collected by centrifugation. The samples 
were stored at -20°C until use.
2.3.5 PCR of purified clones
Clone identities were verified by PCR with the primers originally used to amplify the 
insert. 2pl of purified plasmid DNA were added to the PCR reaction mix described 
previously (section 2.3.1), and the following cycling conditions were used:
Temperature Duration N° cycles
(°C)
95 15min 1
94 30sec
60 30sec 30
72 30sec
72 lOmin 1
5 pi of the PCR products were run on 2% agarose gel.
2.3.6 DNA sequencing
The identity of the clones was also confirmed by DNA sequencing using an 
automated application of the chain-termination method (Sanger et al, 1977). 2pl of
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plasmid DNA were added to 8pl of distilled water, the mix was placed at 100°C for 3 
minutes and centrifuged. 5pi of this was mixed with lpl T7 primer 
(TAATACGACTCACTATAGGG) and 4pl of sequencing mix (containing dATP, 
dCTP, dTTP, dITP, ddUTP, ddGTP, ddCTP, ddATP and DNA polymerase in Tris 
buffer, pH 8.9). The PCR mixture was placed in a thermal cycler and subjected to the 
following conditions:
Temperature
(°C)
Duration N° cycles
96 4min 1
96 20sec
50 20sec 30
60 4min
This sequencing reaction incorporates fluorescent di-deoxynucleotides into daughter 
DNA strands. DNA was precipitated from the sequencing reaction by adding 2pl 
sodium acetate (3M), 2pl EDTA (lOOmM, Sigma) and 1 pi glycogen (20mg/ml, 
Beckman Coulter) in a final volume of 20 pi, vortexing, and then adding 60pl 100% 
ethanol (-20°C) and leaving on ice for 10 minutes. DNA was pelleted by 
centrifugation at 14,000rpm for 15 minutes at room temperature. The supernatant was 
removed, the pellet washed with 200pl 70% ethanol/water (-20°C), and the tube left 
open at room temperature until dry. DNA was re-suspended in 40pl de-ionised 
formamide (JT Baker) for 5 minutes and transferred to a 96-well plate. The sequences 
were determined using an automated capillary DNA sequencer (Beckman Coulter) 
following the manufacturer’s instructions.
2.3.7 PCR of cloned DNA for arrays
The clones were amplified using common pGEM-T Easy vector primers. These 
primers anneal at the terminal base before the TA cloning site:
pGEM 5’ GCATGGCGGCCGCGGGAATT
PGEM 3 ’ GGCGGCCGCGAATTCACTAG
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Similarly, sequences from cellular genes and KSHV were amplified, to use as positive 
and negative hybridisation controls. Probes were amplified from a 1:40 dilution of 
purified plasmid DNA in distilled water by PCR in 96-well plates. The constituents of 
each individual PCR reaction were 77.5pl distilled water, lOpl PCR buffer (20 mM 
MgCh), 2pi dNTPs (10 mM), 4pl each primer (lOOpM), 0.5pl Taq DNA polymerase 
(5U/pl) and 4pl DNA. The cycling conditions used were:
Temperature
(°C)
Duration N° cycles
94 2min 1
94 30sec
55 30sec 40
72 30sec
72 7min 1
2.3.8 PCR product purification
The PCR products were purified using the QIAquick 96 PCR Purification Kit 
Protocol (Qiagen). 3 volumes of buffer PM were added to one volume of PCR 
sample. 200pl of PCR product (for pGEM-T Easy clones this constitutes lOpg DNA) 
were used. The mixtures were added to the QIAquick plate on a vacuum manifold and 
vacuum was applied. After all liquid was pulled through, the vacuum was switched 
off, the wells were washed with 900pl of buffer PE and vacuum-dried for 10 minutes. 
Washing was repeated. Maximum vacuum was applied for an additional 10 minutes 
to dry the membrane. To elute the DNA, lOOpl of buffer EB were added to the centre 
of each well and vacuum was applied for 5min. lOOpl of purified DNA was 
precipitated with 30pl ammonium acetate (8M) and 125pi isopropanol (-20°C). This 
was left on ice for 2 hours and subsequently centrifuged at 2,300g for 1 hour at 4°C to 
pellet the DNA. The plates were inverted to remove supernatant and the DNA pellets 
washed with lOOpl 80% ethanol (-20°C) and centrifuged again at 2,300g for 30 
minutes at 4°C. The plates were inverted once more and all supernatant removed by 
spinning the plates upside down at 20g for 1 minute. Each purified PCR product was 
re-suspended in 5pi of distilled water (2pg/pl) for printing on glass to create the 
HCMV-human microarray.
104
2.3.9 Array printing
HCMV probe DNA sequences along with 5428 probes for human genes (Clark et al, 
2002), were spotted onto glass slides (Nunc, USA). This was performed by Nicola 
Cattini at the Institute of Cancer Research (Sutton, UK), using a Flexis gridder 
(Genomic Solutions, UK).
2.4 Time-courses of infection
Two time-course experiments using O.OlAFU/cell (antigen forming units/cell) of 
ToledoE in fibroblasts and HUVEC at time points 0 (time of inoculum removal), 6, 
12, 24, 48, 72 and 96h were set up. 25cm2 tissue culture flasks were seeded with 106 
cells. Duplicate flasks were grown overnight at 37°C in 5% CO2 . The media was 
removed and the cell sheet washed three times with PBS. Virus was added to the cells 
and incubated at 37°C in 5% CO2 for 1 hour. The viral inoculum was removed and the 
cells washed three times with PBS, replaced with cell culture media and incubated for 
the appropriate time period. RNA was extracted for each time point, which was used 
for subsequent hybridisation with microarrays. An aliquot of the RNA was kept to 
perform RT-PCR, as described in section 2.12. A time-course was also performed 
using AD 169 in MRC-5 cells.
2.5 Total RNA extraction
After the appropriate incubation period the flasks were removed from the incubator 
and the media discarded. 2.5ml TRIZOL (Gibco LifeTechnologies) were added 
directly onto the cell sheet, left for 5 minutes and the cell lysate was passed several 
times through a pipette. 1.25ml aliquots were transferred to RNase-ffee tubes and 
stored at -80°C. The frozen lysate was thawed at 37°C in a water bath and centrifuged 
at 12,000g for 10 minutes at 4°C. The supernatant was transferred to a new tube and 
incubated at room temperature for 5 minutes before 250pl chloroform were added and 
the tube shaken for 15 seconds. The tube was further incubated for 3 minutes at room 
temperature and centrifuged at 12,000g for 15 minutes (4°C). The aqueous phase was 
transferred to a new tube, and the lower phenol phase containing DNA and protein 
was stored at -80°C. 625pi chloroform were added to the aqueous phase, the tube 
shaken for 15 seconds and incubated at room temperature for 3 minutes. The tube was
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centrifuged at 12,000g for 15 minutes (4°C) and the aqueous phase transferred to a 
new tube. 625pi isopropanol were added, the tube vortexed and incubated at room 
temperature for 10 minutes. It was then centrifuged at 12,000g for 15 minutes (4°C). 
The supernatant was removed and 1ml 75% ethanol was added to the RNA pellet. 
Vortexing and centrifugation at 7,500g for 5 minutes (4°C) followed. The supernatant 
was removed and the pellet centrifuged at 13,000rpm for 1 minute at room 
temperature. The last traces of ethanol were discarded and the RNA pellet was air- 
dried at room temperature for 5 minutes. Finally, the pellet was re-suspended in 50pl 
of RNase-ffee water.
DNasel treatment o f RNA
After RNA extraction, the samples were treated with DNasel (Promega) to remove 
contaminating DNA. The following ingredients were added to the RNA:
RNA (lpg/pl) lOOpl
DNase buffer 20pl
DNase I (lU/pl), lOpl 
Distilled water 70pl
The tubes were incubated at 37°C for 1 hour and terminator solution was added (1/10* 
total volume) (0.1M EDTA, lpg/pl glycogen) to stop the reaction.
RNA purification and precipitation
An equal volume of phenol:chloroform:isoamyl alcohol (Sigma) was added to the 
reaction mix, the tube was vortexed for 10 seconds and centrifuged at 13,000rpm for 10 
minutes at room temperature. The top aqueous layer was transferred to a new tube and 
phenol:chloroform extraction was repeated. The top layer was transferred again and 
1/5th volume 8M ammonium acetate and 2.5vol. 95%ethanol were added. The tube was 
incubated at -20°C for 2 hours and centrifuged at 14,000rpm for 30 minutes (4°C). The 
supernatant was removed, and 200pl of ice-cold 80% ethanol were added to the pellet.
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Spinning was repeated as before and the supernatant was removed. The pellet was 
allowed to dry for 5 minutes, re-suspended in 30pl DEPC-water and stored at -80°C.
RNA quantitation
The RNA was quantified by diluting 2pi of the RNA solution in 498pl DEPC water, 
and measuring the absorbance at 260nm in a spectrophotometer. The concentration of 
RNA (pg/ml) was calculated using the following formula:
A260nmX dilution factor x 40(pg/ml)
0.5pg of total RNA was separated electrophoretically on a 1% agarose gel lpg  to 
verify the integrity of the RNA.
2.6 mRNA purification
mRNA was purified from total RNA extracts using the Oligotex mRNA midi kit 
(Qiagen). The reaction mixture volumes were made up according to the total amount 
of RNA that had been extracted per sample. To the lOOpl of RNA solution, 150pl 
DEPC water, 250nl buffer OBB (37°C [20mM Tris-Cl, pH 7.5, 1M NaCl, 2mM 
EDTA, 0.2% SDS]) and 15pl Oligotex™ (incubated at 37°C [10% w/v suspension in 
lOmM Tris-Cl pH 7.5, 500mM NaCl, ImM EDTA, 0.1% SDS, 0.1% NaN3]) were 
added. After mixing, the tubes were incubated at 70°C for 3 minutes followed by 
incubation at room temperature for 20 minutes. The tubes were centrifuged at 
13,000rpm for 2 minutes and the supernatant removed. The pellet was re-suspended in 
400pl buffer OW2 (lOmM Tris-Cl pH 7.5, 150mM NaCl, ImM EDTA) and the 
solution transferred onto the top of a spin column. The columns were centrifuged at 
13,000rpm for 1 minute at room temperature and the flow through discarded. The 
Oligotex was re-suspended in 400pl buffer OW2 and the columns centrifuged for a 
further 1 minute at 13,000rpm. The flow through was discarded and the spin column 
transferred to a new tube. The Oligotex was re-suspended in 200pl buffer OEB 
(incubated at 70°C [5mM Tris-Cl pH 7.5]) and the columns spun at 13,000rpm for 1 
minute. A further 200pl buffer OEB (70°C) were added and the columns were
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centrifuged again. The flow-through containing the mRNA was kept and quantified 
by measuring the absorbance of 50pl of mRNA solution at 260nm in a 
spectrophotometer using an RNase-ffee UVette (Eppendorf). The mRNA samples 
were concentrated by pipetting 400pl of mRNA onto the top of a Microcon-30 filter 
in a Microcon 1.5ml tube (Millipore). The filters were centrifuged at 14,000g for 7 
minutes at room temperature and transferred inverted into a new tube. They were 
finally centrifuged at 1,000g for 3 minutes at room temperature to obtain the purified 
mRNA
2.7 In vitro amplification of RNA
Gene profiling using glass arrays typically requires up to 0.1-1 pg of poly(A) RNA to 
enable enough probe to be synthesized for each hybridisation. However, this causes a 
limitation for the microarray technology, since it is often impossible to obtain enough 
RNA from patient blood samples and biopsies. The same problem can be encountered 
in vitro, where a limited amount of cells must sometimes be used in order to achieve a 
high multiplicity of infection with a low titre virus. Therefore, a technique has been 
developed to allow amplified RNA to be generated (aRNA) (Van Gelder et al, 1990). 
The procedure consists of reverse transcription with an oligo(dT) primer bearing a T7 
promoter and in vitro transcription of the resulting DNA with T7 RNA polymerase, 
generating hundreds of antisense RNA copies of each mRNA in a sample. A 
description of the method follows (Salunga et al, 1999).
The following were mixed in a 0.5ml PCR reaction tube:
Reagent Volume (|il)
Total RNA (lpg) 10
01igodT-T7 primer (0.5pg/|xl) 1
OHgodT(21)-T7 primer (MWG).
5' TCT AGT CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG 
GCG T(21) 3' [56-mer]
These were placed at 70°C for 10 minutes and chilled on ice immediately. The tubes 
were briefly centrifuged and incubated at 42°C for 5 minutes. The first strand master 
mixed was prepared according to the following table.
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Reagent Volume (pi)
5x first strand buffer (Gibco Life Technologies) 4
0.1 DTT (Gibco Life Technologies) 2
1 OmM dNTP mix 1
RNasin (Promega) 1
Superscript RTII (Gibco Life Technologies) 1
The mastermix was added to the samples and incubated at 42°C for 1 hour. 1 pi was 
removed for PCR to check whether intact cDNA was successfully obtained. The 
following PCR mastermix was prepared:
Reagent Volume (pi)
1 OxPCR buffer (Qiagen) 5
lOmM dNTPs (Promega) 1
Forward primer (lOOng/pl) 2
Reverse primer (lOOng/pl) 2
Taq DNA polymerase (5 U) (Qiagen) 0.5
Sterile water 38.5
The mix was subjected to the following cycling conditions and the PCR products 
were run on agarose gels.
Temperature
(°C)
Duration N° cycles
95 2min 1
95 30sec
54 30sec 40
72 2min
72 7min 1
The following second strand master mix was prepared, added to the remainder (19pl) 
of the first strand reaction and placed at 16°C for 2 hours.
Reagent Volume (pi)
Second strand synthesis buffer (Gibco Life Technologies) 30
1 OmM dNTPs 3
DNA poll (Gibco Life Technologies) 4
E.Coli RNaseH (Gibco Life Technologies) 1
E.Coli DNA ligase (Gibco Life Technologies) 1
DEPC water 92
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2pl of T4 DNA polymerase (Gibco Life Technologies) were added and followed by a 
further incubation at 16°C for 10 minutes. The samples were extracted once with 
phenol/chloroform/isoamyl alcohol (25:24:1) (Sigma) and the aqueous layer was 
collected. The aqueous layer was loaded onto a Microcon-100 column (Millipore) and 
the volume in the column was brought up to 500pl with DEPC water. This was 
centrifuged at 500g for ~14 minutes and two more rinses were performed. The 
column was inverted into a clean 1.5ml tube and the sample was collected by 
centrifugation at l,000g. The sample volume was reduced to 8pl by vacuum 
centrifugation.
In vitro transcription (IVT) and purification
The Ampliscribe T7 transcription kit (Cambio) was used for the in vitro transcription. 
The transcription mix was prepared adding the reagents in the following order:
Reagent Volume (pi)
1 Ox Amp T7 buffer 2
ATP 1.5
CTP 1.5
GTP 1.5
UTP 1.5
0.1MDTT 2
These were added to the 8pl of the ds cDNA along with 2pi of T7 RNA polymerase 
and the mixtures were incubated at 42°C for 3 hours. 1 pi of RNase-ffee DNase was 
added and placed at 37°C for 15 minutes. The aRNA was purified as before and 
quantitated using the RNA 6000 Nano Assay (Agilent Technologies), according to the 
manufacturer’s instructions. In some instances two rounds of amplifications were 
performed to obtain enough aRNA for microarray hybridisations. A description of the 
generation of second round aRNA follows. Initially lpl of random hexamers was 
added (Pharmacia) to the aRNA, the mixture was then heated at 70°C for 10 minutes, 
chilled on ice and centrifuged briefly. The sample was allowed to equilibrate at room 
temperature for 10 minutes. The first strand master mix was prepared according to the 
following table:
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Reagent Volume (pi)
5x first strand buffer (Gibco Life Technologies) 4
0.1 DTT (Gibco Life Technologies) 2
1 OmM dNTP mix 1
RNasin (Promega) 1
Superscript RT II (Gibco Life Technologies) 1
The mastermix was added to the samples and incubated at 37°C for lhour to generate 
a cDNA template, lpl of RNaseH was added and further incubation at 37°C for 20 
minutes followed, to remove RNA from the RNA-cDNA hybrids. The hybrids were 
denatured by incubation at 95°C for 2 minutes and subsequently chilled on ice. lpl of 
the oligo(dT) primer was added and placed at 70°C for 5 minutes, followed by 
incubation at 42°C for 10 minutes to enable primer annealing, then chilling on ice and 
brief centrifugation. Double stranded cDNA generation, followed by in vitro 
transcription were performed as described above, resulting in the second round of 
aRNA.
2.8 Labelling
The isolated RNA, either mRNA or cDNA, was labelled using the CyScribe first 
strand cDNA labelling kit (Amersham Pharmacia Biotech). The following reagents 
were added to 5pg of amplified RNA (or 500ng of mRNA) in a 0.5ml PCR tube on 
ice: lpl random nonamers, lpl anchored oligo(dT) and water to a final volume of 
11 pi. The reaction mixture was incubated at 70°C for 5 minutes in a thermal cycler 
followed by incubation at room temperature for 10 minutes. Subsequently, 4pl 5x 
CyScript buffer, 2pl 0.1M DTT, lpl dCTP nucleotide mix, lpl dCTP CyDye-labelled 
nucleotide (Amersham Pharmacia Biotech) and lpl CyScript reverse transcriptase 
were added to the reaction mixtures. The Cy3 labelled nucleotide was used for control 
RNA labelling and the Cy5 labelled nucleotide was used for sample RNA labelling. 
The reaction mixtures were vortexed, centrifuged for 30 seconds at maximum speed 
in a bench top microcentrifuge and finally incubated at 42°C for 1.5 hours in a 
thermal cycler. The RNA was denatured by adding 2.5pl 0.5M EDTA (pH 8.0) and 
lOpl 0.1M NaOH. The reactions were incubated at 70°C for 10 minutes in a thermal 
cycler. To neutralise the reaction mix, the following reagents were added: lOpl 0.1M 
HC1, 3pl CoT-1 DNA (Gibco Life Technologies), and 450pl TE (pH 8.0). 20pl of the
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mixture was taken for electrophoresis and the remainder was transferred to the top of 
a Microcon filter. The filter was centrifuged at 14,000g for 6 minutes at room 
temperature. 20pl of the filtrate was taken for electrophoresis, the filter transferred to 
a new tube and 300pl TE added. The tubes were centrifuged at 14,000g for 6 minutes 
at room temperature. 20pl of the filtrate was taken for electrophoresis, the filter was 
transferred again to a new tube and 300pl TE added. The tubes were centrifuged at 
14,000g for 6 minutes at room temperature. 20pl of the filtrate was taken for 
electrophoresis and the filter was inverted and transferred to a new tube. The tubes 
were finally centrifuged at l,000g for 3 minutes at room temperature. The final 
volume (less than 12pl) of labelled cDNA was measured and l/25th added to 20pl 
DEPC water for electrophoresis. The filtrate samples (20pl each) were run on a 1% 
agarose gel (no ethidium bromide), at 50V for approximately 2 hours. The 20pl 
samples were loaded in 2pl Orange G loading dye, which is non-fluorescent. The gel 
was visualised using the Storm 860 phospor-screen scanner (Molecular Dynamics) 
and the compatible ImageQuant computer software.
2.9 Hybridisation
The Cy3 and Cy5 labelled probes were made up to 14pl with TE (pH 8.0) and the 
hybridisation mixtures were made as follows: 12pl 20x SSPE (Sigma), 1.1 pi 0.5M 
EDTA, 2pl poly CIA40-60 (Amersham Pharmacia Biotech), 2pl yeast tRNA (Sigma), 
14pl Cy3 probe, 14pl Cy5 probe, and finally lpl 10% SDS. The mixture was vortexed 
and incubated at 98°C for 2 minutes followed by incubation at 37°C for 20 minutes. 
After incubation, lpl lOOx Denhardt’s solution (Sigma) was added to the probe 
mixture, and the mix centrifuged at 13,000rpm for 15 minutes at room temperature. 
The arrays were handled with forceps and only held by the very edges to avoid 
damage to the area of the slide containing the DNA. The arrays were denatured by 
immersing them in Milli-Q distilled water (95°C) for 2 minutes, and then in 95% 
ethanol for a further 2 minutes. The arrays were dried by centrifugation in a clean, 
empty 50ml Falcon tube at lOOOrpm for 2 minutes at room temperature. The 
denatured arrays were transferred to the pre-heated hybridisation chambers, which 
were kept at 65°C on top of a hot block. The arrays were placed in the chambers with 
the DNA side facing upwards and were heated for 15 minutes on the hot block. The 
cover slips were cleaned, by immersing them in 95% ethanol for 2 minutes. They
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were then dried by centrifugation at l,000rpm for 2 minutes. The probe (46pl) was 
quickly transferred to the top of the array (on top of a 65°C hot block) in the chamber 
and the cover slip was quickly and carefully placed over the probe. 150pl 4xSSPE 
(65C) were added to the hybridisation chamber next to the array, and the chamber lid 
placed on and secured in place using screws. The chamber was quickly transferred to 
a 65°C water bath and incubated overnight.
The array chamber was removed from the 65°C water bath and transferred to the top 
of a hot block at 65°C for dismantling. The array was carefully removed and 
immersed in 2xSSPE at 50°C until the cover slip became dissociated from the array. 
The array was then immersed in 2xSSPE for 2 minutes at room temperature (with 
rolling). The array was subsequently washed in lxSSPE for 2 minutes at room 
temperature followed by 0.1 x SSPE for 3 minutes at room temperature. Subsequently, 
the array was dried by transferring it to a clean 50ml Falcon tube followed by 
centrifugation at l,000rpm for 2 minutes.
2.10 Array scanning
The arrays were scanned at 10pm resolution using the GenePx 4000B array scanner 
(AmershamPharmacia, Axon instruments, Molecular Dynamics) and the images 
analysed using GenePix Pro 3.0 software. Cy3 and Cy5 fluorophores were 
simultaneously excited at 532 nm and 635 nm respectively and the resultant omitted 
light detected with two PMTs. The voltages across the PMTs were adjusted so that the 
signals from the array elements were balanced (PMT around 900V). The GenePix 
software combines the data from the two channels to create a single composite image. 
A spot location and identification template was fitted over the array image using a 
spot-finding software algorithm. All the elements on each array were checked by eye 
and the template altered if necessary, for example if array elements were poor quality 
for any reason they were flagged as bad. Data were extracted from the image by the 
software using the adjusted template and the normalisation factor (average ratio 
between signals in the Cy3 and Cy5 channels) calculated automatically by the 
GenePix software. If this factor was not 1, the PMT voltages were adjusted and the 
microarray re-scanned. Expression ratios were calculated as the median of the ratios
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between the local background-subtracted Cy3 and Cy5 signals on a pixel-by-pixel 
basis by the software. The data were exported to a spreadsheet created in Excel, 
named ArrayAnalyser. The median of ratios were filtered to remove flagged array 
elements and elements for which the signal to background ratio was below 2 in the 
Cy5 channel or 1.5 in the Cy3 channel.
2.11 Array analysis
The final array data were analysed using Cluster software (Eisen et al, 1998). The 
program Cluster assembles a set of items (genes or arrays) into a tree, where items are 
joined by branches proportional to the distance measure between the element pairs 
(short branches, small distances; large branches, large distances). Array elements for 
which expression measurements had been filtered from 20% or more of the arrays 
were removed and the data converted to log base 2. The arrays and genes were 
median centred (the median expression ratio within each array or of each array 
element across all arrays was set to 0). A self-organising map algorithm is then 
applied, in order apply an orientation of nodes generated by hierarchical clustering. 
Genes and/or arrays were clustered by average-linkage hierarchical clustering and the 
results were visualised using the Treeview software (Eisen et al., 1998).
Mann-Whitney U (Wilcoxon-rank) test
The Mann-Whitney test is the non-parametric alternative of t-test. The filtered data 
for 14 arrays were assembled and filtered for genes present in 80% of the arrays and 
then median centred for both genes and arrays in Cluster as before. The data were 
then exported to Excel and the expression ratio for each array element converted into 
ranks relative to that array element across all arrays. A U-value for each array element 
was calculated by:
Ui = nuni2 + ((nii1(nu+1))/2) -  R,
Where:
rij i = the number of filtered expression ratios for the 1th array element in infected 
fibroblasts,
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riit2 = the number of filtered expression ratios for the ith array element in infected 
endothelial cells,
Ri = sum of ranks for the ith array element in the infected cells.
The U values were converted to the standard normal variable for the ith array element 
(Zj) with the equation:
V (ni,lni.2<ni.1+ni,2+1)/12)
The probability associated with each Z-value was calculated in Excel 
(NORMSDIST(ZO).
2.12 Non-array RT-PCR
RT-PCR was performed using the appropriate primers for each HCMV UL/b’gene, to 
verify results from microarray experiments. The reverse transcription reaction using 
the GeneAmp PCR kit (Perkin Elmer) contained: 2pl lOxPCR buffer, 2.8pi MgCk, 
2pl of each deoxynucleoside triphosphate, 1 pi RNase inhibitor, 1 pi random hexamers, 
lpl reverse transcriptase and lpg RNA sample, made up to 20pl with RNase-free 
water. Following the reverse transcription step, PCR was performed for the genes 
using the appropriate primers. Each reaction mix contained 5pi lOxPCR buffer, lpl 
lOmM dNTPs, 200ng of each primer, 2.5U Taq DNA polymerase and lpl of cDNA 
made up to 50pl with sterile distilled water. The thermal cycling conditions consisted 
of:
Temperature
(°C)
Duration N° cycles
95 15min 1
94 30sec
60 30sec 40
72 30sec
72 lOmin 1
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The PCR products were analysed on 1% agarose gel and visualised using ethidium 
bromide under UV transillumination.
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Chapter 3
Fitness differences between AD169. Towne and Toledo
3.1 Introduction
Traditionally, HCMV detection in a sample has been carried out using tissue culture 
techniques. However, these techniques are time-consuming and have a low inherent 
dynamic range. The availability of modem molecular techniques has overcome these 
problems, enabling us to measure viral load ex vivo. Furthermore, quantitative assays 
have been developed in order to differentiate between active and latent infections in 
patients, also providing us with information on disease progression and efficiency of 
antiviral drugs (Gema et al, 1995, 1995). More specifically, in 1992, a quantitative 
assay was developed for the detection of HCMV nucleic acid in clinical samples, by 
using a modified polymerase chain reaction. This technique involved the construction 
of a control PCR target sequence by PCR mutagenesis to allow the post-amplification 
quantification of HCMV DNA. The control region was identical to a sequence within 
the gB coding part of the virus genome, except that a unique restriction site allowed 
post-amplification of control/non-control target amplified product (Fox et al, 1992).
The quantification of HCMV DNA has prognostic value and provides clues into the 
pathogenesis of viral replication (Bowen et al, 1995, Cope et al, 1997, Mutimer et al, 
1997, Bowen et al, 1998, Gor et al, 1998). Additionally, it is a useful tool for fitness 
determinations of different virus subpopulations in cell culture and in vivo, where 
according to Darwinian competition, replication of mixtures of 2 or more virus strains 
would be expected to result in the eventual selection of the fittest vims. Relative 
fitness values, determined by growth competition experiments between two viral 
populations in cell culture and in vivo, can provide insights into the basic features of 
disease progression (Quinones-Mateu et al, 2000). However, the long-term survival 
probability of a virus includes parameters other than replication capacity, such as 
adsorption, internalisation and transmissiblility.
Subsequent to initial vims entry and replication, HCMV disseminates to many organs 
in vivo. However, certain organs such as salivary glands secrete higher levels of vims 
than others and organs show different types of damage (Grundy, 1990). The 
underlying reasons for these observations are poorly understood. Clinical data have 
demonstrated that HCMV strains exhibit different levels of virulence depending on 
their passage history in cell culture (Quinnan et al, 1984, Brown et al, 1995).
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Extensive comparisons of the restriction enzyme profiles of Toledo and a highly 
passaged variant of Towne revealed an additional region of sequence at the right edge 
of the Toledo UL component (Cha et al, 1996), termed UL/b’ region and encoding 19 
ORFs. Although these genes are not essential for replication in vitro, their 
maintenance in clinical isolates suggests that the encoded proteins are important for 
HCMV pathogenesis in vivo. The importance of fitness determinations became 
evident in 1976, when it was proposed that the infecting strain of HCMV is important 
for clinical outcome (Huang et al, 1976), along with the intensity and duration of viral 
replication. High and low passage HCMV strains exhibit tropism differences in vitro, 
suggesting that different tissue tropism may occur in vivo. Indeed, differences in the 
distribution of HCMV infection in leukocytes from tissues of patients have been 
demonstrated (Sinzger et al, 1996). Furthermore, reports have shown that different 
clinical isolates obtained from transplant patients had specific tropisms for different 
cells (Torok-Storb et al, 1993), suggesting that differences in tropism might account 
for differences in pathogenicity.
Apart from phenotypic differences, isolates from different individuals display 
considerable genomic variation as defined by fingerprinting methods such as 
restriction fragment length polymorphism (RFLP). HCMV strains have been 
classified into 4 genotypes based on RFLP of a fragment corresponding to the 
cleavage site of gB (Chou et al, 1991, Chou and Marousek, 1992). gB is an envelope 
glycoprotein, involved in multiple levels of virus replication such as virus entry as 
well as cell-to-cell spread and syncytium formation (Navarro et al 1993, Tugizov et 
al, 1994, Navarro et al, 1997, Meyer-Konig et al, 1998, Wang et al, 2003). The ease 
of identifying the gB genotypes by restriction endonuclease polymorphism has 
facilitated epidemiological studies of the importance of gB genotype with HCMV 
disease outcome. Although specific gB genotypes have been reported to be associated 
with different clinical outcomes of HCMV infection (Fries et al, 1994, Bongarts et al, 
1996, Shepp et al, 1996, Torok-Storb et al, 1997, Trincado et al, 2000), there is 
controversy on the matter, since a number of studies have found no association 
between gB types and subjects with different risks of developing HCMV disease 
(Rasmussen et al, 1997, Gilbert et al, 1999, Arista et al, 2003).
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The aim of this chapter is to determine the replication dynamics of HCMV strains 
ADI69 and Toledo in vitro as well as compare the ability of ADI69 and Towne to 
bind to cells and mediate cell-to-cell spread of infection using pair-wise competition 
experiments in cell culture.
3.2 Results
3.2.1 HCMV strain identification
In order to confirm the identity of the virus strains used in my experiments, RT-PCR 
was performed using RNA extracted from fibroblasts infected with either AD 169, 
Towne or ToledoE, using specific primers for gB, UL18, UL132 and selected UL/b? 
region genes (Figure 3.1). The Towne strain was obtained from the ATCC and has 
been passaged approximately 135 times in fibroblasts. UL136, UL140, UL148 and 
UL151 transcripts were detected in late-stage Towne-infected fibroblasts. Published 
restriction enzyme profiles of Towne between 25 and 32 passages in culture are 
consistent with the presence of the UL/b’ region in the viral DNA (Huang et al, 
1980). Further support for this conclusion was obtained when a portion of the variants 
in the Towne stock from the ATCC (passage 152) were shown by hybridisation to 
contain sequences highly homologous to the novel sequences of the Toledo UL/b' 
region (Duke et al, unpublished data). Therefore, the Towne strain used in my 
experiments is more similar to wild type HCMV than AD 169. I detected UL148 
transcripts in late-stage AD169-infected fibroblasts. This was not an unexpected 
finding, since AD 169 contains a region that shows homology to a part of the UL148 
gene from Toledo (Figure 3.1).
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Figure 3.1. RT-PCR using RNA extracted from fibroblasts infected separately with AD 169 and 
Towne.
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3.2.2 Time-courses of gB DNA in cells infected with HCMV
Viral DNA in culture supernatant relates to viral particle presence. To assess the 
comparative levels of gB DNA in cell culture, a time-course experiment using 
different multiplicities of infection (MOIs) of AD 169 in HEL cells at time points 6, 
12, 24, 48, 72 and 96 hours was set up. A time-course was also performed using 
ToledoE in HEL cells and HUVEC. The presence of HCMV DNA was initially 
confirmed using qualitative PCR (Figure 3.2A). The levels of gB DNA were 
subsequently quantified using QC-PCR (Figure 3.2B), and plotted against time as 
shown in figures 3.3 and 3.4. The results for the time-course of infection using 
AD 169 at different MOIs indicate that DNA levels rose exponentially for each MOI, 
up to 96 hours after infection. Furthermore, the levels of gB DNA were dose 
dependent with the viral inoculum, with increasing levels of DNA detected at 
increasing multiplicities of infection (Figure 3.3).
Estimation of gB DNA levels in fibroblasts infected with either AD 169 or ToledoE 
showed that AD 169 replicated better than ToledoE in fibroblasts, reaching 1.4xl09 gB 
copies/pg DNA, compared to 8x107 gB copies/pg DNA of ToledoE. Assessment of 
the replication of ToledoE in two different cell types, fibroblasts and HUVEC, 
indicated that the virus replicates more efficiently in fibroblasts, as determined by 
peak virus production after 96 hours (8xl07 and 1.9xl07 gB copies/pg DNA, 
respectively) (Figure 3.4). Additionally, the mean doubling times of AD 169 and 
Toledo were calculated over a 72-hour period (Table 3.1). The doubling times in 
fibroblasts were 6.5 and 6.9 hours for each strain, respectively. The doubling time of 
Toledo in HUVEC was 7.3 hours (Table 3.1), indicating that infected fibroblasts and 
endothelial cells produce virus at the same rate but at varying amounts (in this case, 
less virus is produced in endothelial cells).
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Figure 3.2. Figure showing (A) qualitative gB PCR results for HCMV-infected cells 
and (B) an example of quantitative PCR using DNA extracted from fibroblasts 
infected with AD 169.
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Figure 3.3. Levels of HCMV gB DNA produced during an in vitro time-course of 
HEL cells infected with AD 169 at different MOIs.
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Figure 3.4. Levels of HCMV gB DNA produced during an in vitro time-course of 
HEL cells or HUVEC infected with ToledoE.
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Time pi (h) AD 169 in HEL 
(gB/^g DNA)
ToIedoE in HEL ToIedoE in 
HUVEC
inoculum 2xl06 3x106 3xl06
6 3.2x10s 5.7x10s 2x10s
12 1.5xl06 2.2x10s 6.3x10s
24 106 1.9x10s 8X105
48 0.9x10' 4xl06 8.5x10s
72 1.7x10s 3x10' 8.3x106
96 1.4xl09 8xl07 1.9x10'
ti/2 = 6.5h ti/2= 6.9h ti/2=7.3h
Table 3.1. Table showing the levels of HCMV DNA and doubling times in infected 
cells.
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3.2.3 Assessment of ToIedoE infectivity in different cell types
The level of ToIedoE infection in fibroblasts and endothelial cells was evaluated by 
staining for HCMV immediate early and early (IE/E) antigens with specific 
antibodies. The percentage of infection was detected by visual fluorescent 
microscopic examination of cells on cytospins. 24 hours after virus inoculation, IE/E 
antigens were detected in 80% and 40% of fibroblasts and HUVEC, respectively. This 
finding is consistent with previous results showing that ToIedoE replicates to higher 
levels in fibroblasts than endothelial cells (see section 3.2.2). It has been shown that 
HUVEC are not permissive for AD 169, due to inefficient transport of HCMV DNA 
into the nuclei of infected HUVEC (Slobbe-van Drunen et al, 1998). The slightly 
reduced virus entry into HUVEC might explain why even endothelio-tropic HCMV 
strains like ToIedoE, replicate to higher levels in fibroblasts.
(A) (B)
|
Figure 3.5. Detection of IE/A antigens in (A) fibroblasts and (B) HUVEC infected 
with ToIedoE, using immunofluorescence (detected 24h after inoculation).
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3.2.4 Pair-wise competition experiments in vitro
3.2.4.1 Cells, viruses and infections
AD 169 and Towne virus stocks were titrated by QC-PCR and mixed together in 
known ratios to infect HEL fibroblasts (all experiments were performed in triplicates). 
Cells and supernatants were harvested at several time-points after adsorption and 
DNA was extracted from cells (see section 2.2.1.1). PCR was used to amplify a 
segment of the HCMV gB gene (583-586bp), flanking the gp55 cleavage site (Chou 
and Dennison, 1991), containing the major region of sequence variability within this 
gene (Chou, 1992). For restriction endonuclease digest analysis, PCR products were 
incubated with Maelll and the resulting DNA fragments were separated by agarose 
gel electrophoresis. The number of DNA base pairs in each fragment for Towne was 
281, 153, and 152; and for AD169 was 188, 153, 152, and 90 (Figure 3.6). The ratios 
of the two viral DNA quantities within cells and cell culture supernatants were 
estimated using NIH image software and the relative viral fitness of the two variants 
was calculated using the following formula: S=l/t ln[q(t)p(0)]/[p(t)q(0)], where q is 
the proportion of the more fit variant at time 0 and time t, whilst p is the proportion of 
the less fit variant at time 0 and time t (Goudsmit et al, 1996).
Figure 3.6. HCMV DNA fragments separated on 3% agarose gel after restriction 
fragment length polymorphism analysis. The number of DNA base pairs in each 
fragment for Towne is 281, 153, and 152; and for AD 169 is 188, 153, 152, and 90.
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3.2.4.2 Assessment of virus adsorption
Infection is initiated after attachment of viral particles to cells and subsequent 
internalisation. HCMV infection is likely initiated by the specific binding of the virus, 
via one or potentially several viral envelope proteins, to one or more cellular 
structures, although the structures responsible for these processes are still unclear 
(Kari and Gehrz, 1992, Compton et al, 1993, Wang et al, 2003). Studies with several 
viruses have shown that the receptor selected by a virus may facilitate infection and 
persistence by triggering intracellular events essential for infection. Furthermore, the 
outcome of infection could also rely on differences in the ability of different strains to 
bind to cells.
To mvestigate this, HEL cells were infected with 5x10 genome equivalents of a 
Towne and ADI69 mixture (63/27%, respectively). 1 hour after virus inoculation, the 
ratio of Towne to AD 169 in the supernatant remained virtually unchanged compared 
to the inoculum, while Towne constituted 57% of the total virus population in the 
cells. 3 hours after virus adsorption, AD 169 became the predominant virus population 
in the supernatant, while the amount of Towne in the cells increased to 62%. These 
findings suggest that Towne might be absorbed to cells more efficiently than AD 169 
(Figure 3.7). The same experiment was repeated using a virus mixture comprised of 
equal quantities of the two HCMV strains. Although the ratio of Towne to AD169 in 
the supernatant remained virtually unchanged 1 hour after inoculation, 3 hours later, 
AD 169 comprised 72% of the virus population (Figure 3.8). When comparing the 
content of intracellular virus at 1 and 3 hours after infection, no significant change in 
the distribution of the two variants was observed.
To investigate this further, HEL cells were infected with the virus mixture (40% 
Towne, 60% AD 169) at 4°C, allowing virus adsorption but minimising virus entry. 3 
hours after adsorption, Towne comprised 33% of the total virus population bound to 
cells, while only 17% of the total extracellular virus (Figure 3.9). The cells were 
subsequently transferred to 37°C to facilitate virus entry.
127
(A)
AD169 and Towne adsorption into HEL cells
100
80-
c
60-
(/)D>_ 4 0 -
>
2 0 -
ooo
Extracellular Towne 
Extracellular AD169 
Intracellular Towne 
Intracellular AD169
(B)
Time pi (hours)
Figure 3.7. (A)Levels of Towne (T) and AD169 (A) after infection of HEL cells with 
a mixture of these virus strains, consisting of 63% Towne and 27% ADI 69. (B) DNA 
fragments separated on 3% agarose gel after RFLP.
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Figure 3.8. (A) Levels of ADI69 and Towne after co-infection of HEL cells with 
equal amounts of the two virus strains. (B) DNA fragments separated on 3% agarose 
gel after RFLP.
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Binding of AD169 and Towne to HEL cells
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Figure 3.9. Levels of Towne and AD 169 after infection of HEL cells at 4°C with a 
mixture of these virus strains, consisting of 40% Towne and 60% AD 169.
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3.2.43 Determination of replicative fitness
Serial passage and adaptation of HCMV strains in fibroblasts is associated with 
several phenotypic changes in the passaged strains. The inoculation of fibroblasts with 
laboratory-adapted HCMV strains leads to the development of cytopathic effect in 
less than a week, and a single round of replication resulting in cell free virus in the 
supernatant requires less than 96 hours to complete (Stinski, 1990). In contrast, 
inoculation of fibroblast cell cultures with HCMV from patient samples, such as white 
blood cells, urine or saliva, results in the production o f highly cell-associated progeny 
virus. Development of cytopathic effect in these cultures requires subculture of the 
infected cells and can take several weeks (Ho, 1991).
HEL fibroblasts were co-infected with a mixture of 5xl07 gB copies of Towne and 
AD169 (70% and 30%, respectively), in order to assess the relative replicative fitness 
of the two HCMV variants in vitro. By day 10 Towne slightly outgrew AD169 with a 
fitness difference of 3% (Figure 3.10). However within 17 days o f culture, the 
composition of the virus population changed in favour o f AD 169, with a relative 
fitness gain of 24%. AD 169 levels were also increased in the supernatant.
Additionally, HEL fibroblasts mono-infected with Towne and AD 169 were mixed 
with uninfected fibroblasts and maintained in culture for 7 days. After 7 days, Towne 
was found to be the predominant population in cells, with a fitness gain of 13.5%. It 
also accounted for 80% of the extracellular virus population (Figure 3.11).
Overall, these results indicate that the fitness diferences between AD 169 and Towne 
is variable and dependent upon the status of the virus inoculum. When using a cell- 
free virus inoculum, ADI 69 outgrew Towne within 17 days of culture, with a fitness 
gain of 24%. When cell-associated virus was used as the inoculum, Towne 
predominated in both cells and SN, indicating that it is more efficient in mediating 
cell-to-cell spread of infection and releasing virus into the medium. Cell-to-cell spread 
may be important in vivo, and under such conditions Towne appears to be fitter.
131
(A)
AD169 and Towne co-infection of HEL cells
70-
60-
50-
4 0 -
30-
o oE
•  Extracellular Towne 
Extracellular AD169 
-•—  Intracellular Towne 
—  Intracellular AD169
Time pi (days)
(B)
Z
C/3
X i
£
C/3
&
T3O
is3
3 Z
o C/3
>-a cd•po r-
t-H r-H
Figure 3.10. (A) Levels o f  A D169 and Towne after co-HEL cells were infected with a cell-free 
mixture o f  the two strains at a low MOI. (B) DNA fragments separated on 3% agarose gel after RFLP.
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Figure 3.11. (A) Levels o f  AD169 and Towne after co-infection o f  HEL cells. HEL cells mono­
infected with Towne and AD 169 (50/50% ) were mixed with uninfected fibroblasts and maintained in 
culture for 7 days. (B) DNA fragments separated on 3% agarose gel after RFLP.
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3 3  Discussion
HCMV causes a variety of diseases in immunocompromised individuals, including 
retinitis, mental retardation and pneumonitis among others. These different clinical 
outcomes may be related to host factors, such as the immune response (Riddell et al, 
1992, Mach and Landini, 1993), but also to viral properties (Quinnan et al, 1984, 
Plotkin et al, 1989, Torok-Storb et al, 1993, Fries et al, 1994, Sinzger et al, 1997, 
Gema et al, 2000). High and low passaged HCMV strains vary in genome 
composition, with the latter containing an extra 13kb region, predicted to encode 19 
ORFs (Cha et al, 1996). Additionally, assays in endothelial, hematopoietic and 
macrophage cultures, as well as in SCID-hu mice, have revealed differences in the 
replication capacities among these strains (Waldman et al, 1991, Mocarski et al, 1993, 
Minton et al, 1994, Brown et al, 1995, Plachter et al, 1996, Sinzger et al, 1997). 
These genotypic and phenotypic differences are believed to be the result of extensive 
propagation in fibroblast cell cultures (Sinzger et al, 1999).
To evaluate a possible link between genotype and replication rate, fibroblast cultures 
were infected with HCMV strains AD 169 and ToIedoE. The efficiency of replication 
of ADI69 exceeded that of ToIedoE, by 18-fold, as measured by the number of viral 
genomes in the infected cells. Calculation of the viral load of each of these strains 
showed that AD 169 replicated better than ToIedoE in fibroblasts, reaching 1.4xl09 
genome equivalents/pg DNA, compared to 8xl07 genome equivalents/pg DNA of 
ToIedoE. Furthermore, assessment of the replication of ToIedoE in a different cell 
type, HUVEC, indicated that the virus replicated to higher levels in fibroblasts. 
However, the doubling times of ToIedoE in fibroblasts and HUVEC were 6.9 and 7.3 
hours, respectively, suggesting that infected fibroblasts and endothelial cells produce 
virus at the same rate, but at varying amounts.
The adsorption, internalisation and replication rate (fitness) of HCMV, are processes 
that allow productive infection to occur. In order to investigate subtle differences in 
replication capacity, I performed pair-wise experiments in cell culture to compare the 
ability of HCMV strains AD 169 and Towne to bind to fibroblasts. Towne was found 
to bind to HEL cells with higher affinity compared to ADI69. A study by Taylor et al 
has shown that AD 169 and Towne bind to the same receptor on fibroblasts, with
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similar affinity (Taylor and Cooper, 1989). However, the Towne strain used in those 
experiments did not contain portion of the UL/b’ region. This could account for the 
contradictory data and suggests a role for the UL/b’ region in virus binding.
In the competition experiments, the relative levels of replicative fitness of two HCMV 
strains, AD 169 and Towne, were estimated under controlled in vitro conditions, by 
measuring the rate of change in their proportion as they replicated in cell cultures, 
based on the restriction endonuclease pattern of the gB gene. Virus cell-to-cell spread 
and entry of extracellular or cell-free virus particles frequently share mechanistic 
details, e.g., the use of similar fusion machinery, but cell-to-cell spread can involve 
intracellular and extracellular events that determine virus delivery to cell junctions and 
may be more important in vivo. Direct cell-to-cell spread of viruses in tissues is a 
complex, poorly understood process. A number of viruses have become very adept at 
moving from an infected cell to an adjoining uninfected cell, specifically at sites of 
cell-cell contact (Johnson and Huber, 2002). Cell-to-cell spread is typically rapid and 
efficient, partly because viruses and their cell surface receptors are in close proximity, 
and viruses can move across the narrow spaces between cells, protected from the 
effects of neutralizing antibodies and other immune system components. When using a 
cell-free virus inoculum, AD 169 outgrew Towne within 17 days of culture, with a 
fitness gain of 24%. When cell-associated virus was used as the inoculum, Towne 
predominated in both cells and SN with a fitness gain of 13.5%, indicating that it is 
more efficient in mediating cell-to-cell spread of infection and releasing virus into the 
medium. The amount of cell-associated infectious virus was consistently higher than 
in supernatant culture medium in all the experiments. These results indicate that 
fitness differences between AD 169 and Towne are variable and highly dependent 
upon the status of the virus inoculum. Since cell-to-cell spread may be more important 
in vivo, under such conditions Towne appears to be fitter. The different properties of 
Towne and AD 169 could be the result of genomic diversity between the two strains 
and this will be addressed later in this thesis (Chapter 5).
A study by Mousavi-Jazi et al comparing the growth phenotypes HCMV isolates in 
vitro, showed that the efficiency of replication of rapidly replicating viruses exceeded 
that of the slowly replicating viruses by 10-1,000 fold as measured by the virus in 
culture supernatants (Mousavi-Jazi et al, 2000). This difference in replication was not
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related to gB genotypes or antiviral susceptibility, but to the expression of early viral 
proteins. My data indicate that the replication rates of HCMV AD 169 and ToIedoE 
strains differed in fibroblasts cell cultures. Additionally, infection of fibroblasts and 
HUVEC with ToIedoE resulted in cell type-specific replication levels. Overall, the 
results in this chapter illustrate further phenotypic differences between high and low 
passaged HCMV variants, such as binding onto cells and spread of infection. 
Deciphering the mechanisms underlying HCMV’s interactions with the host will not 
only contribute to our understanding by which HCMV causes disease, but also 
provide the foundation for the development of effective approaches for intervention. 
However, there are limitations to the experimental approaches used here in 
interpreting the mechanisms and the global impact of these replication differences in 
cell/viral transcription. Consequently, the subsequent chapters within this thesis have 
exploited gene array technology to extend these investigations on the replication of 
different virus strains in the same cell type and the same virus strain in different cell 
types.
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Chapter 4
Construction of a HCMV-human array and expression of
the UL/b’ region
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4.1 The HCMV-human array
4.1.1 Introduction
Viral gene function acts within the context of the host cell. Much of molecular 
biology is predicated on the fact that the expression pattern (cell type, time, level) of a 
gene relates to its function, consequently the genes expressed by a cell determine its 
functions and behaviour. The application of DNA array technology to virology has 
broadened our knowledge of cellular responses to infection and virus control of host 
gene expression (Kellam, 2000). Additionally, a single array experiment can reveal 
the complete gene expression programme of the viral genome (transcriptome). The 
first virus to have its transcriptome dissected using DNA arrays was HCMV 
(Chambers et al, 1999). This study used a microarray containing oligonucleotide 
probes for all HCMV ORFs, spotted on glass slides. The array was used to classify all 
viral genes by kinetic class following infection of fibroblasts with HCMV AD 169, 
with the use of classical metabolic inhibitors. Triplicate experiments were performed 
in order to assess the significance of expression changes.
High-density DNA arrays of host genes can offer an unparalleled view of the 
transcriptional events that underlie the host response to viruses. A number of studies 
have shown that DNA arrays can reveal changes in host gene expression that occur 
upon virus infection (see section 1.13). Zhu et al have reported one of the first 
analyses of the interaction of a human pathogen with a host cell using arrays, which 
led to the identification of a number of interesting features of HCMV infection (Zhu 
et al, 1998). Overall, the simultaneous analysis of the expression of thousands of 
genes can identify the features of the “conversation” between host and pathogen, 
novel strategies for prophylaxis and therapy and prognostic markers of outcome 
(Kellam et al, 2003).
Because such global analysis of viral and host gene expression has already provided 
significant clues into the pathogenesis of viral disease, the aims of this chapter were to 
create and to test DNA arrays for the expression analysis of a subset of HCMV genes, 
especially these that are unique in clinical strains of virus rather than the lab adapted
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strains of HCMV, and approximately 5,000 human genes during productive HCMV 
infection in vitro.
4.1.2 Results
4.1.2.1 Production of the HCMV-human array
An HCMV-human microarray was created to allow the analysis of both virus and host 
gene expression during HCMV infection of different cell types, namely fibroblasts 
and endothelial cells. This glass, spotted microarray contains probes for both virus 
and human genes.
To represent the coding potential of the HCMV UL/b’ region genome on the array, a 
set of PCR primers were designed to amplify around 200-3OObp from the 5’ end of all 
the predicted HCMV UL/b’ region ORFs, namely UL133 to UL151 (3’ end for 
UL147 and UL148 ORFs), along with gB, UL18, UL130 and UL132. These latter 
four probes will provide signatures for the known classes of HCMV gene expression, 
namely gB (early), UL18 (late). The primer pairs were used to amplify probe 
sequences from genomic viral DNA are listed in Table 4.1 along with the gene name 
and corresponding region of the HCMV genome. The sequences of the primers used 
can be found in Table 2.1.
The HCMV array probes were cloned into pGEM-T Easy vector. The identity of each 
cloned array probe was confirmed by both PCR with virus probe-specific primers 
(Figure 4.1) and by DNA sequence analysis (see section 2.3.6). All amplified clones 
were the correct sequence, as determined by BLAST searches of the clone sequences 
against the non-redundant nucleotide database of GenBank 
(www.ncbi.nlm.nih.gov/BLAST). This analysis also provided a measure of potential 
probe cross hybridisation with other host or viral sequences. No array probes were 
found to have homology to other sequences beside the sequence they represent.
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Figure 4.1. PCR o f HCMV array clones with clone-specific primers to allow identification o f  correct 
clones. Agarose gels, showing products from 23 unique HCMV array clones after amplification with 
specific primers. All clones are o f  the correct size. All amplifications were performed using purified 
plasmid DNA. Size marker in base pairs is included.
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O RF/G ene Sequence+
HCMV UL130 13113-13462
HCMV UL132 11961-12236
HCMV UL133 51-380
HCMV UL134 718-1059
HCMV UL135 976-1309
HCMV UL136 2018-2353
HCMV UL137 2631-2890
HCMV UL138 2823-3100
HCMV UL139 3944-4238
HCMV UL140 4492-4780
HCMV UL141 5321-5579
HCMV UL142 6508-6822
HCMV UL143 7370-7580
HCMV UL144 8008-8338
HCMV UL145 8911-9151
HCMV UL146 9579-9768
HCMV UL147 10097-10343
HCMV UL148 11286-11529
HCMV UL149 15758-15950
HCMV UL150 17475-17770
HCMV UL151 17565-17867
Ubiquitin 136-440
TMAP 283-573
PPRT 86-390
GAPDH 61-370
a-tubulin 68-379
MHC class I HLA-B 8-270
P-actin 387-747
HBP 42-340
Ribosomal protein S9 61-370
Luciferase 13-327
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TMV 1-319
KSHVK1A 115-420
KSHV ORF4 (CBP) 1142-1448
KSHV ORF6 (ssDBP) 3210-3495
KSHV ORF7 6628-6930
KSHV ORF8 (gpB) 8699-8900
KSHV ORF9 (DNApol) 11383-11680
KSHV ORFIO 14519-14810
KSHV ORF11 15790-16002
KSHV ORF2 (DHFR) 18271-18553
KSHV k3 (IE-IB) 19328-19609
KSHV ORF70 (TS) 20801-21104
KSHV K4 (vMIP-II) 21548-21832
* Abbreviations: Tyrosine 3-monooxygenase activation protein (TMAP), 
pyrophosphate phosphoribosyltransferase (PPRT), glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), highly basic protein (HBP).
+ Nucleotide positions relative to the listed GenBank Accession number file
Table 4.1. HCMV UL/b’ region array probe clones and their corresponding 
sequences. The sequences for the probes used as positive and negative controls are 
also listed.
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Common vector primers were designed to amplify the cloned array probes with a 
minimum of vector sequence (pGEM 5’ and 3’) (Jenner et al, 2001). Previous work 
has developed PCR conditions to allow the consistent amplification of 5 fig of PCR 
product from pGEM-T Easy clones (see section 2.3.7). Sequences from cloned 
cellular “housekeeping” genes were also amplified to use as controls using the same 
conditions. The genes chosen were ubiquitin, tyrosine 3-monooxygenase activation 
protein (TMAP), pyrophosphate phosphoribosyltransferase (PPRT), glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), a-tubulin, MHC class I HLA-B, (3-actin, 
highly basic protein and ribosomal protein S9. Luciferase and tobacco mosaic virus 
(TMV) 180kD protein genes and KSHV genes were also amplified to use as negative 
controls. The cloned DNA for the control genes used for amplification was a kind gift 
from Dr Jenner. PCR amplification (see section 2.3.7) was used to produce 
approximately lOpg of purified DNA for each of the 46 array elements. The integrity 
of the PCR reactions was confirmed by agarose gel electrophoresis of 5pl of the 
purified PCR products and estimating the PCR product size compared to the starting 
clones, taking into account the increase in size due to the vector specific PCR primers 
(Figure 4.2).
These probes were added to a 5428-probe set, consisting of probes that were PCR- 
amplified from sequence verified human cDNA clones (Clark et al, 2002). These 
probes were obtained from the Institute of Cancer Research. The viral and human 
probe sets were printed onto glass slides to create the 5474-element HCMV-human 
microarray by Ian Giddings at the Institute of Cancer Research. The arrays used for 
the analysis of host gene expression in fibroblasts infected with AD 169 (used in 
Chapter 5) contained the same human probe set, but each probe was printed in 
triplicate. Therefore, these arrays contained 15,000 elements.
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Figure 4.2. Purified array probe DNA. Agarose gels showing purified PCR products 
for each array probe. In each panel the first lane represents the size markers (Bioline). 
The lanes containing no bands are water controls.
144
4.1.2.2 Creation of a common reference RNA sample
The two colour microarrays used in this study make use of a common reference RNA, 
labelled with cyanine dye, hybridised to all the arrays in the experiment (see section
1.10.2). This common reference RNA allows interarray normalisation and therefore 
multi-comparative analyses. The reference RNA should ideally provide a signal above 
background in as many different distinct probes as possible as this maximises the 
number of expression ratios that can be generated for each sample. The samples 
analysed in this study are derived from uninfected and HCMV-infected fibroblasts 
and endothelial cells. Therefore, the reference was designed to reflect this range of 
cell types and includes RNA purified from endothelial cells infected with HCMV 
ToIedoE and also uninfected peripheral blood mononuclear cells (PBMC) and MRC-5 
fibroblasts. The composition of the reference RNA mixture used is shown in Figure 
4.3. Batches of each cell type were grown, in order to use the same reference RNA for 
all the experiments, minimising inconsistencies that may be introduced by the use of 
different batches of reference RNA. The inclusion of infected cell RNA in the 
common reference allowed the expression of the virus genes to be detected (Figure 
4.3).
endothelial cells
PBMC
f i brobl as t s
Figure 4.3. Composition of the common reference RNA mixture used with the 
HCMV-human microarray.
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4.1.2.3 Normalisation and filtering of gene expression data
A typical microarray analysis workflow has been documented previously (see section
1.10.2). Before the comparison of array data from multiple samples can take place, 
the data needs to be filtered to remove unreliable gene expression values and 
normalised. Normalisation adjusts for differences in the quantity of RNA used and 
differences in labelling and detection efficiencies for the labels. There are a number of 
normalisation methods, but one of the most common methods still generally applied 
to microarrays is global normalisation (see section 1.11.2). Global normalisation is 
achieved by adding a scaling factor to data from each array so that the median 
expression ratio in all arrays is equal/adjusted to 1. This makes the assumption that 
the majority of genes on the array do not change their expression levels when 
comparing two mRNA samples even if one of the samples is a pooled reference RNA. 
It also assumes that the expression ratio is independent of signal intensity. This is 
generally true for genes of medium to high signal intensity but not for low intensity 
signals. It is therefore necessary to filter out low intensity spots before normalisation. 
Global normalisation was used to compare expression data derived from the HCMV- 
human microarrays.
Each host gene was spotted in triplicate on the arrays used in Chapter 6. The median 
from the triplicate measurements for each gene was calculated and gene expression 
data were analysed using Cluster. To check the reliability of taking the median value, 
the standard deviations (SDs) for the triplicate measurements were calculated in 
Microsoft Excel. This analysis showed that 97.4% of the genes had a standard 
deviation of less than 1, with the majority of them having a SD=0.2 (Figure 4.4A). 
Therefore, the reproducibility of the arrays is high.
Gene expression measurements with a low signal to noise ratio can give rise to 
variation due to imprecisions in detecting low signals. Previous arrays with similar 
arrays showed that filtering the data to remove elements with a signal to background 
ratio below 2 in the Cy5 channel and 1.5 in the Cy3 channel was shown to increase 
the consistency of microarray measurements (Jenner et at). Indeed, after calculating 
the SDs for the same set of gene expression data before and after filtering, the same 
observation was made (Figure 4.4B).
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Figure 4.4. (A) Standard deviations (SDs) calculated for the triplicate gene 
expression measurements on the microarrays (filtered data set) (B) Comparison of the 
standard deviations of gene expression data before (blue line) and after (yellow line) 
filtering.
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4.1.2.4 Generation of amplified RNA for microarrays
Gene profiling using glass arrays typically requires up to 0.1-1 pg of poly(A) RNA to 
synthesize labelled probe for each hybridisation. However, this poses a limitation for 
the microarray technology, since it is often impossible to obtain enough RNA from 
patient blood samples and biopsies. In virology and other “cell exposure” studies, a 
potential confounding issue in classical molecular biology experiments is produced 
when not all cells are equally exposed to the treatment. This can lead to multiple cell 
processes occurring in what is viewed as an otherwise consistent system. One such 
variable in virology is the multiplicity of infection (MOI). When viral titre is low, the 
only way to increase an MOI is to decrease cell numbers. This however also results in 
low RNA recovery. To overcome this limitation, a technique was developed to 
synthesize amplified RNA (aRNA) (Van Gelder et al, 1990). The procedure consists 
of initial reverse transcription with an oligo(dT) primer bearing a T7 promoter 
followed by an in vitro transcription of the resulting DNA with bacteriophage T7 
RNA polymerase, generating hundreds of antisense RNA copies of each mRNA in a 
sample (Figure 4.5).
PCR is not recommended for use in amplification, since there is a concern that the 
exponential amplification will lead to preferential amplification of certain cDNAs and 
to variability from one reaction to another (Wetmur et al, 1968, Peccoud and Jacob, 
1996). The exponential nature of PCR also makes it difficult to determine the point at 
which linear amplification is achieved. RNA amplification using the T7 RNA 
polymerase system does not significantly distort the relative abundance of individual 
mRNA sequences within an RNA population (Pabon et al, 2001). This is most likely 
due to RNA polymerase activity not being affected by the template sequence or the 
relative concentration of sequences in a complex mixture. For the few templates that 
will be transcribed more or less efficiently than others, the aRNA amplification 
procedure may not generate the same number of aRNA molecules from each 
template, but their amplification is reproducible from reaction to reaction. Therefore, 
this allows comparison of expression profiles of different RNA samples following a 
common amplification protocol.
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Amplified RNA obtained from the first round of amplification is the antisense 
sequence relative to cDNA from which it was transcribed (Figure 4.5). In my 
experiments, one round of amplification usually resulted in 2-20pg of aRNA. As 5pg 
of RNA is required for microarray hybridisations, a second round of amplification 
was performed if the aRNA produced after the first round was less than 5pg (see 
section 2.7).
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Figure 4.5. See opposite page. Outline of the procedure used to synthesise aRNA 
from total RNA. The synthesis of first strand cDNA is catalysed by the reverse 
transcriptase in the presence of total RNA and oligodT T7 primer. Second strand 
cDNA synthesis is performed in the presence of RNaseH and DNA polymerase I. In 
vitro transcription of aRNA is performed by T7 RNA polymerase. To regenerate the 
T7 promoter sequence for use in the second round of amplification, the first strand 
cDNA is primed with random hexamers to generate second strand products (see 
section 2.7).
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To formally assess the systematic bias introduced by RNA amplification using my 
protocol, the expression profile of labelled aRNA-based targets was compared to that 
of conventional poly(A) RNA-based targets (Figure 4.6). Statistical analysis of 
expression ratios showed that the microarray sensitivity and precision using aRNA are 
comparable to the standard hybridisation process using unamplified RNA (r=0.96).
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Figure 4.6. Assessment of systematic bias introduced by RNA amplification.
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Similarly, I wished to assess the level of bias introduced after a second round of 
aRNA amplification. I performed pair-wise analysis of normalised microarrays 
hybridised with aRNA or aaRNA (second round amplified) derived from the same 
source, relative to a common amplified reference (Figure 4.7). Statistical analysis of 
the log(2) expression ratios revealed a high correlation coefficient (r=0.83), indicating 
that the use of second round amplified RNA gives reliable results in microarray 
hybridisations.
r = 0.83
S e c o n d  ro u n d  RNA
Figure 4.7. Comparison of aRNA and aaRNA targets from endothelial cells infected 
with human cytomegalovirus (r=0.83).
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4.1.2.5 Fluorescent labelling o f samples
Microarray analysis is usually carried out by hybridising two fluorescently-labelled 
probes prepared from cellular RNA, to DNA targets that have been immobilised on a 
solid support. The most common method for the generation of labelled probes is the 
direct incorporation of fluorescent nucleotides (ie Cy5 and Cy3) into first-strand 
cDNA. In my studies, RNA from the sample of interest was always labelled with Cy5, 
while common reference RNA was labelled with Cy3. To exclude labelling biases 
introduced by dye variation, aRNA and mRNA targets derived from the same RNA 
source were labelled with the reciprocal fluorophore, mixed and hybridised to a 
microarray. The same experiment was then repeated, this time swapping the 
fluorophores between the targets. Statistical analysis of the log(2) expression ratios 
from the two microarray hybridisations indicated that use of the Cy5 and Cy3 
fluorophores gives consistent results (r=0.86) (Figure 4.8).
r = 0.86
6 -4 -2
-2
-4
- f i
2 4 6
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Figure 4.8. Assessement of labelling bias by hybridisation of differentially labelled 
aRNA and mRNA targets derived from fibroblasts infected with human 
cytomegalovirus. This is a reciprocal plot, since the ratios for mRNACy3/aRNACy5 
are inverted.
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4.1.2.6 Cluster analysis of experimental replicates
A requirement for all biological experiments should be repetition to distinguish true 
reproducibility from experimental variation. DNA microarrays are no exception. In 
previous sections I used hierarchical clustering to compare arrays. This becomes 
difficult to interpret when multiple pairwise comparisons can be made between 
samples/arrays. To aid analysis, the correlation coefficients can be converted to 
distance measures and pairs of samples/arrays can be joined by a root and two 
branches based on high correlation which equals low distance. This is known as 
hierarchical clustering. Here, I use hierarchical clustering to confirm that replicate 
experiments gave the same gene expression measurements. The log(2) median of 
ratios from 16 arrays were filtered (see section 5.2.1) and both the arrays and genes 
clustered using average linkage hierarchical clustering, using the program Cluster 
(Eisen et al., 1998). The data contain the results of array analysis of 16 different 
samples. The results show that all replicate samples cluster together because their 
expression patterns are more correlated with each other than either is to any other 
sample (Figure 4.9). The cluster dendrogram relates the samples by their expression 
pattern with branch length being inversely proportional to correlation. The variation 
between experimental replicates is consistently lower than between different samples. 
Therefore, I concluded that the HCMV-human microarray gave consistent results.
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Figure 4.9. Cluster analysis of experimental replicates. Hierarchical clustering of 14 
samples (one per array) based on a filtered set of 2,400 genes. The dendogram relates 
samples by their gene expression pattern, with samples with similar expression 
patterns clustered together. Branch length is inversely proportional to correlation. 
Repeats cluster together, connected by short branches.
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4.1.2.7 Efficiency of cDNA synthesis during aRNA generation
Most eukaryotic mRNAs are polyadenylated; that is, there is a non-template addition 
of a variable number of A nucleotides to the 3-ends of eukaryotic mRNA molecules. 
However, it is not known whether all of the HCMV UL/b’ region genes are 
polyadenylated. The first step in the RNA amplification process involved the 
generation of first strand cDNA from total RNA, using an oligodT primer. 
Additionally, priming with anchored oligodT will direct the start of the synthesis of 
cDNA from the 3’ end of the polyA tail. This is desirable if the hybridisation target 
probes on the microarray are derived from the 3’ region of transcripts. However on 
my microarrays, HCMV probes were derived from the 5’ end of genes. This could 
introduce a problem in hybridisation efficiency if there is incomplete cDNA synthesis. 
To determine the impact of these factors I tested whether all HCMV UL/b’ genes can 
be detected following oligodT primed cDNA synthesis.
Initially, cDNA was generated from lpg of total RNA extracted from late-stage 
HCMV-infected cells, using the oligodT primer. The cDNA was then subjected to 
PCR analysis using specific primers for the HCMV UL/b’ region genes used to 
generate the array probes (see section 2.7). This resulted in the detection of the 
majority of the viral transcripts (Figure 4.10A). However UL135 could not be 
detected, while UL143 was transcribed at very low levels.
To improve the detection of UL135 and UL143, cDNA was generated from lpg of 
total RNA extracted from late-stage HCMV-infected cells, using random hexamers. 
PCR was then performed with specific primers for UL135 and UL143, showing that 
UL143 was a low abundance transcript, while failing to detect UL135 transcripts 
(Figure 4.1 OB). The outcome was consistent with results from studies on the 
chimpanzee CMV genome, which showed that UL143 is not likely to encode a gene 
(Davison et al, 2003). My results indicate that cDNA synthesis using oligodT is 
efficient for the majority of transcripts and also indicates that all of the predicted 
HCMV UL/b’ genes produce polyadenylated RNA. Finally, these data confirm the 
computational analysis of HCMV (Davison et al, 2003), showing the absence of a
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UL143 ORF and adds UL135 to this category of predicted but not transcribed and 
therefore not functional sequences.
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Figure 4.10. Agarose gels illustrating the transcription pattern of the HCMV UL/b’ 
genes in late-infected fibroblasts. PCR with specific primers for the viral genes was 
performed from cDNA primed with (A) an oligodT primer and (B) random hexamers.
156
76
4.2 Expression of the UL/b9 region of Toledo
4.2.1 Introduction
In 1990, sequence analysis of the laboratory strain AD 169 by Chee et al predicted that 
the virus encoded 208 predicted open reading frames, encoding approximately 189 
unique proteins, due to duplication and splicing events (Chee et al, 1990). At that 
time, it was the largest viral genome sequence available. Since then, several other 
betaherpesviruses have been sequenced, including murine CMV (Rawlinson et al, 
1996), HHV-7 (Megaw et al, 1998) and rat CMV (Vink et al, 2000). In 1996 it was 
reported that 22 open reading frames present in HCMV clinical isolates and the low 
passaged Toledo strain, termed UL/b’ region, were not found in AD 169 and other 
high passage laboratory strains of the virus (Cha et al, 1996). However, despite the 
high level of gene homology between Toledo and wild type virus, some differences 
exist (Prichard et al, 2001). Therefore, no laboratory strain can be considered 
genetically complete. Since the sequence of the AD 169 genome is still being further 
characterised and there is still no data on HCMV sequences derived from clinical 
samples, the full wild type genomic composition remains unclear. Recently, in an 
effort to improve the interpretation of HCMV, its sequence was compared to the 
chimpanzee CMV sequence (Davison et al, 2003), the closest known relative of 
HCMV. In this study it was proposed that AD 169 contains 145 genes, while the wild 
type HCMV possibly encodes 164 to 167 genes. Because of the complexity of the 
HCMV genome, function has not yet been assigned to a large number of genes. This 
is particularly true in the case of the UL/b’ genes, which have only recently been 
discovered. As summarised in the introduction, herpesvirus genes are expressed 
sequentially in three phases, termed immediate early (IE or a), early (E or (3) and late 
(L or y), according to the onset of transcription (Stinski, 1990). The timing of a gene’s 
expression also gives clues as to its function (see section 1.3).
DNA array technology is a powerful tool for identifying programmes of herpesvirus 
gene expression, since it can provide simultaneous measurements of gene expression. 
In 1999 the generation of a viral DNA array chip for parallel expression 
measurements of nearly all known open reading frames of HCMV was described 
(Chambers et al, 1999). RNA extracted from fibroblasts infected with Towne was
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hybridised to chips containing DNA probes for all the genes present in AD 169 and 
four from Towne (UL147, UL152-UL154). Viral genes were then categorised as 
immediate-early, early or late according to their expression in the presence of 
cyclohexamide and inhibitors of viral replication (ie ganciclovir). The CMV chip did 
not detect all the IE genes, however no false positive signals were detected. 
Additionally, the majority of the genes were found to belong to late expression 
classes, with the UL/b’ UL147 gene being classified as an E-L gene. Overall the study 
described the expression of 151 ORFs, showing 90% agreement with published 
studies. The expression pattern of the majority of the HCMV UL/b’ genes and how 
this relates to the ordered series of events that occurs during replication, remain 
largely unknown. The aims of this section of the chapter are to use the HCMV-human 
array to analyse HCMV UL/b’ gene expression during lytic replication in both 
fibroblasts and endothelial cells.
4.2.2 Gene expression analysis by HCMV-human arrays
The HCMV-human array was used to monitor virus gene expression in fibroblasts and 
endothelial cells after infection with ToledoE. Cells were harvested over a 96-hour 
time-course, total RNA was purified, amplified and labelled with Cy5 and hybridised 
to the arrays. The reproducibility of the arrays was confirmed by performing duplicate 
hybridisations representing 0 (time of virus inoculum removal), 6, 12, 24, 48, 72 and 
96 hours after infection (see section 4.1.2.6), showing that duplicate samples give 
highly similar gene expression patterns. The data from the time-course were ordered 
with a self-organising map and the genes grouped by hierarchical clustering. 
Hierarchical clustering separated the genes into branches in which genes share similar 
patterns of expression. Analysis showed arrays were specific with no HCMV signals 
detected in the absence of HCMV infection and no cross hybridisation to KSHV gene 
probes. This analysis showed the viral genes were all grouped in the same cluster 
(Figure 4.9). To aid interpretation of the gene expression values, each time point was 
expressed as a ratio change relative to time 0, allowing the effective increase in each 
gene expression over time to be assessed. In certain cases (ie early time points) viral 
transcripts were not detected, probably because they were below the threshold of 
sensitivity of the microarrays.
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Figure 4.11. Hierarchical clustering of gene expression data. This figure is an 
expanded view of the cluster containing the viral genes. Each row represents a 
separate gene on the array; each column represents the results from one array. Shades 
of red indicate detectable expression above and shades of green illustrate expression 
below the median level of expression for each gene (black). The dendrogram on the 
left represents the gene expression distance of the patterns of expression between 
different genes (short branch lengths equate to similar gene expression profiles). The 
gene names are listed on the right hand side. Lanes 1 and 2 represent uninfected 
fibroblasts and endothelial cells, respectively. Lanes 3 to 9 show time points after 
infection of fibroblasts with ToledoE, while lanes 10 to 16 show the array results from 
ToledoE-infected endothelial cells.
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Viral gene expression was found to increase over time after infection with the virus 
(Figure 4.11). Different genes reached significant levels of expression at different 
time points. By 48 hours, intense signals for the majority of the genes could be 
detected, suggesting a prompt escalation of viral gene expression. The expression of 
gB increased significantly (—4 log(2)) within 48 and 72 hours after infection of 
fibroblasts and HUVEC, respectively, consistent with its classification as an early-late 
gene. UL18 transcripts were also detected at late time points after infection. UL18 is 
homologous to MHC class I and although there is contradictory data about its 
function, it is thought to have a role NK evasion (Reybum et al, 1997). It has been 
shown that cells infected with HCMV exhibit a marked decrease of MHC class I 
molecules on their surface, which makes them susceptible to NK cell lysis. Therefore, 
the expression of UL18 at late time points is concomitant with the reported down- 
regulation of MHC class I molecules and consistent with its proposed function.
UL130 levels increased by -4  log(2) at 72 hours after infection, while UL132 
transcription occurred at 96 hours. 8 of the 19 genes that are missing from laboratory- 
adapted strains were detected using the arrays, namely UL136-UL138, UL144, 
UL144, UL148, UL150 and UL151. These were all transcribed at late time points 
after infection. The highest level of expression was observed for UL150, whose 
transcript levels increased 32 times, by 72 and 96 hours in fibroblasts and HUVEC, 
respectively.
4.23 Gene expression analysis by RT-PCR
Because array sensitivity sometimes prevents detection of low abundance transcripts, 
and in order to confirm the array-based gene expresion profiles, I analysed expression 
of the UL/b’ genes by RT-PCR using the array probe PCR primer sets. Total RNA 
was prepared from several time-points (0, 6, 12, 24, 48, 72, 96h) after infection of 
fibroblasts and HUVEC with HCMV ToledoE. cDNA was synthesized from lpg of 
total RNA primed with the T7 oligodT primer using Superscript II. lpl of cDNA was 
then added to a HotStart Taq (Qiagen) PCR mix, containing specific primers (lOOng) 
for each viral gene. The PCR products were separated on agarose gels.
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UL141 and UL148 were expressed within 1 hour of HCMV infection, consistent with 
immediate early gene functions. UL134, UL142, UL144 and UL146 transcripts 
started accumulating at 48 hours after infection. Genes encoding proteins that form 
part of the virus particle are expressed late in the virus life cycle. The rest of the 
UL/b' genes were detected between 6-24 hours post infection, implying a role in 
DNA replication, repair and immune evasion. These results show that the HCMV 
transcriptional profile changes as the virus progresses through the life cycle, with 
individual genes having distinct expression kinetics. The majority of the genes 
(UL137, UL138, UL141, UL144, UL145, and UL144-UL150) exhibited the same 
transcription patterns in both cell types. There was no detectable expression of UL135 
and UL143 during infection, consistent with Davison et al, while UL142 was 
expressed only in HUVEC. The remaining genes (UL133, UL134, UL136, UL139, 
UL140, UL151) were transcribed with delayed kinetics in fibroblasts compared to
HUVEC 
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Figure 4.12. RT-PCR with specific primers for the genes located at the UL/b’ region 
of the HCMV genome.
HUVEC (Mann Whitney, p<0.05). 
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4 3  Discussion
43.1 The HCMV-human array
I have created a DNA array to identify the transcription profile of a region of the 
HCMV genome thought to be crucial for disease pathogenesis in vivo. This will 
enhance our understanding of HCMV behaviour. The array also contains probes for 
over 5,000 human genes, allowing simultaneous measurements of gene expression for 
both host and virus. The results from this type of study can unravel interactions 
between the virus and host and give an insight into disease pathogenesis.
When using arrays for the measurement of gene expression, multiple control 
experiments are required to ensure the arrays are reliable (Schena et al, 1995, 1996, 
Lockhart et al, 1996). The precise identity of the probes on an array has to be 
confirmed. Firstly, the identity of each cloned array probe spotted on the HCMV array 
was confirmed by PCR with probe-specific primers (Figure 4.1) and DNA sequencing 
(see section 2.3.6). Cloned array probes were also checked for the possibility of cross- 
hybridisation, both against each other and against host genes, by searching GenBank 
using pair-wise sequence analysis (www.ncbi.nlm.nih.gov/BLAST). The HCMV- 
human array shows reproducible measurements of expression both within arrays and 
between arrays. This analysis showed that 97.4% of the genes had a standard 
deviation of less than 1 among triplicate spots, with the majority of them having a 
SD=0.2 (Figure 4.4A). Additionally, the variation between experimental replicates is 
lower than between different samples, confirming the consistency of the array. These 
results compare well with findings from previous studies (DeRisi et al, 1997, Chen et 
al, 1998, Mayne et al, 2001).
Many of the most productive applications of functional genomics to date have been in 
the study of homogeneous cultured cells (DeRisi et al, 1997, Heller et al, 1997, Chu 
et al, 1998, Iyer et al, 1999, Hughes et al, 2000). To detect rare messages and to 
simplify the analysis of complex expression patterns, isolation of the cell type of 
interest is often essential. Dissection and cell sorting can be used to reduce the 
complexity of cell types from which RNA is isolated (Sirivatanauksom et al, 2000).
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With these techniques, however, it is often difficult to obtain the quantities of RNA 
required for a transcript profiling technology such as DNA arrays. A technique 
capable of amplifying small amounts of RNA without significantly distorting the 
information content of the sample has been described (Van Gelder et al, 1990). This 
technique amplifies the mRNA population by in vitro transcription of cDNA. The 
amplification based on the protocol first described by Eberwine et al faithfully 
maintains relative mRNA levels when starting with lpg of total RNA (Salunga et al, 
1999). Application of additional rounds of amplification from much smaller amounts 
of RNA gives reproducible results for a single RNA sample and allows detection of 
differences between samples consistent with those detected without amplification 
(Luo et al, 1999, Wang et al, 2000). Recently, an optimised protocol has allowed 
faithful amplification of just 2ng of total RNA (Baugh et al, 2001). RNA 
amplification has been used by several research groups, to generate significant 
amounts of RNA from biological tissue (Phillips and Eberwine, 1996, Pabon et al, 
2001, Hu et al, 2002). In my experiments, in vitro transcription of lpg of total RNA 
resulted in the generation of 5-20fig of aRNA, which was sufficient for the microarray 
hybridisations. Statistical analysis of expression ratios showed that the microarray 
sensitivity and precision using aRNA are comparable to the standard hybridisation 
process using unamplified RNA (r=0.96). Similarly, the use of second round 
amplified RNA gives reliable results in microarray hybridisations (r=0.83).
The experiments discussed in the first part of this chapter offer controls for the 
biological interpretation of the array-based expression measurements that take place 
in the second part of the chapter and in chapters 5 and 6. The HCMV-human array 
was used to examine (i) HCMV gene expression during active replication of HCMV 
in fibroblasts and endothelial cells, (ii) host-specific responses to HCMV Toledo and 
(iii) host responses to different strains of the virus.
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4.3.2 Expression of the UL/b’ region of ToledoE
The expression of the majority of the HCMV UL/b’ genes has not been analysed 
before. The HCMV-human array and RT-PCR were used to analyse expression of 
these genes during active replication in fibroblasts and endothelial cells. These 
technologies provide simple methods of assessing when the expression of viral genes 
becomes detectable. In this case both methods were required due to inconsistencies in 
detected low abundance transcripts by microarrays.
Analysis of the array results showed that the viral genes are expressed at different 
times after infection and with cell type-specific patterns. It is widely accepted that the 
relative time at which the expression of a gene is detected correlates with the stage of 
the life cycle in which it is thought to act. UL141 and UL148 were expressed within 1 
hour of HCMV infection, consistent with immediate early gene functions. Recent 
unpublished data presented showed that the expression of UL141 in fibroblasts takes 
place two days after infection and a function in NK cell evasion was proposed for this 
gene (Wilkinson et al, unpublished data).
UL134, UL142, UL144 and UL146 transcripts started accumulating at 48 hours after 
infection. The expression patterns observed for UL144 does not agree with previously 
published data. Lurain et al showed that UL144 is a TNFR homologue, expressed 
early after infection and retained in an intracellular compartment (Lurain et al, 1999). 
In my study UL142 was classified as a late gene. This gene has a role in NK evasion, 
and combined with previous data on UL18 (see section 4.2.2), shows that both of 
these genes that are thought to mediate inhibition of NK cell lysis have similar 
expression patterns. Expression of UL142 was only detected in endothelial cells. 
Experiments performed by a different group also found it to be transcribed with late 
kinetics, and also failed to detect expression in fibroblasts (Wills et al, unpublished 
data).
The majority of the UL/b’ genes were detected between 6-24 hours post infection, 
implying a role in DNA replication, repair and immune evasion. This is consistent 
with the function that has been proposed for UL147 in virus modulation of the
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immune system, due to its homology to an alpha chemokine (Penfold et al, 1999). 
UL135 and UL143 transcripts could not be detected in any of the two cell types 
infected with the virus. This agrees with the study by Davison et al, which discounted 
UL143 from being a gene (Davison et al, 2003).
Some of the HCMV UL/b’ region genes share sequence homology with human genes 
(Table 4.2). Therefore, these genes may represent acquisitions from the host genome. 
My analysis shows that genes belonging to the same functional group have similar 
expression profiles and has helped to assign functions to genes for which there is no 
available information. The classification of the three basic groups of transcripts is 
generally based however on measurement of transcript abundance in infections where 
virus-induced DNA and protein synthesis are blocked with metabolic inhibitors. 
Although it would be useful to monitor expression with inhibitors of translation and 
herpesvirus DNA polymerase, these disturb the system and, in the case of the 
inhibition of translation, have wide-ranging effects on the host cell.
HCMV Homology Kinetic class Proposed function
UL137 Protease - -
UL139 Neurotoxin - -
UL142 MHC class I Late NK evasion
UL143 dUTP nucleotide hydrolase - -
UL144 TNF receptor Immediate early Immune evasion
UL146 a  chemokine - Neutrophil attraction
UL147 a  chemokine Late Neutrophil attraction
Table 4.2. Table showing information on HCMV UL/b’ genes (homology to cellular 
genes, expression pattern and current proposed function).
The additional region at the right end of UL in Toledo was described to contain 19 
genes absent from AD 169 (Cha et al, 1996). A recent study, however, has discounted 
five of these genes, namely UL134, UL137, UL143, UL149 and UL151. The use of 
DNA arrays and RT-PCR has allowed to test these findings. UL143 transcripts could 
not be detected in either fibroblasts or endothelial cells, while expression of the rest of 
the genes was observed, demonstrating these regions of the genome are transcribed. It 
is clear that the virus expression programme is determined by genome content and
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cell type. My data suggest that viral genes are differentially regulated at the level of 
transcription and may have distinct functions in the virus life cycle.
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Chapter 5
Differential modulation of cellular transcriptomes bv
HCMV Toledo
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5.1 Introduction
HCMV genes and induced cellular factors have the potential to exert profound effects 
on host cell gene expression. The very first steps of HCMV infection, binding and 
entry, generate a number of cellular signalling responses and the induction of 
interferon response genes (Albrecht et al, 1990, Boldogh et al, 1990, 1991, Zhu et al, 
1997, Navarro et al, 1998, Zhu et al, 1998, Yurochko and Huang, 1999). This 
indicates that viral cell surface binding plays a predominant role in stimulating host 
cell gene expression. Binding of ultraviolet light-inactivated virions to cells can also 
trigger intracellular signalling cascades (Boldogh et al, 1993, Yurochko et al, 1995). 
Additionally, soluble forms of viral proteins gB or gH able to stimulate cells on their 
own (Yurochko et al, 1995, Boyle et al, 1999, Simmen et al, 2001). It is possible that 
many of the early changes in cellular genes are not specific to gB or gH, but are 
caused by the triggering of an innate defensive pathway that detects attachment or 
entry of a variety of viruses in general and leading to general immune system gene 
transcription. Alternatively, cell surface binding induced gene expression changes 
may be necessary for effective viral infection and replication. As infection proceeds, 
expression of viral proteins then regulates cellular signalling pathways and gene 
expression to aid viral replication (Stinski, 1977, Albrecht et al, 1984, Santomenna 
and Colberg-Poley, 1990, Rodems and Spector, 1998).
HCMV is an intracellular parasite and therefore relies on host cell to provide 
functions to allow viral replication, such as DNA metabolism enzymes, DNA 
polymerase (Hirai and Watanabe, 1976), transcription factors (Boldogh et al, 1990, 
Sambucetti et al, 1989, Yurochko et al, 1997) and cell cycle genes (Jault et al, 1995, 
Dittmer and Mocarski 1997, Salvant et al, 1998, Sinclair et al, 2000). The fact that 
HCMV infection stimulates host cell proliferation suggests a possible involvement in 
chronic proliferative disorders, such as vascular diseases (Spector and Spector, 1984, 
Thompson et al, 1993, Epstein et al, 1996).
Detection of the cellular transcription pathways that are activated or repressed during 
viral infection can lead to a better understanding of the virus-host interaction and to 
the discovery of new targets for therapy. DNA array technology has the potential to 
offer an unparallel view of the transcription changes that underlie the host response to
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pathogens. Zhu et a l  (Zhu et a l  1998) reported the first analyses of the interaction of 
a HCMV with a host cell using microarrays. They catalogued 258 genes whose 
expression levels varied 4-fold early in the virus replication cycle, up to 24 hours post 
infection. Some of these were further confirmed by northern blotting. This study and 
the majority of other studies investigating the replication of HCMV have used human 
fibroblasts. Nevertheless, HCMV infects a wide variety of cell types in vivo, including 
fibroblasts, endothelial cells, epithelial cells and macrophages. As these cell types are 
diverse and express different gene sets, the interaction of the virus with the cellular 
machinery however, may differ from cell type to cell type. This interaction may 
profoundly influence HCMV replication and pathogenesis. Endothelial cells have an 
essential role in HCMV pathobiology, since they can function as reservoirs of 
persistent virus as well as carriers of the virus in the HCMV dissemination pathway 
(Fish et a l  1995). They also are an important component of the inflammatory 
response, since they are located between blood and tissue and are constantly exposed 
to circulating leukocytes (Pober, 1999). Finally, they can be induced by cytokines to 
function as antigen presenting cells (Pober et a l  2001).
The combination of DNA arrays and RT-PCR has allowed us to identify the 
transcription profile of a region of the HCMV genome thought to be crucial for 
disease pathogenesis in vivo, and provide insights into the functions of previously 
uncharacterised HCMV genes (see sections 4.2.2 and 4.2.3). The aims of this chapter 
are to use the HCMV-human microarray to identify fibroblast and endothelial cell 
responses to HCMV infection.
5.2 Results
5.2.1 Sample preparation
To test the hypothesis that HCMV causes specific cell type gene expression changes 
that relate to disease pathology, gene expression of ToledoE-infected cells was 
analysed at several time points after infection (0, 6, 12, 24, 48, 72 and 96 hours). Two 
types of cells were used, MRC-5 fibroblasts and human umbilical vein endothelial 
cells (HUVEC). Uninfected MRC-5 cells and HUVEC were also included in the 
analysis. In addition, fibroblasts infected with AD 169 or ToledoF were analysed (96
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hours). Total RNA was purified from all samples and the quality assessed by agarose 
gel electrophoresis (Figure 5.1). mRNA was purified, amplified and labelled with Cy5 
using RT-PCR. Labelled cDNA was mixed with Cy3-labelled reference RNA and 
hybridised to the HCMV-human microarray. A common reference RNA mixture was 
used to permit comparison across the whole sample set (see section 4.1.2.2).
5.2.2 Gene expression in fibroblasts
The arrays were used to determine the host gene response to HCMV Toledo infection 
of fibroblasts. To confirm the reproducibility of the arrays, duplicate hybridisations 
were performed for the time-course of infection in fibroblasts, giving consistent 
results (Figure 4.9). One array was selected for each of the 9 samples and the data 
were filtered to produce a set of 1,203 human genes. The data were examined by 
cluster analysis to identify patterns in the gene expression data and identify 
relationships between the samples. Both the genes and samples were ordered using a 
self-organising map algorithm, which minimises the differences between adjacent 
nodes. This ordering was then used to control the orientation of the nodes of the 
dendrograms subsequently generated by hierarchical clustering. HCMV causes 
different gene expression patterns at different time points during lytic infection. This 
resulted in two clusters of gene expression, revealing a demarcation between early 
and late events in viral replication at the level of the host genes (24-48h) (Figure 5.2). 
Early-infected cells cluster together, indicating that they share the same gene 
expression pattern, while all late stage-infected cells form a separate cluster. The two 
final major branches are composed of cell infected with AD 169 and ToledoF, 
respectively. Their clustering indicates they have similar gene expression patterns 
compared to cells infected with ToledoE.
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Figure 5.1. Purified total RNA. (A) Total RNA was quantified by UV 
spectrophotometry and lpl separated by agarose gel electrophoresis. The position of 
28S and 18S ribosomal RNA is indicated. The numbers indicate hours after infection.
(B) Composition of reference RNA. (C) RNA extracted from fibroblasts infected with 
AD 169 and ToledoF.
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Figure 5.2. Hierarchical clustering of gene expression data. Each column represents 
the results from one array and each row one gene. Columns 1 to 7 show fibroblasts at 
successive time points in hours post infection with HCMV ToledoE. Columns 8 and 9 
show fibroblasts infected with ToledoF and AD 169, respectively.
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5.23 Gene expression programmes in fibroblasts and HUVEC
Gene expression of HCMV-infected cells was analysed at several time points after 
infection with Toledo (0, 6, 12, 24, 48, 72 and 96 hours). The programme TreeView 
(Eisen et al., 1998) was used to visualise the expression of the filtered set of 1746 
genes (Figure 5.3) to reveal how expression of the genome varies throughout the time- 
course of HCMV infection and how gene expression in infected fibroblasts relates to 
that in infected endothelial cells. The analysis resulted in two clusters of gene 
expression, showing a clear distinction between the two time-courses and cell types 
(Figure 5.3). In turn, within each time-course, a separation between the early and late 
time points is evident. The two last branches of the tree (columns 8, 9) are composed 
of late stage cells infected with ToledoF and AD 169, respectively. Their clustering 
indicates they have similar gene expression patterns compared to fibroblasts and 
endothelial cells infected with ToledoE. Overall, the clustering shows that at late 
times after infection (96h), all cell types, irrespective of infecting virus, look similar 
in terms of host gene expression. This is not surprising, since at that point cells are 
producing virus and dying. At 96 hours after infection, a decrease in the amount of 
cellular mRNAs hybridising to the arrays was observed. Earlier time points are cell 
type specific, showing that up to 72 hours the virus manipulates each cell type 
specifically.
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Figure 5.3. Hierarchical clustering of 16 samples and a filtered set of 1746 genes. The 
dendrogram on the left represents the relationship between genes in terms of their 
expression pattern. Gene expression is shown as a pseudo-coloured representation of 
log(2) expression ratio with red being above and green below the row/column median 
level of expression (set to 0) as shown by the scale. Columns 1 to 14 show fibroblasts 
and HUVEC at various time points in hours post infection with HCMV ToledoE. 
Columns 15 and 16 show fibroblasts infected with ToledoF and AD 169, respectively.
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In order to aid interpretation I used knowledge of the “domain” to order the arrays by 
time and cell type, producing a set of 1909 human genes (Figure 5.4). The genes and 
samples were ordered using a self-organising map algorithm and subjected the genes 
to hierarchical clustering. This revealed how expression of the genome changes 
throughout the time-course of infection with HCMV Toledo. A number of gene 
expression signatures can be identified in the data. Clustering of data from the time- 
courses in fibroblast and endothelial cells indicated that the levels of certain classes of 
host genes were notably affected in response to HCMV infection. A subset of these 
genes has been previously, reported, to be modulated by the AD 169 strain in 
fibroblasts. Some examples include induction of cyclin E, CD54, Toll-like receptor 2, 
caspase 2 and complement C lr transcripts (Browne et al, 2001). I observed the same 
transcriptional patterns in fibroblasts after infection with HCMV Toledo. 
Nevertheless, I found these genes to be down regulated in endothelial cells, 
emphasising a degree of divergence of cell responses to viral infection.
In the following sections I will investigate how the virus modulates gene expression 
in the two cell types and compare it to previous findings. To make this manageable, I 
will break down the analysis into distinct cellular processes or disease phenotypes.
175
Figure 5.4. Hierarchical clustering of gene expression data. Each column represents 
the results from one array and each row one gene. Columns 1 and 2 show uninfected 
fibroblasts and HUVEC. Columns 3 to 9 show fibroblasts at successive time points in 
hours post infection with HCMV Toledo. Columns 10 to 16 show HUVEC at 
successive time points post infection. The dendrogram on the left represents the 
relationship between genes in terms of their expression pattern. Gene expression is 
shown as a coloured representation of log(2) expression ratio with red being above 
and green being below the median level of expression.
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5.2.3.1 Apoptosis
Apoptosis is a way of ridding the body of unwanted cells, contributing to normal 
physiology. Furthermore, it is an antiviral defence mechanism that the host uses to 
eliminate infected cells and restrict viral propagation. To overcome this response, 
many viruses encode proteins that prevent or attenuate apoptosis in infected cells 
(O’Brien, 1998). Productive HCMV infection confers resistance to apoptosis induced 
by a variety of stimuli such as ligation of the death receptor Fas or TNFR1 and serum 
withdrawal (Kovacs et al, 1996, Goldmacher et al, 1999). HCMV encodes 4 proteins 
with anti-apoptotic function, IE1, IE2, UL37 and UL36 (Zhu et al, 1995, Goldmacher 
et al, 1999, Skaletskaya et al, 2001). HCMV can directly modulate various cellular 
genes in order to prevent apoptosis in infected cells (Zhu et al, 1995). Previous studies 
have shown that infection of fibroblasts with AD 169 suppresses caspases 1, 2 and 8 
(Browne et al, 2001, Skaletskaya et al, 2001). Sequential activation and over- 
expression of caspases plays a central role in the execution-phase of apoptosis. I 
found caspases 4 and 7 to be dramatically down regulated by Toledo in both 
fibroblasts and endothelial cells (at 72 and 48h pi respectively), indicating an 
interference of the virus in the caspase cascade at two additional positions (Figure 
5.5A). Caspase 6 levels were preferentially down-regulated in endothelial cells, 
indicating a specific role for this gene in endothelial cells.
5.2.3.2 Cell cycle progression
Different viruses have different effects on the host cell cycle. Array analyses have 
shown that this variability may be due to differential effects on host gene expression. 
HPV infection stimulates entry into the cell cycle through viral gene E7 (Dyson et al, 
1989, Munger et al, 1989, Nees et al, 2000) and the up-regulation of host genes that 
mediate cell cycle progression (Chang and Laimins, 2000). Endothelial cells latently 
infected with KSHV down-regulate GADD45 and p57-KIP2, involved in cell cycle 
arrest in Gi, and over-express cell cycle progression genes (Moses et al, 2002). The 
up-regulation of proliferation-associated genes by HPV and KSHV may explain their 
oncogenic potential.
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HSV-1, reovirus serotype 3, echovirus 1 and HIV-1 infections lead to cell cycle arrest 
at the G2/M stage. All of these viruses up-regulate GADD45 (Hobbs and DeLuca, 
1999, Khodarev et al, 1999, Pietiainen et al, 2000, Corbeil et al, 2001, Poggioli et al,
2002), a cdc2 kinase inhibitor (Wang et al, 1999), suggesting this may be a common 
mechanism for virus induction of cell cycle arrest. In addition to the up-regulation of 
GADD45, reovirus serotype 3 up-regulates two inhibitors of cdc2 kinase activity in 
M-phase, and a number of mitotic spindle checkpoint genes. Furthermore, reovirus 
serotype 1, which does not cause cell cycle arrest, has no elfect on the expression of 
these genes (Poggioli et al, 2002).
HCMV is known to cause cell cycle arrest. Quiescent fibroblasts infected in vitro with 
AD 169 start synthesising several enzymes required for DNA replication. This 
activation however does not seem to lead to cell division, but in Gl/S arrest. This 
virally-induced block can take place at multiple points in the cell cycle, depending on 
the phase of the cell cycle at which infection occurs (Jault et al, 1995, Biswas et al,
2003). It seems that the virus creates a favourable environment for its own replication, 
at the host’s expense. A number of cyclins are regulated by HCMV, including cyclin 
B, D3, E2 and G1 (Salvant et al, 1998, Browne et al, 2001). I identified a number of 
genes that were suppressed in fibroblasts and endothelial cells at late time points after 
infection, that are also required for cell cycle progression (Figure 5.5B).
Cell division cycle 2 plays a key role in the control of the eukaryotic cell cycle and is 
essential for Gl/S and G2/M phase transitions of eukaryotic cell cycle. Cell cycle 
progression 2 suppresses G1 arrest. The transcript levels of these genes were 
suppressed by 72 hours after infection in both cell types. E2F-related transcription 
factor was also reduced. This gene can bind DNA cooperatively with E2F family 
members through the E2 recognition site, found in the promoter region of a number of 
genes whose products are involved in cell cycle regulation or in DNA replication. The 
DP2/E2F complex, functions in the control of cell cycle progression, from G1 to S 
phase. Cyclin D1 forms a complex with and functions as a regulatory subunit of 
CDK4 or CDK6, whose activity are required for cell cycle Gl/S transition. This 
protein has been shown to interact with tumor suppressor protein retinoblastoma (Rb) 
with its expression regulated positively by Rb. Cyclin D1 levels were reduced by 48 
and 24 hours after infection in fibroblasts and HUVEC, respectively. This reduction in
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cell cycle genes coincides with increased accumulation of viral transcripts (see section 
4.2.2).
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Figure 5.5. Changes in fibroblast and HUVEC gene expression profiles, induced by 
HCMV Toledo. mRNAs affected are involved in (A) apoptosis and (B) cell cycle 
progression.
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§.2.3.3 Host cytoskeleton, transcription and signal transduction
Several studies indicate that viruses can induce cytoskeletal modifications in host 
cells (Kang et al, 2002, Bost et al, 2003, Nunbhakdi-Craig et al, 2003, Yang et al,
2003). HCMV infection causes a rapid, progressive disruption of the host 
cytoskeleton that correlates with actin depolymerisation. The disruption can be seen 
within two minutes of infection by electron microscopy (Jones et al, 1986). Actin 
appears to be the primary cytoskeletal target involved during HCMV infection, while 
a loss of microtubuli has also been documented within 12 hours after infection 
(Pfeiffer et al, 1983). These disruptions could facilitate viral infectivity by inhibiting 
the transport of host proteins that are essential for presentation of antigens to the 
immune system. Additionally, these early events correlate with a transient interruption 
of cellular mRNA translation and may represent a process whereby HCMV gene 
expression becomes competitive with that of the host cell (Jones and Kilpatrick, 
1988). The Arp2/3 complex is required for the formation of actin filaments, 
presumably at the nucleation step (Higgs and Pollard, 2001, Narumiya and Mabuchi, 
2002). I observed a down-regulation of ARP3, and ARP2/3 protein complex subunits 
p34 and p21 (Figure 5.6). This down-regulation could represent a strategy that HCMV 
uses to mediate its effects on actin depolymerisation and subsequent disruption of host 
cytoskeleton.
The cluster also contains four metallothionein genes, suggesting that there may be a 
common transcriptional regulatory machinery for the metallothionein genes (Figure 
5.6). Metallothionein I (MT-I) and MT-II have been implicated in the protection of 
cells against reactive oxygen species (ROS), heavy metals, and a variety of 
pathological and environmental stressors. Studies have demonstrated that MT-I and 
MT-II can be significantly induced in the liver and lung following experimental 
influenza virus (Ghoshal and Jacob, 2001). A recent study showed however, that 
coxsackievirus B3 infection leads to suppression of metallothionein genes and 
increased accumulation of environmental pollutants (Funseth et al, 2002). These 
findings suggest that HCMV may interfere with the normal host responses during 
acute infections by down-regulating detoxifying processes in favour of acute-phase 
viral protein synthesis.
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Figure 5.6. This cluster represents genes that are under-expressed in fibroblasts and 
HUVEC. The cluster contains genes that are involved in regulation of transcription 
and translation and in signal transduction. Lanes 1 and 2 represent uninfected 
fibroblasts and endothelial cells, respectively. Lanes 3 to 9 show time points after 
infection of fibroblasts with ToledoE, while lanes 10 to 16 show the array results from 
ToledoE-infected endothelial cells.
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TGF-beta (transforming growth factor beta) receptors form a heteromeric complex 
after binding TGF-beta at the cell surface and act as signal transducers (Hayes et al,
2002). The receptor for TGF-beta is down-regulated in fibroblasts, but to a further 
extent in HUVEC (Figure 5.6). The TGF-beta receptor is one of the substrates for the 
paired basic amino acid cleaving enzyme (PACE4) (Yoshida et al, 2001). The protein 
encoded by this gene belongs to the subtilisin-like proprotein convertase family. The 
members of this family are proprotein convertases that process latent precursor 
proteins into their biologically active products. PACE4 protein is a calcium-dependent 
serine endoprotease that can cleave precursor protein at their paired basic amino acid 
processing sites. My results show that TGF-beta receptor and PACE4, two 
functionally related genes, share the same expression profile, and therefore may be 
co-ordinately regulated.
5.2.3.4 HCMV disease associations 
Atherosclerosis
A link between HCMV infection and atherosclerosis has been suggested by 
experimental, clinical and epidemiological studies (see section 1.9.5). Since 
endothelial cells infected with HCMV may be involved in the atherosclerotic 
pathway, I looked at HCMV-induced gene expression changes. I observed a loss of 
anti-coagulant gene expression in endothelial cells (Figure 5.7). These included 
members of the plasminogen subfamily. Plasminogen is the inactive precursor of the 
serine protease plasmin, which after activation is converted to plasmin, unfolding a 
potent enzymatic domain that dissolves the fibrinogen fibres that trap the blood cells 
in a blood clot, in a process called fibrinolysis. Plasminogen mRNA levels decreased 
by a factor of 9 by 24 hours after infection with HCMV. Other genes with sequence 
homology to plasminogen and with fibrinolytic activity were also down-regulated in 
infected endothelial cells, such as the hepatocyte growth factor proteins. Expression 
of heparan sulfate 3-O-sulphotransferase was also suppressed. Heparan sulfate is a 
linear polymer covalently attached to the protein cores of proteoglycans, which are 
abundant and ubiquitously expressed in almost all animal cells as integral membrane 
proteins, glycosylphophatidylinositol-linked membrane proteins, and proteins of the 
extracellular matrix. It assembles by the action of a large family of enzymes, with 
tissue-specific and developmentally regulated expression of enzyme isoforms (eg at
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least four V-deacetylation/V-sulfotransferases, three 6-O-sulfotransferases, and five 3- 
Osulfotransferases produce HS chains with distinct sequences) (Shworak et al, 1997,
1999). These different sequences enable interactions to occur with a broad array of 
protein ligands that modulate a wide range of biological functions in development, 
differentiation, homeostasis, viral entry, and coagulation cascade. Since heparan 
sulfate 3-O-sulfotransferase is required for the anti-coagulant properties of heparan 
sulfate, its suppression in HCMV-infected endothelial cells may contribute to the 
increased coagulation observed in infected individuals.
The virus was also shown to up-regulate the expression of two genes that contribute to 
the acceleration of coagulation; phospholipid scramblase, which plays a central role in 
the initiation of fibrin clot formation (Basse et al, 1996) and placental bikunin, an 
inhibitor of plasminogen and hepatocyte growth factor proteins (Hamasuna et al, 
2001) (Figure 5.7). Transcript levels of the matrix metalloproteinases (MMP) 2 and 
13, were reduced by 6 and 24 hours, respectively, in infected HUVEC. Several studies 
have documented the fibrinolytic activity of MMPs, and their essential role in 
neovessel formation in vitro and in vivo (Hiraoka et al, 1998). Finally, the MMP 
activators cathepsins D, H and L, were also down-regulated by 24 hours after 
infection. Overall, the results are compatible with previous evidence that the virus 
might have pro-coagulant properties (Pryzdial and Wright, 1994, Yonemitsu et al, 
1998, Neumann et al, 2000). The combination of the pro-coagulant effects o f HCMV 
infection and decreased fibrinolysis may promote the development of atherosclerosis. 
Additionally, CD59 was down-regulated at late time points of infection regardless of 
the virus strain or cell type used. CD59 is a crucial membrane complement-regulatory 
protein that prevents host cells from membrane attack complex (MAC)-induced 
cytolysis. Impaired endothelial CD59 activity may render vascular cells susceptible to 
MAC-induced proliferation and contribute to the development of vascular 
proliferative disorders.
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Figure 5.7. Expression of anti-coagulant genes decreases in HCMV-infected 
HUVEC, while the levels of placental bikunin (plasminogen inhibitor) and 
phospholipid scramblase (involved in fibrin clot formation) transcripts increase.
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Other disease-associated genes
In the setting of immunosuppression, HCMV can affect both the central and 
peripheral nervous systems. Neurological manifestations of HCMV infection include 
encephalitis, hearing loss, mental retardation, ventriculitis, myelitis, retinitis and 
peripheral neuropathies (Maschke et al, 2002). Studies have shown that defects in the 
gene transforming growth factor beta-induced (TGFBI) can cause five corneal 
dystrophies (Fujiki et al, 2000, Hirano et al, 2001, Schmitt-Bemard et al, 2002, 
Sakimoto et al, 2003). My results show that TGFBI mRNA is reduced by 24h after 
infection of endothelial cells with Toledo HCMV (Figure 5.8). Additionally, I found 
genes involved in eye lens structure and transmission of the visual signal to be 
significantly down regulated in HUVEC after virus infection HRG4, cone-specific 
cGMP and crystalline genes.
Defects in the pro-a2 chain of collagen type XI (coll la2) are the cause of a skeletal 
dysplasia, which is accompanied by severe hearing loss (Vikkula et al, 1995, McGuirt 
et al, 1999, De Leenheer et al, 2001). The coll la2 mRNA was reduced considerably 
by 24h after infection with Toledo. Furthermore, defects in dihydroxyacetone 
(GNPAT) cause severe growth and mental retardation, retinal pigmentary 
degeneration, sensorineural deafness (Burdette et al, 1996). GNPAT mRNA levels 
were decreased within an hour after HCMV infection of endothelial cells (Figure 5.8). 
The modulation of these genes by the virus could contribute to the development of 
HCMV-associated diseases.
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Figure 5.8. HCMV replication in HUVEC represses activation of genes that are 
essential for transmission of the visual signal (TGFBI, HRG4, cone-specific cGMP, 
crystalline) and proper functioning of the nervous system (protease inhibitor 12, 
collagen XI, dihydroxyacetone).
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5.2.3.5 Mitochondrial genes
Studies have shown that HCMV AD 169 disrupts the fibroblast reticular mitochondrial 
network (McCormick et a l, 2003, Hertel et al, unpublished data) and stimulates 
mitochondrial DNA synthesis as well as lipid turnover (Furukawa et al, 1976). My 
data indicate that HCMV Toledo enhanced the mitochondrial transcription in 
endothelial cells 6 hours after infection, while mRNA levels in fibroblasts remained 
relatively unaltered (Figure 5.9).
Genes affected include mitochondrial membrane transporters and members of the 
respiratory chain, all of them encoded by the nuclear genome, apart from NADH- 
ubiquinone oxidoreductase, which is mitochondrially-encoded. The consequences of 
these modifications are not yet understood. One possibility is that endothelial cells 
have a low metabolic potential. To replicate efficiently in such an environment, 
HCMV may need to increase energy production in order to complete its replication 
cycle.
fc<X
COX17
Cytochrome b-5 
ADP, ATP carrier protein 
Cytochrome c1 
Cytochrome c-1 
Cytochrome c oxidase
ATP synthase , H+ transporting 
V oltage-dependent anion channel
Mitochondrial ATP syn thase  
Ubiquinol-cytochrome c reductase  
NADH-ubiquinone oxidoreductase 
Succinate  dehydrogenase  1
Figure 5.9. Expression of genes involved in ATP production increases in HCMV-
infected HUVEC.
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S.2.3.6 Immune responses
A virus capable of causing lifelong persistent infection must be able to effectively 
avoid the host’s immune response. HCMV has developed various evasion strategies to 
deal with almost every immune effector mechanism (see section 1.8.3). Little is 
known however about the viral regulation of host immune genes in different cell types 
as a further strategy in immune evasion. This section presents and compares 
alterations to such genes, induced as a result o f HCMV infection of fibroblasts and 
endothelial cells.
Toll-like receptors
Toll-like receptors (TLRs) are a family of ten receptors involved in microbial 
recognition by the immune system (Takeda and Akira, 2003). TLRs recognise a broad 
spectrum of ligands, including modified lipids, proteins and nucleic acids. This 
observed diversity in TLR ligands has raised the suggestion that different TLRs may 
activate different downstream responses and that these differences may help shape the 
immune responses to be effective against specific organisms. For example, it was 
recently demonstrated that TLR4 induces responses that are not activated by TLR2 
(Barton and Medzhitov, 2002, Mun et al, 2003). All TLRs however, activate a 
common signalling pathway that results in the activation of nuclear factor NF-kB 
transcription factors (Barton and Medzhitov, 2003), thereby generating an innate 
immune response. Apart from recognising bacteria and plant viruses, TLRs may also 
function in the recognition of viruses in mammals (Whitham et al, 1994). 
Experimental evidence has shown that the respiratory syncytial virus (RSV) persists 
longer in the lungs of Toll-like receptor 4 (TLR4)-deficient mice (Kurt-Jones et al,
2000), indicating the importance of TLR4 in the pathogenesis of RSV disease. 
Additionally, vaccinia virus may evade host immune responses by suppressing TLR- 
dependent intracellular signalling (Bowie et al, 2000, Harte et al, 2003). Therefore, 
activation of TLRs may be involved in protecting the host from virus infection.
It has recently been shown that mere cell contact by HCMV particles leads to 
profound modulation of cellular gene expression, including induction of inflammatory 
cytokines and interferon-stimulated genes characteristic of innate immune detection
188
(Simmen et al, 2001). These findings suggested that a membrane receptor recognizes 
a HCMV envelope protein(s), leading to innate immune activation. Indeed, recent 
studies by Compton et al demonstrated that TLR2 recognizes HCMV virions and 
triggers inflammatory cytokine production, mediated via TLR2-dependent activation 
of NF-kB (Compton et al, 2003). Interestingly, I observed a suppression of TLR2 
transcription by a factor of 9, 12h after infection of endothelial cells but not 
fibroblasts. A decrease in TLR2 levels in response to HCMV infection could reflect 
the shutdown of the NF-kB pathway. Consistent with a suppression of the activation 
of the NF-kB pathway in endothelial cells, I observed a down-regulation of several 
other molecules involved in the activation of this pathway (interleukin-1 receptor 
associated kinase, TNF type 2 receptor associated protein, TNF receptor 2 and cell 
death protein RIP) (Cusson et al, 2002, Jiang et al, 2002, Koay et al, 2002). Recent 
studies have also shown that HCMV infection of monocytic cell lines resulted in a 
reduction in cell surface expression of TNF-alpha receptor (TNFRI) (Baillie et al,
2003). Therefore, it seems that HCMV infection prevents external signalling to the 
cell in order to optimise the cellular environment for virus replication.
Interferon response and inflammation
Following infection, mammalian cells initiate a transcriptional program in order to 
create an antiviral response. This is usually embodied by the synthesis and secretion 
of type I and II interferons (IFN). Infection by EBV, KSHV, Marek’s disease virus, 
rhesus rotavirus, measles virus, RSV, pneumonia virus of mice (PVM), hepatitis C 
virus (HCV) and HIV-1 all lead to an increase in the expression of interferon- 
stimulated genes (Bigger et al, 2001, Browne et al, 2001, Corbeil et al, 2001, Morgan 
et al, 2001, Bolt et al, 2002, Cuadras et al, 2002, Domachowske et al, 2002, Poole et 
al, 2002, Tian et al, 2002), indicating the activation of the cellular anti-viral response 
(Goodboum et al, 2000). The function for interferon responsive genes in the anti-viral 
response is further supported by array analysis showing that the induction of 
interferon-responsive genes in the liver during HCV infection of a chimpanzee 
correlates with the clearance of viraemia (Bigger et al, 2001). Some viruses are able 
to suppress the transcriptional induction of host anti-viral genes, such as HP Vs 
(Chang and Laimins, 2000, Nees et al, 2000). Similarly, there is no substantial 
induction in the expression of interferon responsive genes upon HSV-1 and influenza
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virus infection ( Geiss et al, 2001, Mossman et al, 2001). Array data therefore suggest 
that HSV-1, influenza virus and HPV all express genes that prevent the host anti-viral 
response at the transcriptional level.
Studies have shown that while the AD 169 strain of HCMV inhibits IFN signal 
transduction in fibroblasts, it also activates some IFN-responsive genes (Zhu et al, 
1998). The number of interferon-response genes up-regulated by UV-inactivated 
HCMV is also greater than for transcriptionally active virus (Browne et al, 2001). 
Treatment of cells with HCMV gB alone results in the induction of the host 
interferon-response genes, suggesting that gB binding is responsible for this up- 
regulation (Simmen et al, 2001). I found that the low passage strain of HCMV, 
Toledo, strongly induces the accumulation of IFN-responsive RNAs very early during 
its replication cycle in endothelial cells (6-12h pi) (Table 5.1). Interestingly, the 
induction is weak and delayed in fibroblasts.
One cluster of genes that are strongly induced in endothelial cells after HCMV 
infection are those with known anti-viral properties or that are induced by interferon 
(Figure 5.10A). The anti-viral cluster contains genes that act within cells to inhibit 
virus replication, such as IRF-1, IFI27 and STAT1 (Samuel, 2001). The interferon- 
induced 17 kD protein (interferon stimulated gene (ISG) 15), which is released upon 
virus infection (Cook et al,. 1995) and interferon-inducible protein 1-8U are also up- 
regulated strongly in endothelial cells, as indicated by my data. The virus also 
increases the expression levels of two genes that are transcribed in response to IFN- 
gamma, namely death-associated protein kinase 1 (Cohen et al, 1997, Inbal et al, 
1997, Chawla-Sarkar et al, 2003) and NMI (Zhu et al, 1999, Zhou et al, 2000, Chen 
and Naumovski, 2002). Genes responsible for antigen presentation are also contained 
within the anti-viral cluster, such as MHC class I and tapasin, a protein involved in 
the association of MHC class I with transporter associated with antigen processing 
(TAP) and in the assembly of MHC class I with peptide (Momburg and Tan, 2002, 
Garbi et al, 2003, Vilches, 2003) (Figure 5.10B). Overall, my results indicate that the 
virus affects IFN signalling differentially in fibroblasts and endothelial cells, inducing 
a vigorous response in the latter cell type. This could be a tactic that HCMV employs 
in order to reduce its replication levels, facilitating its long-term association with the 
host.
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The same cluster contains four inflammatory genes, proteoglycan 1, CD9 antigen, 
leukotriene A4 hydrolase and microsomal glutathione S-transferase (Broberg et al, 
2002, Haeggstrom et al, 2002, Sherratt et al, 2003, Zaitsu et al, 2003) (Figure 5.10C). 
The latter two genes mediate prostaglandin synthesis. It has been shown that the 
synthesis of prostaglandin E2 is activated by the induction of cox-2 in HCMV- 
infected fibroblasts (Zhu et al, 1998). Furthermore, experiments using cox-2 
inhibitors in fibroblast cultures showed that there is a dose-dependent inhibition of 
HCMV growth in vitro. It therefore seems likely that the virus requires this pathway 
to complete its replication cycle. We observed increased accumulation in 
prostaglandin synthesis in endothelial cells compared to fibroblasts, occurring at just 1 
hour after infection (leukotriene A4 hydrolase, microsomal glutathione S-transferase) 
(Figure 5.10C). This could have significant clinical applications, since it suggests that 
inhibitors may have differential effects in different cells in the body.
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Figure 5.10. Induction of immune response genes after HCMV infection of 
fibroblasts and HUVEC.
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MHC-ll and complement
One of the major mechanisms of immune recognition that HCMV must overcome is 
presentation of antigens by MHC class II to stimulate the adaptive immune response. 
A number of reports indicate that HCMV interferes with both MHC class I and II 
pathways of antigen presentation (Gil-Torregrosa et al, 1998). Under normal 
circumstances, IFN-gamma is a potent inducer of MHC class II expression in antigen 
presenting cells and other cell types such as endothelial and epidermal cells (Fritchley 
et al, 2000, Skovseth et al, 2002). However, in HCMV-infected cells, IFN-gamma is 
unable to induce the production of MHC class II mRNA, suggesting an interference 
with the Jak/Stat signal transduction pathway (Sedmak et al, 1994, Miller et al, 1998). 
There is also considerable evidence that HCMV may disrupt MHC class II expression 
in infected monocytes (Moutaftsi et al, 2002). My results show that the virus induces 
a sharp shutdown in MHC-II transcription in endothelial cells within an hour after 
infection and lasting for 72h pi, possibly preventing a full cytotoxic T cell (CTL) 
response by modulating the T helper response and leading to persistence of the virus 
in the body (Figure 5.11).
Another arm of the immune system that HCMV must combat is the humoral response. 
Viruses may be eliminated from the body via complement-mediated lysis of infected 
cells. HCMV infection increases the fibroblast cell surface expression of two proteins, 
membrane cofactor protein (or CD46) and decay accelerating factor (CD55), two 
members of the regulator of complement activation (RCA) gene cluster, by up to 
eightfold (Spiller et al, 1996). Under normal conditions, these proteins protect host 
cells from complement-mediated cell lysis by inhibiting C3 convertases (Lindahl et 
al, 2000, Miwa and Song 2001). The role of CD55 in protection of HCMV virions 
against complement-mediated cell lysis was established by stripping virions of CD55 
and showing that these virions were more susceptible to lysis, while reconstitution of 
CD55 restored resistance to lysis (Spear et al, 1995). My analysis showed that HCMV 
Toledo induces up-regulation of CD46 and CD55 in both fibroblasts and HUVEC, but 
to higher levels in the latter cell type. Additionally, the complement components 1, C2 
and 8 were suppressed at 6h after infection only in HUVEC (Figure 5.11). Overall, 
the inhibition of the complement cascade was more prominent in endothelial cells 
compared to fibroblasts. The down-regulation of complement proteins in endothelial
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cells has not been shown before and represents a unique strategy of HCMV for 
modulation of the complement cascade. The circumvention of complement attack can 
lead to persistence of HCMV-infected endothelial cells in the circulation and 
subsequent spread of the virus to different sites in the body.
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Figure 5.11. (A) Different cellular transcriptional responses to HCMV Toledo infection using DNA  
microarrays. When HUVEC and fibroblasts were infected, differential gene expression occurred in the 
two cell types. (B) Detail o f  the cluster. Infection o f  HUVEC results in down regulation o f  MHC class 
II and complement genes.
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Gene Change of gene 
expression in 
fibroblasts
Change of gene 
expression in 
HUVEC
Cell cycle genes
Cyclin E Induced Suppressed
Cell division cycle 2 Suppressed Suppressed
Cell cycle progression 2 Suppressed Suppressed
E2F-related transcription factor Suppressed Suppressed
Cyclin D1 Suppressed Suppressed
Interferon-responsive genes
IFN-inducible protein 1-8U Induced Induced strongly
IFN-induced 17kD Induced Induced strongly
Interferon regulatory factor 1 (IRF1) Induced Induced strongly
IFI27 Induced Induced strongly
DAP-kinase Induced Induced strongly
NMI Induced Induced strongly
Tapasin (NSG-17) Induced Induced strongly
Apoptotic genes
Caspase 4 Suppressed Suppressed
Caspase 6 Induced Suppressed
Caspase 7 Suppressed Suppressed
GT197 partial ORF Suppressed Suppressed
E1B 19K/Bcl-2-binding protein Mip3 Suppressed Suppressed
Complement pathway genes
Complement C1 r Induced Suppressed
Complement C2 Induced Suppressed
Complement 8 Induced Suppressed
CD46 Induced Suppressed
CD55 Induced Suppressed
Prostaglandin synthesis genes
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Leukotriene A4 hydrolase Induced Induced strongly
Microsomal glutathione transferase Induced Induced strongly
Mitochondrial genes
COX 17 Suppressed Induced
Cytochrome b-5 Induced Induced
NAD-dependent methylene Induced Induced
ADP, ATP carrier protein Suppressed Induced
Cytochrome cl Suppressed Induced
Cytochrome c-1 Suppressed Induced
Cytochrome c oxidase Suppressed Induced
ATP synthase, H+ transporting Suppressed Induced
Voltage-dependent anion channel Suppressed Induced
Mitochondrial ATP synthase subunit Suppressed Induced
Ubiquinol-cytochrome c reductase Suppressed Induced
NADH-ubiquinone oxidoreductase Suppressed Induced
Succinate dehydrogenase 1 Suppressed Induced
Atherosclerosis-related genes
Hepatocyte growth factor-like protein Induced Suppressed
Plasminogen Induced Suppressed
Macrophage stimulating 1 Induced Suppressed
Heparan sulfate Induced Suppressed
Placental bikunin Induced Induced
Phospholipid scramblase Suppressed Induced
Disease-associated genes
TGF beta-induced Suppressed Suppressed
Protease inhibitor 12 Induced Suppressed
Collagen XI Induced Suppressed
Dihydroxyacetone Unchanged Suppressed
Table 5.1. Representative list of cellular RNAs modulated as a result of HCMV 
infection of fibroblasts and HUVEC.
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5.2.3.7 Mann-Whitney test
The Mann-Whitney U test is a non-parametric version of the t-Test, has been used in a 
number of array studies to assess the stastical significance of differential gene 
expression (Chambers et al, 1999, Hedenfalk et al, 2001, Notterman et al, 2001, Zhan 
et al, 2002). Using this technique, the differential gene expression of many genes in 
fibroblasts and HUVEC was found to be highly statistically significant (p<0.005) 
(Figure 5.12). This does not detect differences because of virus infection, but 
illustrates constant cell type specific differences. The expression levels of some of 
these genes remained relatively constant within the 48 hours of infection in each cell 
type. This is supporting of the fact that a number of cellular RNAs are expected to 
remain unchanged even after virus infection. Genes that are expressed at very low 
levels in HUVEC include ones involved in extracellular matrix formation and cell 
adhesion, such as alpha-3 collagen, tenascin C, procollagen-proline, CDH3, CD44, 
fibronectin 1, laminin, and collagen binding protein 1 (Erickson, 2002, Duguay et al, 
2003, Hirano et al, 2003). The bottom part of the Mann-Whitney diagram includes 
genes that are expressed at high levels in HUVEC. This cluster is mainly composed of 
genes that are part of the antiviral response to infection, such as inflammatory genes 
(TNF-alpha stimulated ABC protein, azurocidin 1) (Richard et al, 1998, Edens and 
Parkos, 2003) and interferon-inducible genes (DAP-kinase, Nmi mRNA).
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Figure 5.12. Ordering of 1990 genes using a Mann-Whitney U test, comparing gene 
expression differences between fibroblasts and endothelial cells. Each column 
represents one sample and each row one gene.
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53 Discussion
Regulation of infection and in vivo pathogenesis involves multiple points of 
interaction between viral and host factors. Deciphering the mechanisms by which 
HCMV interacts with the cell can increase our understanding of the basic biology of 
virus-host interactions, uncover genes whish are essential in pathogenesis and help to 
create appropriate strategies to combat disease.
To date, there have been no reports comparing the effects of HCMV in fibroblasts and 
endothelial cells, two cell types that clearly play a pivotal role in vivo during HCMV 
infection. In addition, most studies have used the laboratory-adapted strains of 
HCMV, which may not be fully representative of the wild type virus. In this study I 
have identified similarities and differences in viral and host transcriptional patterns 
after infection of these two cell types with a low passage strain of HCMV, using DNA 
microarrays.
Initially, the arrays were used to monitor host gene expression in fibroblasts after 
infection. The data were examined by cluster analysis to identify patterns in gene 
expression and identify relationships between the samples. Both the genes and 
samples were ordered using a self-organising map algorithm, resulting in two major 
clusters of gene expression. This revealed a separation between early and late events 
in viral replication at the level of the host genes, with the separation occurring 
between 24 and 48h after infection (Figure 5.2). Early time point infected cells 
clustered together, indicating that they share similar gene expression pattern, while 
late stage-infected cells formed a separate cluster. To assess and compare patterns of 
host and viral gene expression during HCMV infection in both fibroblasts and 
endothelial cells, the data were combined and filtered to produce a set of 1909 human 
genes. Clustering of data from the time-courses in fibroblast and endothelial cells 
indicated that the levels of certain classes of host genes were notably affected in 
response to HCMV infection. A subset of these genes has been previously, reported to 
be moderated by the AD 169 strain in fibroblasts. I found these genes to be down- 
regulated in endothelial cells, emphasising a degree of deviation of cell responses to 
viral infection. Comparative microarray analysis of VZV-infected T cells, fibroblasts 
and skin has also demonstrated many differences in the response phenotype of host
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cell genes in each gene type, including ones involved in signal transduction and 
apoptosis (Jones and Arvin, 2002). Common pathways of host gene expression were 
identified in fibroblasts and endothelial cells, including a shutdown of signal 
transduction, an inhibition of apoptosis and cell cycle progression, an increase in 
overall MHC class I transcription and the induction of an interferon-based antiviral 
response. Nevertheless, cell-type specific responses to HCMV infection were also 
observed, including increased pro-thrombotic activity, prostaglandin synthesis and the 
induction of mitochondrial-associated genes in endothelial cells but not fibroblasts. 
Surprisingly, immune responses were suppressed to a further extent in endothelial 
cells compared to fibroblasts.
The majority of genes modulated by the virus include ones that mediate host immune 
responses to infection. One reason that HCMV carries a great abundance of genes is 
that this collection provides the virus with ways to respond to different host immune 
control. Innnate and adaptive immune clearance presents a clear and present danger to 
the virus and is the target of virus immune regulation. Interestingly, a dramatic 
suppression of TLR2 RNA expression was observed after infection of endothelial 
cells but not fibroblasts. This decrease in TLR2 levels could inhibit the NF-kB 
mediated inflammatory response and subsequently lead to viral persistence in 
endothelial cells. Consistent with these findings, HCMV infection also circumvents 
the NF-kB pathway in retinal pigment epithelial (RPE) cells (Cinatl et al, 2001). This 
circumvention could explain the pathological features of HCMV in the eye, such as 
low inflammatory responses, that lead to the development of HCMV retinitis.
It has been shown that the virus also interferes with antigen presentation, apoptotic 
mechanisms and the complement cascade. My results show that the virus induces a 
rapid decrease in MHC class II expression in endothelial cells within an hour after 
infection and lasting for 72h pi. This would inhibit the presentation of viral antigens 
to T helper cells, altering CD8 T cell responses and leading to an environment 
conducive to the maintenance of the virus in the body (Figure 5.11). Furthermore, a 
strong inhibition of the complement cascade was observed in endothelial cells, and 
three novel genes in this cascade that the virus manipulates were identified, namely 
complement 1, C2 and 8 (Figure 5.11). This escape from complement attack can lead 
to persistence of HCMV-infected endothelial cells in the circulation. Another way by
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which HCMV can achieve this persistence is by inhibiting the apoptosis of infected 
cells. Indeed, in our experiments, caspases 4 and 7 were found to be significantly 
down regulated by Toledo in both fibroblasts and endothelial cells, indicating an 
interference of the virus in the caspase cascade at two additional positions (Figure 
5.5 A). All the strategies that HCMV employs can lead to persistence of infected cells 
in the circulation and subsequent spread of the virus to different sites in the body.
A startling feature of HCMV infection is how the host can be tricked into committing 
its immune response to aiding virus dissemination. For example, the results in this 
chapter indicate that the virus affects IFN signalling differentially in fibroblasts and 
endothelial cells, mounting a vigorous response in the latter cell type. This could be a 
tactic that HCMV employs in order to reduce its replication levels, facilitating its 
long-term association with the host. Previous studies suggested that HCMV requires 
the synthesis of prostaglandins to maintain its growth in fibroblasts, since the use of 
prostaglandin inhibitors reduced replication levels in culture. I found a stronger up- 
regulation of these genes in endothelial cells compared to fibroblasts, implying that 
inhibitors of prostaglandin synthesis may have differential effects in different cells in 
the body and careful consideration must be taken before their appliance. Therefore, 
this comparison of gene expression levels in two different cell types can potentially 
have significant clinical applications.
Epidemiologic data and pathologic studies suggest a link between HCMV infection 
and atherosclerosis. My results showed a down-regulation of anti-coagulants and 
genes involved in fibrinolysis, consistent with previous evidence that the virus might 
have pro-coagulant properties (Pryzdial and Wright 1994, Yonemitsu et al, 1998, 
Neumann et al, 2000). Additionally, the levels of CD59, a complement inhibitor, were 
suppressed in cells after HCMV infection. The combination of the pro-coagulant 
effects of HCMV infection, decreased fibrinolysis and MAC-induced proliferation 
may contribute to the development of vascular proliferative disorders.
HCMV has been found in many areas of the body including the lungs, GI tract, 
oesophagus and most commonly the retina. Not only is retinal infection by HCMV the 
most common site for the virus to manifest itself, it is also the most common 
opportunistic infection seen in patients with AIDS. Although most patients are
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asymptomatic, retinitis continues to be a chronic ophthalmologic problem among 
HIV-1-infected patients who do not respond to highly active anti-retroviral therapy, 
with symptoms ranging from floaters to dramatic vision loss. Although HCMV 
retinitis occurs during HIV-1-induced immunosuppression, the precise mechanisms 
that fail during the immunopathogenesis of AIDS to allow onset and progression of 
HCMV retinal disease remain undefined. Additionally, studies have failed to explain 
how HCMV gains access to and initiates infection of the retina. In eyes with HCMV 
retinitis, viral presence has been demonstrated in glial, retinal pigment epithelial, 
neuronal, and endothelial cells (Read et al, 1999). A model of HCMV retinal infection 
has been proposed, suggesting that infection of endothelial cells leads to infection of 
surrounding glial and neuronal cells, with eventual spread to the RPE cells.
A study by Brody et al looking at 21 AIDS patients with HCMV retinitis showed that 
90% of these patients contained corneal endothelial deposits (Brody et al, 1995). 
Studies have demonstrated that defects in transforming growth factor beta-induced 
gene (TGFBI) can cause 5 comeal dystrophies (Fujiki et al, 2000, Hirano et al, 2001, 
Schmitt-Bemard et al, 2002, Sakimoto et al, 2003). My results showed a reduction in 
the mRNA of this gene by 24h after infection of endothelial cells with Toledo HCMV 
(Figure 5.8). Additionally, I found genes involved in eye lens structure and 
transmission of the visual signal to be significantly down regulated in HUVEC after 
virus infection (HRG4, cone-specific cGMP and crystalline genes) (Kubota et al, 
2002, Fu and Liang, 2003). The suppression of these mRNAs could contribute to the 
development of eye abnormalities in HIV patients infected with HCMV.
In the setting of HIV infection, cytomegalovirus can affect both the central and 
peripheral nervous systems. Apart from retinitis, neurological manifestations of 
HCMV infection include encephalitis, ventriculitis, myelitis and peripheral 
neuropathies (Bray et al, 1981, Maschke et al, 2002). Protease inhibitor 12 may be 
required for the formation or reorganisation of synaptic connections as well as for 
synaptic plasticity in the adult nervous system. Defects in this gene are the cause of 
familial encephalopathy. I observed a decrease in its mRNA in endothelial cells 6h 
after infection, which could contribute to the development of encephalopathy 
observed in HIV infected patients.
202
HCMV is the leading viral cause of congenital abnormalities, with an incidence of 1- 
2.4% of live births, of whom severe classic "cytomegalovirus inclusion disease" is 
observed in 10%. Congenital HCMV infection is the leading infectious cause of brain 
damage and hearing loss in children. Defects in the pro-a2 chain of collagen type XI 
(coll la2) are the cause of a skeletal dysplasia, which is accompanied by severe 
hearing loss. The collla2 mRNA was reduced considerably by 24h after infection 
with Toledo. It is possible that this decline could contribute to the development of 
hearing loss in foetuses congenitally infected with HCMV. Defects in the cDNA for 
dihydroxyacetone (GNPAT) cause severe growth and mental retardation. GNPAT 
mRNA levels were decreased within an hour after HCMV infection o f  endothelial 
cells (Figure 5.8). HCMV potentially could modulate GNPAT in endothelial cells, 
contributing to the development of mental retardation in children congenitally 
infected with the virus.
Detection of the host transcriptional networks that are modulated as a result of viral 
infection can contribute to our understanding of the mechanisms by which by which 
HCMV causes disease and provide the keystone for the development of novel 
therapeutic strategies. Microarray experiments can provide a large amount of 
information to stimulate further research and give clues to what cellular genes the 
virus needs for its replication. Since the first isolation of HCMV in 1956, this virus 
has been routinely passaged in fibroblast cell cultures. However, several pieces of 
evidence suggest that the resulting combinations of viral strains/cell lines are not 
faithful paradigms of disease pathogenesis in humans. First, HCMV is tropic for 
endothelial cells, monocytes and multiple cells of epithelial cells in origin in vivo 
leading to hepatitis, retinitis, pneumonitis, enteritis and a possible contribution to 
atherosclerosis. Second, these diseases occur with different frequencies in distinct 
groups of infected patients, implying a host contribution to viral pathogenesis. In this 
chapter I have reported the use of arrays to examine pathways of HCMV interaction 
with the cellular machinery of fibroblasts and endothelial cells. Although common 
profiles of cellular gene transcripts were induced or suppressed in these cell types, 
significant alterations in cellular gene regulation were also observed and have been 
focused on here, suggesting specific differences in the biological consequences of 
HCMV infection related to the target cell. I have also pinpointed several genes, which 
may be implicated in the development of HCMV disease, although these roles remain
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highly speculative. However, since these genes are modulated as a result of the host- 
pathogen interaction, they deserve further examination. Overall, the use of 
microarrays to demonstrate differences in effects on host cell genes in biologically 
relevant cell types provides detailed information for experiments to link these various 
response phenotypes with mechanisms of HCMV pathogenesis that are important for 
the natural course of human infection.
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Chapter 6
HCMV strain-specific effects on host transcription
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6.1 Introduction
Gene expression changes may reveal key regulatory differences that lead to different 
virulence patterns between closely related pathogen strains. For example, variations in 
virulence of Listeria monocytogenes serotypes have been correlated with differential 
transcription of PrfA-regulated virulence genes (Bohne et al, 1996, Sokolovic et al, 
1996).
Comparisons of the nucleotide sequences of AD 169, Towne, Toledo and several 
clinical isolates of HCMV indicated that clinical isolates and Toledo contain a DNA 
segment composed of 19 open reading frames that are not present in AD 169 and a 
13kb fragment that is absent from Towne (Cha et al, 1996). This suggested that wild 
type HCMV contains genes that may be lost during repeated laboratory propagation 
and that these genes may contain viral determinants of cell or tissue tropism that can 
be lost during passage in culture. Indeed, several studies have reported growth 
differences between HCMV strains propagated in various cell lines. For example, it 
was demonstrated that clinical isolates but not AD 169 or Towne could productively 
infect endothelial cells (Sinzger et al, 1997). Additionally, a HCMV clinical isolate 
could efficiently infect fibroblasts, smooth muscle cells and endothelial cells, whereas 
AD 169 could efficiently infect only fibroblasts. The maintenance of these ORFs in 
clinical isolates suggests that the encoded gene products are important for HCMV 
pathogenesis in vivo and may represent virulence factors.
When the replication of different HCMV strains was evaluated in SCID-hu retinal 
tissue implants, in vivo, neither AD 169 nor Towne replicated in the implant tissue to 
titres observed after infection with the Toledo strain (Bidanset et al, 2001). Another 
study showed that after infecting thymus and liver implants engrafted in SCID mice, 
Toledo replicated to titres that were 2-3 orders of magnitude higher than those 
observed for ADI69 (Brown et al, 1995). Furthermore, when ADI69, Towne and 
Toledo were tested in controlled human trials, AD 169 and Towne were shown to be 
avirulent in HCMV seronegative volunteers. In contrast, the low passage strain 
Toledo, produced clinical disease when administered to healthy adult volunteers 
(Quinnan et al, 1984). Such studies are of particular interest, since ORFs UL133 to 
UL151, like other unique genes of individual herpesviruses, might only be relevant 
for replication in the natural host organism. Additionally, because HCMV exhibits a
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very narrow host range, it is possible that these genes are adaptations that benefit 
replication in the human host.
Because of the putative application of AD 169 and Toledo as vaccines, it is important 
to study and compare the interactions of these viruses with the host in detail. 
Recently, Northern blot analysis of 58 cellular genes revealed no differences in gene 
expression induced by the AD 169 and Toledo strains of HCMV (Zhu et al, 1998). 
Despite these findings, it has been demonstrated that clinical isolates of HCMV 
induce changes in normal cell functions different or at different levels to that induced 
by the laboratory-adapted strains. For example, infection of HUVEC with a clinical 
isolate induced an increase in their proliferation, while AD 169 failed to do so. The 
clinical isolate also affected cytokine production and the expression integrin receptors 
for fibronectin and laminin (Woodroffe et al, 1994, 1997).
A broader understanding of the transcriptional changes associated with viral infection 
will reveal important details on how the host responds to ADI 69 and Toledo. DNA 
microarray techniques and oligonuclaotide arrays provide sensitive and reliable 
methods for this purpose. In this chapter I used the DNA microarrays to identify 
global changes in host transcription induced by these two HCMV strains and 
attempted to determine the functional effects of the additional genes present in the 
clinical strains.
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6.2 Results
6.2.1 Sample preparation
Gene expression of AD169-infected HEL fibroblasts was analysed at several time 
points after infection (0, 6, 12, 24, 48, 72 and 96 hours). Uninfected HEL cells were 
also included in the analysis. Total RNA was purified from all samples and the quality 
assessed by agarose gel electrophoresis (Figure 6.1). mRNA was purified and labelled 
with Cy5 using RT-PCR. Labelled cDNA was mixed with Cy3-labelled reference 
RNA and hybridised to the HCMV-human microarray. A common reference RNA 
mixture was used to permit comparison across the whole sample set (see section 
4.1.2.2).
6.2.2 Analysis of gene expression
The arrays were used to monitor host gene expression in fibroblasts after infection 
with HCMV AD 169. The data were filtered and assembled with data from Toledo- 
infected MRC-5 fibroblasts, to produce a set of 1477 human genes. The data were 
examined by cluster analysis to identify patterns in the gene expression data and 
identify relationships between the samples. The genes were ordered using a self- 
organising map algorithm, which minimises the differences between adjacent nodes. 
This ordering was then used to control the orientation of the nodes of the dendrograms 
subsequently generated by hierarchical clustering. The programme Tree View (Eisen 
et al, 1998) was used to visualise the expression of the filtered set of 1477 genes 
(Figure 6.1). This analysis reveals how expression of the genome varied throughout 
the time-course of HCMV infection and how gene expression in AD169-infected 
fibroblasts related to that in Toledo-infected fibroblasts. The analysis resulted in two 
clusters of gene expression, showing a clear distinction between the two time-courses 
(Figure 6.1). In turn, within each time-course, a separation between the early and late 
time points is evident. The data were also subjected to hierarchical clustering for both 
genes and samples, in order to follow the exact changes occurring throughout the 
time-courses of infection (Figure 6.3).
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Figure 6.1. Hierarchical clustering of 16 samples and a filtered set of 1477 genes. 
Each column represents one sample and each row one gene. The dendrogram on the 
left represents the relationship between genes in terms of their expression pattern. 
Gene expression is shown as a pseudo-coloured representation of log(2) expression 
ratio with red being above and green below the row/column median level of 
expression (set to 0) as shown by the scale.
I used microarrays to investigate the effect o f  AD 169 and Toledo infection in 
fibroblasts. The analysis identified genes from a range o f host cell pathways that show 
changes in expression levels after viral infection. Previous microarray analysis of 
fibroblasts infected with AD 169 revealed a number of cellular genes whose 
expression was enhanced by the virus (Zhu et al, 1998, Browne et al, 2001). AD 169 
was shown to increase transcript levels of the IFN-induced 17kD protein, 
characteristic of an innate response to infection. The mRNA for decay accelerating 
factor (DAF), a complement mediator, was also up-regulated in infected cells, among 
others. Nevertheless, virus infection resulted in the suppression o f a number o f host 
transcripts, including ones involved in cell cycle regulation, apoptosis and 
cytoskeletal structure (Zhu et al, 1998). Our results are in agreement with these 
findings. Some of the genes we confirmed are shown in Figure 6.2.
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Figure 6.2. A selection of genes whose expression levels after infection of fibroblasts 
with HCMV confirms previous findings.
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63 Common sets of host genes modulated by both strains
Analyses of the data suggest that the viruses induce both general and specific changes 
in host gene expression over a 4-day time-course (Figure 63). Initially, I was 
interested in which groups of genes possessed similar expression profiles during 
infection and whether sets of co-expressed genes would be functionally related. 
Hierarchical clustering (Eisen et al, 1998) of 1474 genes revealed groups of genes that 
were induced or suppressed in response to both virus strains at one or more points 
during the infection time-course. The genes were classified based on their known or 
putative functions and clustered according to their expression profiles. Functional 
classification showed that some of these genes are associated with immune responses, 
cell proliferation, protein transport and cytoskeletal structure.
63.1 Host genes induced by both strains
Microarray hybridisations have revealed that diverse RNA viruses elicit the 
expression of common sets of genes in plants, including genes involved in defence 
and stress responses (Whitham et al, 2003). I observed the induction of an antiviral 
immune response in fibroblasts, consisting of IFN-responsive genes, by both AD 169 
and Toledo. These include ISG20 (HEM45), tryptophanyl-tRNA synthetase (Fleckner 
et al, 1991), IFI27, HLA-C (Gobin et al, 1999) and IFN-gamma up-regulated, IFN- 
alpha induced, and IFN-induced 17kD proteins. Differential display analysis has 
shown that both strains strongly activate the accumulation of interferon-responsive 
RNAs (Browne et al, 2001), supporting these findings. The induction of IFN- 
responsive genes has also been documented after HPV-16 infection. Oligonucleotide 
arrays were used to investigate the effect of integration of HPV-16 on gene expression 
in cervical keratinocytes (Alazawi et al, 2002). The authors identified 85 genes that 
showed changes in expression levels after viral integration. Interestingly, integration 
was associated with up-regulation of IFN-responsive genes, in comparison with a 
baseline of episomally infected cells, suggesting that the physical risk of high-risk 
HPV may influence the response to IFN in infected keratinocytes.
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Figure 6.3. Detail showing common sets o f genes induced by both AD169 and Toledo after infection 
of fibroblasts. This cluster is enriched for IFN-responsive genes (in orange), nuclear genes (in blue), 
genes involved in the complement pathway and apoptosis (in red), and ones mediating intracellular 
signalling (in black). Columns 1 and 2 show fibroblasts before infection. Columns 3 to 9 show 
fibroblasts at successive time points in hours post infection with HCMV AD 169. Columns 10 to 16 
show fibroblasts infected with ToledoE.
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Apart from IFN-response genes, the cluster also contains genes that mediate the host 
antiviral response to infection. These include genes of the classical complement 
pathway (C4/C2 activating component, complement components C ls and C lr) and 
ones involved in apoptosis (apoptotic protease, KLAA0670) (Rawal and Pangbum, 
2003, Schwerk and Schulze-Osthoff, 2003). Furthermore, infection of fibroblasts with 
the two strains led to increased levels of genes involved in intracellular signalling, 
such as GTP binding protein (ARL3) (Hillig et al, 2000) and myristoylated C-kinase, 
a protein kinase C (PKC) substrate. An induction of PDGF-A was observed, 
consistent with previous findings (Srivastava et al, 1999), along with an increase in 
GRB10 transcript levels. GRB10 has been shown to bind PDGF receptor and is 
essential for insulin receptor signalling (Giovannone et al, 2003). Additionally, 
increased levels of GrblO elevate several metabolic responses such as glycogen 
synthesis, glucose transport, amino acid synthesis, and fatty acid processing (Deng et 
al, 2003). Interestingly, the cluster contains genes that are involved in these responses, 
such as TPRD, histidyl-tRNA synthetase and nuclear phosphoprotein (protein 
synthesis), insulin receptor and enolase (glucose uptake), along with mitochondrial 
genes that mediate fatty acid catabolism. The analysis revealed that genes are 
clustered according to their function. For example, the insulin receptor shares the 
same expression profile with MAPKAPK3 kinase, consistent with its role in MAPK 
induction. Furthermore, GRB10 clusters next to tax interaction protein 2. Both of 
these genes bind receptor tyrosine kinases. Additionally, this cluster contains genes 
that are part of closely-related cellular pathways.
Finally, the cluster contains four genes that encode nuclear proteins, such as NUP88, 
H2B/1, DNA polymerase alpha and histone-binding protein. NUP88 is a major protein 
of the nuclear pore complex (Griffis et al, 2003), while H2B/1 functions in chromatin 
condensation. Gene delivery studies have suggested that exogenous DNA present in 
the cytoplasm is initially docked to and translocated through a nuclear pore by the 
nuclear import machinery. As DNA enters the nucleus, it is quickly condensed into a 
chromatin-like structure, which provides a mechanism for threading the remaining 
worm-like molecule through the pore (Zanta et al, 1999). Accordingly, this can be a 
strategy that HCMV employs in order to enter the host cell’s nucleus and initiate 
replication. Overall, my results indicate that AD 169 and Toledo both induce a number 
of immunoregulatory, signalling and nuclear genes. The ability of the two strains to
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elicit common gene expression changes could reflect the importance of these genes to 
viral infection processes.
6J.2 Host genes suppressed by both strains
Hierarchical clustering of gene expression data revealed a common set of mRNAs that 
were suppressed as a result of infection with either AD 169 or Toledo. These consisted 
mainly of genes involved in cell proliferation, apoptosis and protein synthesis and 
transport. The expression of host genes modulated either through viral action or by 
host reaction involves a “struggle” between the expression of pro-apoptotic and anti- 
apoptotic (proliferative) molecules. There is normally a balance between apoptotic 
and anti-apoptotic signals, and cell death occurs in response to a persistent shift in this 
balance. Although the expression of various apoptotic and anti-apoptotic signalling 
molecules were differentially regulated in this study, their potential diverse and 
unknown functions make it difficult in some instances to draw strong conclusions 
regarding the impact of their transcriptional regulation. Of note, however, is the 
down-regulation of DAP-1, caspase 3, caspase 7 (Mch3) and adenylate kinase 2 after 
infection (Figure 6.4). The down-regulation of these molecules appears to contribute 
to cell survival. This may represent a host stress response aimed at cell survival or a 
strategy that HCMV employs in order to promote cell viability for virus replication. 
HCMV infection activates both proliferative and anti-proliferative signals in infected 
cells, depending on cell type. HCMV is known to induce non-permissive cells to enter 
the cell cycle, while infection of permissive cells results in cell cycle arrest. My 
analysis showed that transcript levels of genes that promote cell cycle progression 
were down-regulated, including NTAK (Nakano et al, 2000), cyclin I, and histone 
deacetylases 1 and 3 (Yoshida et al, 2003) among others (Figure 6.4). These results 
are consistent with previous findings showing a suppression of proliferative mRNAs 
after infection with AD 169, the laboratory-adapted HCMV strain. Furthermore, they 
illustrate that the wild type virus may also induce these effects.
It is thought that interaction of viral proteins with the host machinery involved in the 
cellular transport system permits the transport of newly synthesised viral capsids in 
the cytoplasm (Sodeik, 2000). A recent study has identified two host proteins 
associated with HCMV particles, ESI30 and p i80 (Ogawa-Goto et al, 2002). ESI30
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is a member of the kinectin family, while pi 80 functions in membrane proliferation 
and secretion (Rezaee et al, 1993, Becker et al, 1999). The authors also reported high 
levels of the pi 80 protein in HCMV-infected cells, suggesting that the level of 
expression of pi 80 may be an essential factor for HCMV replication. The dependence 
of virus transport on host factors has also been demonstrated for HPV-16, where 
studies showed that binding to beta-actin facilitates viral transport across the 
cytoplasm during infection (Yang et al, 2003). Viruses have also been shown to 
interfere with the cellular transport machinery. When the effect of poliovirus infection 
on protein transport was studied, it was found that transport of both plasma membrane 
and secretory proteins was inhibited early in the infectious cycle (Doedens and 
Kirkegaard, 1995, Gustin and Sarnow, 2001). Hepatitis C virus was also found to 
inhibit ER-to-Golgi traffic (Konan et al, 2003). Additionally, the host cell transport 
machinery can be engaged differentially by different strains of a virus (Gamer and 
LaVail, 1999).
I found several genes involved in protein synthesis and transport to be down-regulated 
in fibroblasts infected with either AD 169 or Toledo (Figure 6.4). The majority of 
these genes were associated with the ER. These consist of calnexin, beta-cop, ER 
lumen protein retaining receptor (KDELR2), calumenin (Vorum et al, 1999), 
phosphatidylinositol-glycan and ADP-ribosylation factor 6 (ARF6). Calnexin, a gene 
essential for the retention of incorrectly folded proteins in the ER, clustered next to 
KDELR2 and beta-cop, two genes that are also involved in ER protein retention 
(Norkin et al, 2002, Lu et al, 2003, Oda et al, 2003, Yamamoto et al, 2003). ARF6 
was suppressed in infected fibroblasts, but to a further extent in Toledo-infected cells 
(by a factor of 4). The potential role of ADP-ribosylation factor in vesicular 
trafficking was demonstrated in 1992, using an in vitro assay that efficiently 
reconstituted transport between the ER and Golgi compartment in mammalian semi­
intact cells, a population of cells in which the plasma membrane is physically 
perforated to reveal intact ER and Golgi compartments. ARF inhibitors were shown to 
inhibit transport of the vesicular stomatitis virus (VSV) G protein between the ER and 
cis-Golgi compartment rapidly and irreversibly (Balch et al, 1992). These results 
suggested that ARF might play an important role in the cycling and fusion of transport 
vesicles mediating ER to Golgi trafficking.
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Figure 6.4. Detailed analysis, showing genes suppressed by both ADI69 and Toledo 
after infection of fibroblasts. These clusters contain proliferative and anti-proliferative 
genes (in blue) and genes involved in protein synthesis and transport (in black). 
Columns 1 and 2 show fibroblasts before infection. Columns 3 to 9 show fibroblasts 
at successive time points in hours post infection with HCMV AD 169. Columns 10 to 
16 show fibroblasts infected with ToledoE.
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6.4 Strain-specific effects on host transcription programmes
6.4.1 Host genes induced by Toledo
Many human viruses can cause chromosomal anomalies and damage to the mitotic 
apparatus, including herpes simplex 1 and 2, adenovirus, cytomegalovirus, Epstein- 
Barr virus, poliovirus and papillomavirus (Luleci et al, 1980, Aranda-Anzaldo, 1992, 
Deng et al, 1992, Duensing and Munger. 2002, Fortunato and Spector, 2003). 
Chromatid breaks, translocations and over-condensation are some of the irregularities 
seen. All of the above viruses cause non-specific chromosomal abnormalities, except 
from the oncogenic adenoviruses; infection of human cells with adenovirus type 12 
has been shown to result in fragility in four common sites (Schramayr et al, 1990). 
Several reports have shown that HCMV infection causes random chromatid breaks 
and gaps in vitro. However, it was recently reported that the virus induces two 
specific breaks in chromosome 1, at positions lq21 and lq42 (Fortunato et al, 2000). 
Hierarchical clustering of the gene expression data revealed a cluster of genes that are 
strongly suppressed after infection of fibroblasts with AD 169 but induced after 
infection with Toledo (Figure 6.5). Interestingly, 27 of these genes are located on 
chromosome 1. More specifically, 10 of the genes are located at position lq21, the 
major HCMV chromosomal breakpoint (Figure 6.5A). These include: the SI00 genes 
calgranulin A and CAAF1, involved in cell cycle regulation (Holly et al, 1995, 
Hitomi et al, 1998); mucin 1, a cell adhesion gene (Mitchell et al, 2002, Truant et al, 
2003); adenosine deaminase, which destabilises double stranded RNA (Saunders and 
Barber, 2003); the mitochondrial genes HAX1 and metaxin (Bomstein et al, 
Marenholz et al, 2001); the guanine nucleotide regulatory factor, which is involved in 
the control of cell shape and size (Mayer et al, 2001); and the IL-6 receptor 
(Takashiba et al, 2003). The cluster also contains genes that are involved in the 
regulation of chromatin structure, such as KIAA0166, PHD finger 1 (Jones et al,
2000), CDC46 and Mi-2 protein (Ishimi et al, 1996) (Figure 6.5B). CHC1, a gene that 
regulates chromosome segregation (Nishimoto et al, 1994), was up-regulated by a 
factor of four 48 hours after Toledo infection, along with DNAS1L3, which is 
involved in cleavage of chromatin DNA (Yakovlev et al, 1999) (Figure 6.5B). These 
results suggest that the specific chromosomal abnormalities that are induced after 
HCMV infection could be the result of viral modulation of host genes.
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Figure 6.5. Genes that are modulated differentially after infection of fibroblasts with 
either AD 169 or Toledo. This gene expression signature contains (A) genes located at 
chromosomal position 1 q21 and (B) genes that are involved in the regulation of 
chromatin structure.
6.4.2 Host genes suppressed by Toledo
Hierarchical clustering of gene expression data revealed a cluster of mRNAs that were 
strongly suppressed as a result o f infection with Toledo (Figure 6.6). Although I 
identified several genes involved in protein synthesis and transport, to be down- 
regulated in fibroblasts infected with either AD 169 or Toledo (Figure 6.4), this cluster 
contains some genes involved in intracellular protein transport that are preferentially 
suppressed after infection with HCMV Toledo. One such gene is the ER lumen 
protein retaining receptor 2 (KDELR2), which is essential for the retention of luminar 
ER proteins and for normal vesicular traffic through Golgi (Majoul et al, 2001). 
KDELR2 is suppressed by a factor of four, 72 hours after infection with Toledo. 
Other genes include the clathrin coat assembly gene, involved in vesicle transport, and 
the ADP ribosylation factors 1 and 4, which mediate vesicle budding and uncoating 
within Golgi (Moss and Vaughan, 1995, Chavrier and Goud, 1999). Clathrin- 
associated mRNA is suppressed by a factor of three, 96 hours after Toledo infection. 
This gene initiates coat formation and links clathrin to receptors in coated vesicles 
that are involved in endocytosis and Golgi processing. These results indicate that wild 
type HCMV may down-regulate a number of vesicle-associated genes, which could 
lead to inhibition of antigen presentation at the cell surface and subsequent 
accumulation of intracellular virus.
The cluster also contains genes that are involved in cell adhesion and extracellular 
matrix composition, such as SPARC/osteonectin (Bomstein, 2002, Brekken et al, 
2003), integrin, beta-sarcoglycan (Crosbie et al, 1999), and CD44 (Navaglia et al, 
2003). Fibronectin 1 and Cyr61, two cell adhesion genes required for embryogenesis, 
are also suppressed after infection of fibroblasts with Toledo (O’Brien and Lau 1992, 
Armstrong and Armstrong, 2003). Cell adhesion is an essential process for 
embryogenesis. Therefore, the suppression of cell adhesion by HCMV could 
contribute to the development of problematic pregnancies in infected individuals.
Finally, a number of mRNAs that are highly expressed in muscle tissue are located in 
the same cluster (Figure 6.6). These include lysyl hydroxylase, glucan, DNAse I-like 
and ras-related GTP-binding proteins (Gromov et al, 1995, Valtavaara et al, 1997). 
Furthermore, the expression of DOC1 (putative oral tumor suppressor) and calponin
3, proteins involved in muscle contraction, is reduced by a factor o f five in Toledo- 
infected fibrolasts (Kaneko et al, 2000). Overall, these results suggest that infection 
with wild type virus may lead to reduced contractility of the cardiac muscle, 
contributing to the development o f cardiovascular disease in HCMV-infected 
immunocompromised patients.
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Figure 6.6. Detail showing genes that are down-regulated after infection of fibroblasts with 
Toledo. This cluster contains cell adhesion genes (in orange), genes involved in intracellular 
protein transport (in black) and ones that play a role in muscle function (in blue). Columns 1 
and 2 show fibroblasts before infection. Columns 3 to 9 show fibroblasts at successive time 
points in hours post infection with HCMV AD 169. Columns 10 to 16 show fibroblasts 
infected with ToledoE.
6.5 Com parison o f gene expression patterns betw een uninfected fibroblasts
Gene expression of AD169-infected HEL fibroblasts was analysed at several time 
points after infection (0, 6, 12, 24, 48, 72 and 96 hours). The data were filtered and 
assembled with data from Toledo-infected MRC-5 fibroblasts, to produce a set of 
1477 human genes. Mock-infected MRC-5 and HEL fibroblasts were also included in 
the study, to enable comparison with data derived from the time-course experiments. 
Pair-wise analysis of two normalised microarrays was performed, each hybridised 
with RNA derived from uninfected MRC-5 or HEL fibroblasts (Figure 6.7). Statistical 
analysis of the log(2) expression ratios revealed a correlation coefficient o f r=0.67, 
indicating that fibroblasts derived from different sources have slightly different gene 
expression patterns.
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Figure 6.7. Comparison of RNA targets from MRC-5 and HEL fibroblasts (r=0.67).
6.6 Discussion
Several studies have taken place aiming to identify cellular genes that are responsible 
for the pathological differences observed between infections with different viruses. 
One such study used DNA arrays to compare the interactions between HSV-1 and 
HSV-2 with the cellular machinery. The results identified a group of genes that was 
differentially expressed during infection of cells with the two viruses, providing new 
information about host defence against viral infections and clues to the molecular 
basis for the differences between infections with HSV-1 and HSV-2 (Paludan et al, 
2002).
Different viral strains also have different potentials to cause disease, based on the 
contributions of specific viral proteins to the ability of the virus to replicate and 
spread within the host and to escape host protective responses. Attenuation of disease 
potential can occur following passage of virus in cell culture in the absence of the 
selective pressures of the host cell machinery, tissue architecture and host immune 
system or by selection for rapid dissemination in cell culture (Bower et al, 1999). This 
is the case for HCMV and encephalomyocarditis virus (EMCV), which become 
attenuated for growth in vivo, after passages in cell culture (Waldman et al, 1991, 
Grefte et al, 1995, Denis and Koenen, 2003).
Comparison of virulent and attenuated strains of a virus can identify key genes that 
are important for disease pathogenesis. Arrays were used to compare the genomes of 
15 different Helicobacter pylori isolates, which showed that 22% of the genes were 
dispensable in one or more strains (Salama et al, 2000). These genes included 
restriction modification genes and genes encoding cell surface proteins. Although no 
clinical data were available for these strains, the authors postulated that some of these 
genes might be associated with virulence. Spotted microarrays were also used to 
compare Mycobacterium tuberculosis, Mycobacterium bovis and different members 
of the family of Bacille Calmette-Guerin (BCG), the anti-tuberculosis vaccine 
produced by attenuating M. bovis (Behr et al, 1999). 91 genes were absent from one 
or more virulent strains of M. bovis. 38 genes were present in M. tuberculosis and M. 
bovis but absent in BCG strains. This suggested that the different genes missing from 
the BCG strains reflected a progressive adaptation of BCG to laboratory conditions
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that may have impaired their ability to stimulate a durable immune response in the 
host. M. tuberculosis cDNA arrays were used to identify segments of DNA that are 
present in the sequenced strain but missing from clinical isolates (Kato-Maeda et al, 
2001). Genomic deletions were detected in the clinical isolates, with varying 
distributions. Interestingly, strains with a large amount of deleted DNA were less 
likely to cause cavitary pulmonary disease than strains with fewer deletions. Since 
cavitary pulmonary disease is a transmissible form of tuberculosis, it was suggested 
that the accumulation of deletions might cause a decrease in bacterial fitness 
(Gillespie et al, 2002). Alternatively, this loss of genes may be a consequence of the 
adaptation to a new environment.
Reports have demonstrated that different virus strains have different effects on host 
expression, possibly contributing to varying disease pathogenesis. Contrary to their 
counterparts in HPV-16, E6 and E7 from benign HPV-6b have no effect on host gene 
expression (Nees et al, 2000). Also, in vivo infection by the pathogenic J3666 strain 
of PVM induces expression of interferon response genes, whereas the non-pathogenic 
strain 15 does not (Domachowske et al, 2002). Therefore, the host response against 
viral infection varies according to pathogenicity. The suppression of the interferon 
response by some viruses and not others may reflect differences in the replication 
strategy. For example, the initiation of KSHV lytic replication is accompanied by an 
increase in the host anti-viral response to the virus in DMVECs (Poole et al, 2002). 
Differences in host gene expression may also reflect the mechanism by which the 
virus counters the anti-viral response. For example, viruses can inhibit the function of 
interferon-response genes at the post-transcriptional level (Goodboum et al, 2000).
Results to date argue that the alteration in cellular mRNA levels induced by AD 169 
and Toledo is identical (Zhu et al, 1998). However, only a limited number of genes 
were assayed. In this chapter we used DNA microarrays to identify global changes in 
host transcription induced by these two HCMV strains. The analysis identified genes 
from a range of host cell pathways that show changes in expression levels after viral 
infection, and showed that the viruses induce some common changes in host gene 
expression over the 4-day time-course (Figure 6.3). I observed the induction of an 
antiviral immune response in fibroblasts, consisting of IFN-responsive genes, by both 
AD 169 and Toledo. Additionally, the analysis revealed a common set of mRNAs that
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were suppressed as a result of infection with either AD 169 or Toledo, consisting 
mainly of genes involved in cell proliferation, apoptosis and protein synthesis and 
transport.
Interestingly, the analysis revealed that the laboratory and clinical isolates of HCMV 
alter cellular gene expression differentially. Hierarchical clustering of gene expression 
data revealed a cluster of genes that are strongly suppressed after infection of 
fibroblasts with AD 169 but induced after infection with Toledo (Figure 6.5A). 
Interestingly, 27 of these genes are located on chromosome 1. More specifically, 10 of 
the genes are located at position lq21, which was shown to be the major HCMV 
chromosomal breakpoint, along with lq42 (Fortunato et al, 2000). Fortunato et al 
identified a number of genes that are located in these breakpoints. Overall, my 
findings suggest that the specific chromosomal abnormalities induced after HCMV 
infection could be the result of viral modulation of host genes. Furthermore, the 
cluster also contained GNPAT (cDNA for dihydroxyacetone), a gene located at lq42. 
It has been shown that defects in this gene can result in cataract and mental 
retardation (Burdette et al, 1996). Therefore, the deletion of this gene because of 
HCMV-induced breakage could potentially be linked to the development of the 
mental retardation observed in infants congenitally infected with the virus.
After the initiation of viral genomic replication in the cell nucleus, progeny capsids 
are assembled and bud into the perinuclear space after acquiring a primary envelope. 
The subsequent maturation is a poorly understood process. Reports have shown that 
nucleocapsids are released into the cytoplasm and then acquire final envelopment by 
budding into a cytoplasmic compartment (Severi et al, 1988, Radsak et al, 1996, 
Sanchez et al, 2000). The mechanism of capsid transport in the cytoplasm, however, 
is entirely unknown. Since movement of viral particles through the cytosol is not 
likely to occur by free diffusion but rather most likely by the cellular transport system, 
it is most probable that interaction of viral proteins with the host machinery involved 
in the cellular transport system permits an active process (Sodeik et al, 2000). 
Interestingly, the array analysis revealed a number of mRNAs that were preferentially 
down-regulated by HCMV Toledo (Figure 6.6), with some of them required for 
intracellular protein transport. Inhibition of the protein transport machinery by wild
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type HCMV could be a strategy that the virus employs to prevent the onset of 
antiviral responses.
It is thought that mutations in cellular sarcomeric proteins can cause hypertrophic 
cardiomyopathy (HCM), a disease characterised by impaired cardiac myocyte 
contractility (Marian et al, 1997). Additionally, tissue culture experiments have 
shown that coxsackie virus replication in the myocardium can impair cardiac 
contractile function and lead to dilated cardiomyopathy (Morita et al, 1984, Fujioka 
and Kitaura, 2001). HCMV infection in the setting of heart transplant and HIV 
patients is associated with the development of cardiovascular disease (Li et al, 1996). 
The analysis of gene expression data from HCMV-infected fibroblasts indicated that 
infection with Toledo led to a reduction in the expression of mRNAs that are highly 
expressed in muscle and are involved in muscle contractility. Infection with AD 169 
did not have the same outcome. My findings are in agreement with published data 
from Filippov et al (Filippov et al, 2001). The authors of the study assessed the 
condition of the cardiovascular system in HIV-infected patients with HCMV 
infection, showing that HCMV affected the morphologic and functional parameters of 
the cardiac muscle, with one evident symptom being low myocardial contractility. I 
suggest that one or more of the UL/b’ genes may be involved in the modulation of 
host genes involved in muscle function, leading to reduced contractility of the cardiac 
muscle, potentially contributing to the development of cardiovascular disease.
It has been reported that atherosclerotic lesions contain genomic material belonging to 
HCMV, suggesting a viral etiology for the development of atherosclerosis. 
Additionally, infection of endothelium with HCMV induces increased expression of 
adhesion molecules, resulting in an increased adherence of leukocytes, which is 
suggested to be one of the earliest events associated with endothelium cell damage 
(Span et al, 1991, Shahgasempour et al, 1997, Knight et al, 1999). We found a 
differential modulation of cell adhesion molecules in fibroblasts. Analysis of gene 
expression data revealed a suppression of these molecules after infection with Toledo. 
This modulation can have profound effects in the process of embryogenesis. During 
placental development, specialised cells called cytotrophoblasts, differentiate into the 
trophoblast population of floating villi and anchoring chorionic villi (Damsky and 
Fisher, 1998). The cytotrophoblasts of the anchoring villi then aggregate into columns
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and invade the endometrium and the first third of the myometrium. By midgestation, 
invasive cytotrophoblasts have completely replaced the endothelial lining and much 
of the smooth muscle wall of these arteries, forming a hybrid vasculature, composed 
of fetal and maternal cells. During placentation, a molecular differentiation program is 
initiated, that is required for normal pregnancy (Fisher et al, 1993, Cross et al, 1994, 
Norwitz et al, 2001). For example, invading cytotrophoblasts in the anchoring villi 
begin to express adhesion molecules and proteinases required for invasion, such as 
integrin and matrix metalloproteinase 9 (Maidji et al, 2002). My results suggest that 
low-passage but not laboratory-adapted virus, induces a shut down in the transcription 
of such molecules, which could be mediated by the UL/b’ region genes. For example, 
the RNA expression of metalloprotease was decreased by 12 hours after infection. 
This down-regulation could lead to decreased invasiveness of cells during 
placentation, leading to the development of pregnancy abnormalities that manifest in 
HCMV-infected individuals. Indeed, in support of my data, previous findings have 
demonstrated that HCMV infection of purified cytotrophoblasts from first-trimester 
placentas led to a down-regulation of integrin, and impaired ability of these cells to 
invade Matrigel in an in vitro invasion assay (Fisher et al, 2000).
The in vitro plan outlined in this chapter, has enabled the charting of prominent 
patterns of gene expression in HCMV-infected fibroblasts and the separation of varied 
and potentially significant gene expression events. Interestingly, analysis of the gene 
expression data revealed a Toledo-specific down-regulation of host genes, due to 
unique genes in the UL/b1 region, which could explain Toledo’s increased 
pathogenicity in vivo.
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Chapter 7
General discussion and directions for future research
227
The interactions between viruses and the cells they infect are complex and multifaceted. While 
viruses strive to take over cellular functions to their advantage, the cell strives to impede these 
efforts by mounting a variety of defensive responses. These responses may include the 
induction of interferon, stress responses, or apoptotic pathways, all of which are accompanied 
by changes in gene expression. Some viruses consistently win this war while others succumb to 
cellular defence mechanisms. The viral and cellular factors that determine the outcome are 
mostly still unknown. With the advent of functional genomics, potent new technologies are 
now available to analyse the complexities of virus-host interactions in ever increasing depth and 
detail. I illustrate here efforts to use microarrays to focus on the changes in gene expression that 
occur in HCMV-infected cells and to use these technologies to unlock some of the mysteries of 
virus-host interactions.
In this thesis I have described the creation of DNA arrays and their use in the analysis of 
HCMV and host gene expression in fibroblasts and endothelial cells. The HCMV-human array 
shows reproducible measurements of expression both within arrays and between arrays. The 
arrays are specific and provide reproducible measurements of expression. I have demonstrated 
that array analysis reveals the transcriptional changes that control HCMV replication and the 
relationship between HCMV and the transcriptional machinery of the host. I have created a 
DNA array to identify the transcription profile of a region of the HCMV genome thought to be 
crucial for disease pathogenesis in vivo, which will enhance our understanding of HCMV 
behaviour. The array also contains probes for over 5,000 human genes, allowing concomitant 
measurements of gene expression for both host and virus. The results from this type of study 
can unravel interactions between the virus and host and give an insight into disease 
pathogenesis.
One of the factors required for successful viral replication is the ability to gain access into a
susceptible cell. HCMV infection begins by the low affinity attachment of the virus on the cell,
followed by high affinity attachment, fusion of the viral envelope with the cell membrane,
uncoating of the nucleic acid and transport of the viral DNA to the cell nucleus. Findings
suggest that annexin II, a 30kD member of the lipocortin family, is the principal HCMV
receptor involved in virus binding to cells and cell to cell spread (Wright et a/, 1994, Bold et al,
1996). However, another group using a different cell type, demonstrated that neutralisation of
cell surface annexin II was inconsequential for direct cell to cell spread of the virus (Pietropaolo
and Compton, 1999). It is therefore possible that the role of annexin II in HCMV entry, as well
as the entry mechanism itself, differs from cell type to cell type. Therefore, the extent of
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genome expression in any given cell type shapes the pattern of the virus-host interaction. It was 
illustrated recently, that EGFR is a necessary receptor for HCMV (Wang et al, 2003). Wang et 
al showed that HCMV infects cells through interaction of viral gB with EGFR, triggering an 
intracellular signalling cascade. During HCMV lytic replication viral genes are expressed 
sequentially in three phases, termed immediate early (IE or a), early (E or P) and late (L or y), 
according to the timing of transcription (Table 1.2). HCMV replication in a particular cell type 
is dependent on the virus strain. In vitro studies have shown that endothelial cells are not 
generally permissive for infection with high-passage strains of HCMV (Friedman et al, 1981). 
However, these cells are permissive for infection with some low passage HCMV isolates (Ho et 
al, 1984, Waldman et al, 1989). Similarly, monocyte-derived immature dendritic cells were 
shown to support the full replication cycle of endothelial cell tropic strains of HCMV in vitro, 
resulting in the expression of IE, E and L genes and production of infectious virus (Riegler et 
al, 2000).
Different HCMV strains also display biological differences, the genetic basis for which is still 
being investigated. ADI69, Towne and Toledo are HCMV strains commonly used in the 
laboratory environment. Clinical data have demonstrated that HCMV strains exhibit different 
levels of virulence depending on their passage histoiy in cell culture. Extensive comparisons of 
the restriction enzyme profiles of Toledo and a highly passaged variant of Towne revealed an 
additional region of sequence at the right edge of the Toledo UL component (Cha et al, 1996), 
termed UL/b’ region and encoding 19 ORFs. Although these genes are not essential for 
replication in vitro, their maintenance in clinical isolates suggests that the encoded proteins are 
important for HCMV pathogenesis in vivo. The importance of fitness determinations became 
evident in 1976, when it was proposed that the infecting strain of HCMV is important for 
clinical outcome, along with the intensity and duration of viral replication. High and low 
passage HCMV strains exhibit tropism differences in vitro, suggesting that different tissue 
tropism may occur in vivo. Indeed, differences in the distribution of HCMV infection in 
leukocytes from tissues of patients have been demonstrated (Sinzger and Jahn, 1996). 
Furthermore, reports have shown that different clinical isolates obtained from transplant 
patients had specific tropisms for different cells (Torok-Storb et al, 1993), suggesting that these 
different tropisms might account for differences in pathogenicity.
One of the aims of this thesis was to determine the replication dynamics of HCMV strains
AD169 and Toledo in vitro as well as compare the ability of AD169 and Towne to bind to cells
and mediate cell-to-cell spread of infection using pair-wise competition experiments in cell
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culture (Chapter 3). Assessment of viral replication using quantitative PCR measure of virus 
over time for each of these strains, showed that AD 169 replicated better than ToledoE in
Q 7fibroblasts, reaching 1.4x10 gB copies/pg cellular DNA, compared to 8x10 gB copies/pg 
cellular DNA of ToledoE. Furthermore, assessment of the replication of ToledoE in a different 
cell type, HUVEC, indicated that the virus replicated to higher levels in fibroblasts. However, 
the doubling times of ToledoE in fibroblasts and HUVEC were 6.9 and 7.3 hours, respectively, 
suggesting that infected fibroblasts and endothelial cells can replicate their DNA at comparable 
rates but that the amount of virus ultimately produced is different. Towne was found to bind to 
HEL cells with higher affinity compared to AD 169. Overall, my results indicate that fitness 
between AD 169 and Towne is variable and dependent upon the status of the virus inoculum. 
When using a cell-free virus inoculum, ADI 69 outgrew Towne within 17 days of culture, with 
a fitness gain of 24%. When cell-associated virus was used as the inoculum, Towne 
predominated in both cells and supernatants, indicating that it is more efficient in mediating 
cell-to-cell spread of infection and releasing virus into the medium. Cell-to-cell spread may be 
important in vivo, and under such conditions Towne appears to be fitter. Since these 
experiments are difficult to perform and the results likely to reflect differences in viral and host 
cell parameters, I decided to investigate the use of microarrays to assess viral and cellular 
transcription patterns using distict HCMV strains and distinct cell types.
The experiments discussed in the first part of chapter 4 provide important controls for the
biological interpretation of the array-based expression measurements that take place in the
second part of chapter 4 and in chapters 5 and 6. The HCMV-human array was used to examine
(i) HCMV gene expression during active replication of HCMV in fibroblasts and endothelial
cells, (ii) host-specific responses to HCMV Toledo and (iii) host responses to different strains
of the virus. The expression of the majority of the genes within the HCMV UL/b’ genes has not
been previously investigated. The HCMV-human array and RT-PCR were used to analyse
expression of these genes during active replication in fibroblasts and endothelial cells. My
analysis shows that genes belonging to the same functional group have similar expression
profiles and has helped to assign functions to genes for which there is no available information.
The classification of the three basic groups of transcripts is generally based however on
measurement of transcript abundance in infections where virus-induced DNA and protein
synthesis are blocked with metabolic inhibitors. Although it would be useful to monitor
expression with inhibitors of translation and herpesvirus DNA polymerase, these disturb the
system and, in the case of the inhibition of translation, have wide-ranging effects on the host
cell. My results show that the HCMV transcriptional profile changes as the virus progresses
230
through the life cycle, with individual genes having distinct expression kinetics. The majority 
of the UL/b’genes (UL137, UL138, UL141, UL144, UL145, and UL144-UL150) exhibited the 
same transcription patterns in both cell types. There was no detectable expression of UL135 and 
UL143 during infection, consistent with the most recent predictions of Davison et al based on 
comparisons between the gene coding content of human and chimpanzee cytomegalovirus, 
while UL142 was expressed only in HUVEC. The remaining genes (UL133, UL134, UL136, 
UL139, UL140, UL151) were transcribed with delayed kinetics in fibroblasts compared to 
HUVEC (Mann Whitney, p<0.05). This data suggest that these viral genes are differentially 
regulated at the level of transcription and may have distinct functions in the virus life cycle.
The HCMV array could be used to screen for expression of viral and host genes in other types 
of endothelial cells infected in vitro. Additionally, the identification of groups of co-regulated 
genes by cluster analysis could reveal the genes that are transcribed in monocytes during 
latency. Once the arrays have identified such genes, other techniques could then be used to 
verify expression of these genes. Furthermore, the analysis of the promoter sequences of each 
group of genes could provide information on the regulation of the HCMV genome.
To understand how HCMV interacts with the host cell, it will be important to find which 
HCMV genes are expressed in vivo. Expressed genes could be identified by RT-PCR or DNA 
array analysis of amplified RNA. In addition, the synchronized analysis of host gene expression 
during HCMV infection can provide useful knowledge on how the viral and host genomes 
interact to direct the fate of the host cell.
Infection with HCMV results in complex interactions between viral and cellular factors, which
perturb many cellular functions. HCMV is known to target the cell cycle, cellular transcription
and immunoregulation and it is believed that this optimises the cellular environment for viral
DNA replication during productive infection or during carriage in the latently infected host.
Detection of the cellular transcription pathways that are activated or repressed during viral
infection can lead to a better understanding of the virus-host interaction and to the discovery of
new targets for therapy. The aim of chapter 5 was to use the HCMV-human microarray to
identify fibroblast and endothelial cell responses to HCMV infection. To date, there have been
no reports comparing the effects of HCMV in fibroblasts and endothelial cells, two cell types
that clearly play a pivotal role in vivo during HCMV infection. In addition, most studies have
used the laboratory strains of HCMV, which may not be fully representative of the wild type
virus. In this study I have identified similarities and differences in viral and host transcriptional
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patterns after infection of fibroblasts and endothelial cells with a low passage strain of HCMV, 
using DNA microarrays.
Gene expression patterns of HCMV-infected cells were analysed at several time points after
infection (0, 6, 12, 24, 48, 72 and 96 hours). Two types of cells were used, MRC-5 fibroblasts
and human umbilical vein endothelial cells (HUVEC). The programme TreeView (Eisen et al,
1998) was used to visualise the expression of the filtered set of 1746 genes (Figure 5.3). This
reveals how expression of the genome varies throughout the time-course of HCMV infection
and how gene expression in infected fibroblasts relates to that in infected endothelial cells. The
analysis resulted in two clusters of gene expression, showing a clear distinction between the
two time-courses (Figure 5.3). In turn, within each time-course, a separation between the early
and late time points is evident. A number of gene expression signatures can be identified in the
data. Clustering of data from the time-courses in fibroblast and endothelial cells indicated that
the levels of certain classes of host genes were notably affected in response to HCMV infection.
mRNAs modulated by the virus include ones involved in the complement cascade, coagulation,
inflammation, apoptosis, cell cycle, interferon response, transcription, cytoskeleton, cell
adhesion, tumorigenesis and mitochondrial function. I identified common pathways of host
gene expression in fibroblasts and endothelial cells. These included a decrease in transcription
and signal transduction, an inhibition of apoptosis and cell cycle progression, an increase in
overall MHC-I transcription and the induction of an interferon-based antiviral response.
Interestingly, differences in gene expression between the two cell types occurred even before
HCMV infection. Increased coagulation, pro-thrombotic activity, prostaglandin synthesis and
induction of mitochondrial-associated genes were only identified in endothelial cells. Other
endothelial-specific responses included strong down-regulation of MHC-II, NF-kB and
complement pathways. Previous studies have shown that infection of fibroblasts with AD 169
suppresses caspases 1,2 and 8 (Browne et al, 2001, Skaletskaya et al, 2001). I found caspases 4
and 7 to be significantly down regulated by Toledo in both fibroblasts and endothelial cells (at
72 and 48h pi respectively), indicating an interference of the virus in the caspase cascade at two
additional positions. This manipulation of various cellular genes by HCMV in order to prevent
apoptosis, could be a way by which the virus persists in the infected host. HCMV can cause cell
cycle arrest, depending on the state of the cell. Quiescent fibroblasts infected in vitro with
AD 169 start synthesising several enzymes required for DNA replication. This activation
however does not seem to lead to cell division, but in Gl/S arrest. This virally-induced block
can take place at multiple points in the cell cycle, depending on the phase of the cell cycle at
which infection (Jault et al, 1995, Biswas et al, 2003). It seems that the virus creates a
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favourable environment for its own replication, at the host’s expense. A number of cyclins are 
regulated by HCMV, including cyclin B, D3, E2 and G1 (Salvant et al, 1998, Browne et al,
2001). I identified a number of genes required for cell cycle progression, that were suppressed 
in fibroblasts and endothelial cells at late time points after infection. A number of genes 
associated with host trascription, translation and signal transduction showed a decrease in their 
expression after infection of fibroblasts and endothelial cells with HCMV. These cluster 
together with genes required for maintenance of cytoskeletal structure and cell cycle 
progression.
A link between HCMV infection and atherosclerosis has been suggested by experimental, 
clinical and epidemiological studies (see section 1.9.5). I observed a reduction of anti­
coagulants transciption in endothelial cells (Figure 5 .7), including members of the plasminogen 
subfamily. The virus was also shown to up-regulate the expression of two genes that contribute 
to the acceleration of coagulation; phospholipid scramblase, which plays a central role in the 
initiation of fibrin clot formation (Basse et al, 1996) and placental bikunin, an inhibitor of 
plasminogen and hepatocyte growth factor proteins (Hamasuna et al, 2001). This combination 
of events in HCMV-infected endothelial cells may contribute to the increased coagulation 
observed in infected individuals and promote the development of atherosclerosis. The 
biological consequences of these findings at a transcriptional level require investigation through 
in vitro and in vivo studies.
In the setting of immunosuppression, cytomegalovirus can affect both the central and peripheral 
nervous systems. Neurological manifestations of HCMV infection include encephalitis, hearing 
loss, mental retardation, ventriculitis, myelitis, retinitis and peripheral neuropathies (Maschke et 
al, 2002). Defects in the pro-a2 chain of collagen type XI (coll la2) are the cause of a skeletal 
dysplasia, which is accompanied by severe hearing loss (Vikkula et al, 1995, McGuirt et al, 
1999, De Leenheer et al, 2001). Furthermore, defects in the cDNA for dihydroxyacetone 
(GNPAT) cause severe growth and mental retardation, retinal pigmentary degeneration, 
sensorineural deafness (Burdette et al, 1996). The levels of these RNAs were reduced 
considerably after infection of endothelial cells with Toledo, which could contribute to the 
development of HCMV-associated diseases (Figure 5.8).
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TLR2 recognizes HCMV virions and triggers inflammatory cytokine production, mediated via 
TLR2-dependent activation of NF-kB (Compton et al, 2003). Interestingly, I observed a 
suppression of TLR2 transcription after infection of endothelial cells but not in fibroblasts. A 
decrease in TLR2 levels in response to HCMV infection could lead to viral persistence in 
endothelial cells, by inhibiting the NF-kB mediated inflammatory response. Consistent with a 
suppression of the activation of the NF-kB pathway in endothelial cells, a down-regulation of 
several other molecules involved in the activation of this pathway was observed. These findings 
suggest that HCMV infection prevents external signalling to the cell in order to optimise the 
cellular environment for virus replication.
I found that the low passage strain of HCMV, Toledo, strongly induced the accumulation of 
IFN-responsive RNAs very early during its replication cycle in endothelial cells (6-12h pi) 
(Table 5.1). Interestingly, the induction was weak and delayed in fibroblasts. A startling feature 
of HCMV infection is how the host can be tricked into committing its immune response to 
aiding virus dissemination. For example, my results indicate that the virus affects IFN 
signalling differentially in fibroblasts and endothelial cells, mounting a vigorous response in the 
latter cell type. One cluster of genes that are strongly induced in endothelial cells after HCMV 
infection is enriched for those with known anti-viral properties or that are induced by interferon 
(Figure 5.10A). The anti-viral cluster contains genes that act within cells to inhibit virus 
replication, such as IRF-1, IFI27 and STATI (Samuel, 2001). Overall, these results indicate 
that the virus affects IFN signalling differentially in fibroblasts and endothelial cells, mounting 
a vigorous response in the latter cell type. This could be a tactic that HCMV employs in order 
to reduce its replication levels, facilitating its long-term association with the host.
This anti-viral cluster also contains four inflammatory genes, two of which mediate 
prostaglandin synthesis (Broberg et al, 2002, Haeggstrom et al, 2002, Sherratt et al, 2003, 
Zaitsu et al, 2003) (Figure 5.10C). It has been shown that the synthesis of prostaglandin E2 is 
activated by the induction of cox-2 in HCMV-infected fibroblasts and that prostaglandin 
inhibitors can reduce HCMV replication levels (Zhu et al, 1998). I observed increased 
accumulation in prostaglandin synthesis in HUVECs compared to fibroblasts, occurring at just 
1 hour after infection (leukotriene A4 hydrolase, microsomal glutathione S-transferase) (Figure 
5.8C). This could have significant clinical applications, since it suggests that inhibitors may 
have differential effects in different cells in the body. Future experiments could comprise 
infectivity assays (plaque assay, IF A, PCR etc), in which fibroblasts and HUVEC would be
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infected with Toledo and subsequently a prostaglandin inhibitor (ie aspirin) would be added at 
increasing concentrations. In this case, the IC50 should be lower in HUVEC.
The analysis also shows that HCMV Toledo induces up-regulation of CD46 and CD55 in both 
fibroblasts and HUVEC, but to higher levels in the latter cell type. Additionally, the 
complement components 1, C2 and 8 were suppressed at 6h after infection (Figure 5.1 IB) only 
in HUVEC. Overall, the inhibition of the complement cascade was more prominent in 
endothelial cells than in fibroblasts. The down-regulation of complement proteins in endothelial 
cells has not been shown previously and represents a unique strategy of HCMV for modulation 
of the complement cascade. The circumvention of complement attack can lead to persistence of 
HCMV-infected endothelial cells in the circulation and subsequent spread of the virus to 
different sites in the body.
There is substantial genetic heterogeneity not only among different laboratory strains, but also 
between laboratory strains and clinical isolates, and genetic differences between human and 
animal strains are profound. Given these genetic differences, one would anticipate differences 
in biological activity between strains. Comparison of virulent and attenuated strains of a virus 
can identify important genes that are important for disease pathogenesis. Results to date argue 
that the alteration in cellular mRNA levels induced by AD 169 and Toledo is identical (Zhu et 
al, 1998). However, only a limited number of genes were assayed in these studies. In chapter 6, 
DNA microarrays were used to identify global changes in host transcription induced by these 
two HCMV strains. The analysis identified genes from a range of host cell pathways that show 
changes in expression levels after viral infection, and showed that the viruses induce some 
common changes in host gene expression over the 4-day time-course (Figure 6.3). The 
induction of an antiviral immune response was observed in fibroblasts, consisting of IFN- 
responsive genes, by both AD 169 and Toledo. Additionally, the analysis revealed a common 
set of mRNAs that were suppressed as a result of infection with either AD 169 or Toledo. These 
consisted mainly of genes involved in cell proliferation, apoptosis and protein synthesis and 
transport.
Interestingly, my analysis revealed that the laboratory and clinical isolates of HCMV alter
cellular gene expression differentially. Since the genetic differences between these isolates are
essentially the presence of the UL/b’ region, these differential effects may give clues to the
function of these gene products. Hierarchical clustering of gene expression data revealed a
cluster of genes that are strongly suppressed after infection of fibroblasts with AD 169 but
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induced after infection with Toledo (Figure 6.5A). Interestingly, 27 of these genes are located 
on chromosome 1. Overall, my findings suggest that the specific chromosomal abnormalities 
induced after HCMV infection could be the result of viral modulation of host genes. Interaction 
of viral proteins with the host machinery involved in the cellular transport system permits an 
active process (Sodeik, 2000). The array analysis also revealed a number of mRNAs that were 
preferentially down-regulated by HCMV Toledo (Figure 6.6), with some of them required for 
intracellular protein transport (KDELR2, clathrin coat assembly gene and ADP ribosylation 
factors 1 and 4). Inhibition of the protein transport machinery by wild type HCMV could be a 
strategy that the virus employs to prevent the onset of antiviral responses. HCMV infection in 
the setting of HIV patients is associated with the development of cardiovascular disease (Li et 
al, 1996). The analysis of gene expression data from HCMV-infected fibroblasts indicated that 
infection with Toledo led to a reduction in the expression of mRNAs that are highly expressed 
in muscle and are involved in muscle contractility. Infection with AD 169 did not have the same 
outcome, suggesting that the UL/b’ genes could be responsible for this outcome. I propose that 
modulation of host genes involved in muscle function by HCMV could lead to the reduced 
contractility of cardiac muscle, potentially contributing to the development of cardiovascular 
disease.
Differential modulation of cell adhesion molecules in fibroblasts was also observed. Analysis 
of gene expression data revealed a suppression of these molecules after infection with Toledo. 
This modulation can have profound effects in the process of embryogenesis. The results suggest 
that low passage but not laboratory-adapted virus, induces a shut down in the transcription of 
such molecules. For example, the expression of metalloprotease was decreased by 12 hours 
after infection. This down-regulation could lead to decreased invasiveness of cells during 
placentation, leading to the development of pregnancy abnormalities that manifest in HCMV- 
infected individuals. Indeed, in support of this data, previous findings have demonstrated that 
HCMV infection of purified cytotrophoblasts from first-trimester placentas led to a down- 
regulation of integrin, and impaired ability of these cells to invade Matrigel in an in vitro 
invasion assay (Fisher et al, 2000). However, on the other hand, this down-regulation could be 
a way of allowing infected cells to stop adherence and therefore traffic around the body to 
initiate new infections.
Since the first isolation of HCMV in 1956, this virus has been routinely passaged in fibroblast
cell cultures. However, several pieces of evidence suggest that the resulting combinations of
viral strains/cell lines are not faithful paradigms of disease pathogenesis in humans. First,
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HCMV is tropic for endothelial cells, monocytes and multiple cells of epithelial cells in origin 
in vivo leading to hepatitis, retinitis, pneumonitis, enteritis and a possible contribution to 
atherosclerosis. Second, these diseases occur with different frequencies in distinct groups of 
infected patients, implying a host contribution to viral pathogenesis. Third, HCMV strains 
passaged in fibroblasts in vitro lack approximately 22 open reading frames, which encode 
putative pathogenicity genes. In this thesis I have explored the use of gene arrays to examine 
expression of these novel viral genes in endothelial cells in parallel with expression in 
fibroblasts by means of amplification of viral DNA to overcome the inherent low multiplicity 
of infection of HCMV in vitro. The results also demonstrate modulation of distinct host genes 
in these two cell types and so identify candidate genes of viral and cellular origin, which may 
interact during natural infection to cause disease in distinct patient populations. Furthermore, 
they illustrate how gene array technology may be applied to bypass cellular restrictions 
imposed by the current inability to propagate authentic target cells in vitro, and so may be 
relevant for studies of other human viral pathogens. Unravelling the complex interplay between 
HCMV, the host cell and the whole organism will ultimately lead to improved understanding of 
viral pathogenesis and open up new avenues for therapeutic control.
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HCMV clone sequences
The identity of each cloned array probe spotted on the HCMV array was confirmed by 
PCR with probe-specific primers (Figure 4.1) and DNA sequencing (see section 
2.3.6). Cloned array probes were also checked for the possibility of cross- 
hybridisation, both against each other and against host genes, by searching GenBank 
using pair-wise sequence analysis (www.ncbi.nlm.nih.gov/BLAST).
>clone UL132
TTCATAGCGGTACTGATCGCQGTAGTTTACTCCTCGTGTTGCAAGCACCCGGGCCGC
nTCGTTTCGCCGACGAAGAGGCCGTCAACCTGTTGGACGACACGGACGACAGTGGCGGCAG
CAGCCCGTTTGGCAGCGGTTCCCGACGAGGTTCTCAGATCCCCGCCGGATTTTGTTCCTCGAG
CCCTTATCAGCGGTTGGAAACTCGGGACTGpGACGAGGAGGAGGAGGCGTCCGCGGCCCGCG
AGCGCATGAAACATGATCCTGAGAACGTCATO
>cloneULJ36
CTCGGGATAATGACAGCCGCAAAATAGATCGTGGAGCATGTCTCGCCAACTGTCCT 
GGTGGT AAT ATCTTAAGT ACGCGATGAGCGCGCCGATGGCC AT AATC AT AAGCGT AAGC AAA 
ACGGCACAGATAACGTGAAACACCGCGGTCATCCAAGTCGGGCGGCGTCGGGGACGCGGTGG 
GTCGGTTTCTCTTACGCCGGCGCCATTCAGCCACCACACCCGTAGCCGACATTCCCAGAACCG 
GTGAATGCGACTCAGGGCCTTTCGACGCCGCCATTTATTTCCAACGTCCAAGTCCCACGTCAT 
TTCTGGCATCTCCACGCCCTTGACTGACAT 
>cloneUL133
GTAACACGCTGAACAGCAGCGGCTGCAGGNNCCCGAGATGCATTTACAGCTGCACT
TACAGCTGCAGCTGCAGTAGCGCACCCATCGGCAGGTGAAGACGTCGATTACGGAGTCCTTG
AAGAATTCCCGGTAACGGATGAGATACGCGCAGAGGAAAATCATGAAAACAGAACAGCCGA
CTACGGCTGCGATGCCGGGTCCCGAAAACGTATTCGATGATCCTACCAAACACCAAATTCCCA
GGGCCGCGCATGTTATCCAGGCCACAATAATCGTGGGAACGCCCCATTGGCATTGCCACGAA
GGATCGTGCACGTCGCAACCCAT
>cloneUL134
ACCAGGGAAGCCAGTCCGGTACCGCCGAGGAGCCCGATGCCGAGCCATATCCACAC
CATGATCTTCTCTCCTGCTTGGAATCTCAAACTCCGTGTTGGGAAGGGCCGGTGTACGGACAT
TTATGCCTTGGATTTCTGGAAACGTCATTniTGGCAAGGAATGTGTTTATTGTCCAAACATTG
AGGAAGGAGATGTGCGCCAAGTCGGAAAATTCCTTATCGCACCGGGGGCGGGTTACGTTCCG
GTCTGATGCTGCTGCTGTTGTTGTAGAGCCGCGGCCACGGCCGCCTGCACGGCAGCTTGTACC
GCCTCGGCCACGCCGGGTGGCATCTGCGGCATGG
>cloneUL,135
rATCGGCAGACCATCCTCTCCTATGTAGAGCGACGTACACCGCGGCACCTGCGGCGT 
CGGCGGGTGGGTGGCCACCCGCATGAGCCCCAGTTCCAGATCCAGCGGCTCGACGACGTCTT 
CTTTCGGATTTCGATAGCAGCACGCGCAGGCACCACGCTTATCAGAAGCAGCACCCGGGAGC 
CGGCCTCGCGACGAAGTCTCGTCGGATCGCTTGCGGCCTCGGCGCTGGGTAAATAAGGAAAT 
GGCCAGGACCAGGGAAGCCAGTCCGGTACCGCCGAGGAGCCCGATGCCGAGCCATATCCACA 
CCAT GAT CTTCTCTCCTGCTTGGAATCTC A 
>cloneUL138
?ATQGGA£GATCTGCCGCTGAATGTGCGGGTGTACCCATNCATCGGCGTGATGCTCGT
GCTGATCGTGGCCATCCTCTGCTATGCTGGCTTACCACTGGCACGACACCTTCAAACTGGTGC
GCATGTTTCTGAGCTACCGCTGGCTGATCCGCTGTTGCGAGCTGTACGGGGAGTACGAGCGCC
GGTTCGCGGACCTGTCGTCTCTGGGCCTCGGCGCCGTACGGCGGGAGTCGGACAGGCGATAC
CXjTTTCTCCGAACGGCCCGACGAGATCTTGGTCCGTTGA
>cloncgB
ajTCGACGGTGGAGATACTGCTGAGGTCAATCNATGCGTTTGAAGAGGTAGTCCACGT
a c t c g t a g g c c g a g t t c c c g g c g a t g a a g a t c t n g g a g g c t g g g a a g c t g a c a t t c c t c a g t
GCGGTGGTTGCCCAACAGGATTTCGTTGTCCTCA
>cloneUL18
GnAGCTGTCGGGTGA'iCAGGGACCTCCCCCGAGGAACTGTCGTCAGGTGAGGTAA
CGCTGATGGGGATTTCCACCGTCCAATTACCGTGTGTAACGCGGCAGGTGTAGTTTTGATTGC
AAAAGATGGCTACGTAACATCCCTGATGGAAAGTCCCATCCAAGGTGGGAAGTAGCGGATTG
CATTGAGGCTCGCTATC
>cloneUL140
CGCTCAGACTAACGCGACTACCACCGTGCACCCGCACGACGCAAAAAACGGCAGCG
GCGGTAGTGCCCTGCCGACCCTCGTCGTTTTCGGCTTCATCGTTACGCTACTTTTCTTTCTCTT
TATGCTCTACTTTTGGAACAACGACGTGTTCCGTAAGCTGCTCCGCTGCGCTTGGATCCAGCG
CTGCTGCGACCGCTTCGACGCGTGGCAAGACGAGGTCATCTACCGTCGTCCATCACGTCGTTC
CCAGAGCG ACGACG AGAGTCGT ACT AAC AGCGTGTC ATCGT ACG
>cloneUL141
OCa t g c g t c t c t g t g a a a a Ag g g a a g a a a a g a a t c a t c a t g t g c c g c c g g g a g t c g
CTCCGAACTCTGCCGTGGCTGTTCTGGGTGCTGTTGAGCTGCCCGCGACTCCTCGAATATTCTT
CCTCTTCGTTCCCCTTCGCCACCGCTGACATTGCCGAAAAGATGTGGGCCGAGAATTATGAGA
CCACGTCGCCGGCGCCGGTGTTGGTCGCCGAGGGAGAGCAAGTTACCATCCCCTGCACGGTC
ATGACACACTCCTA
>cloneULl42
CGGTCATTATCCTATCGTTACCACTTGGAATCTAATTCATCTACCAACGTGGTTTGCA 
ACGGAAAC ATTTCCGTGTTTGT AAACGGC ACCCTAGGTGTGCGGT AT AAC ATT ACGGT AGG A 
ATCAGTTCGTCTTT ATTAATAGGAC ACCTTACTAT AC AAGT ATTGGAATC ATGGTTC AC ACCC 
TGGGTCCAAAATAAAAGTTAC AACAAACAACCCCTAGGTGAC ACTGAAACGCTTT AT AATAT 
AG AT AGCGAAAAC AT AC^TCGCGT ATCTC AAT ATTTTC AC AC AAGAT GG AT AAAAT CTCTGC A 
AGAGAATTCACACTTGCQ 
>cloneUL143
oACGATTCGGATTCAACACATATACTCCCCACGGATCCTCGAACACCTTACAGCATA 
TGAGCAAAAAACAAGAAAGTATAGCCACAATCACATTTGGGCGAATAACATGCTGTCATCCA 
CTAGCGTCT ATT AATCTAATGTTTAACGGGAGCTGTACTGTCACCGTT AAAAT ATCCATGGGA 
ATCAACGGGTCAACCAACGTCCATCAGCTT 
>cloneUL144
ATGAAGCCTCTGATAATGCTC ATCTGCTTTGCTGTGAT ATT ATTGC AGCTTGGAGTG 
ACTAAAGCGTGTCAGCATAATGAAGTGCAACTGGGCAATGAGTGCTGCCCTCCGTGTGGTTC 
GGGACAAAGAGTTACTAAAGTATGCACGGATTATACCAGTGTAACGTGTACCCCTTGCCCCA 
ACGGCACGTATGTATCGGGACTTTACAACTGTACCGATTGCACTCAATGTAACGTCACTCAGG 
TCATGATTCGTAACTGCACTTCCACCAATAATACCGTATGCGCACCTAAGAACCATACQTACT 
TTTCCACTCCAGGCGTCCAACATC 
>cloneUL145
CCATC ATGCGTCGT ATCACGCGAACTATGGAGCNATACGCCGTGTT AATGGCTACAT 
CGCAAAGAAAGTCCCTAGTGTTACATCGATACAGTGCCGTGACAGCCGTGGCCCTGCAGCTC 
ATGCCTGTTGAGATGCTCCGCAAGCTAGATCAGTCGGACTGGGTGCGGGGTGCCTGGATCQT 
GTCAGAGACTTTTCCAACTAGCGACCCCAAAGGAGTTTGGAGCGACGATGACTCCTCGATG 
>cloneULI46
GTCTCGGTCCTGGTG ATNTTCGTT ATGTT AAC ANNTATACC ACCT ATT ATCGTTGTGT 
TTGTCTAACCATTTTGAGAAGAGGTGATCGGGCGATAAACAGTACTCCAGGTCCAGGCGGTTT 
CCTTCCGTCTGGATACAATAAATGTTCATTTTTATCGCATCCGGGCCCTCTGGGATCGCGATG 
AAGCCAATA 
>cloneUL148
A.GATGGCCTTACAGGTGGAGATTCTAAGCCACGCGGCGTACGTCACCGCGCTATTAT
CCACCATCCGAAGCTACAGCCGGGCGTTGGCCTGTGGATAGATTTCTGCGTGTACCGCTACAA
CGCGCGCCTGACCCGCGGCTACGTACGATACACCCTGTCACCGAAAGCGCGCTTGCCCGCAA
AAGCAGAGGGTTGGCTGGTGTCACTAGACAGATTCATCGTGCAGTACCTCAACACATTGC1
>cloneUL150
GCGACATGTTGCTTCGTCTATGCACTGCCGCAGCAGACACCAGCGGACACCGCCATC
TGCCACCACACATGGCCCATGTGCTCCGACGTCCCGCATCCTACGTCGTCTGCTCACAACACG
GCGCTTTCTTCCCCGCACGCCATCTCCATCGAACACCGTCTGCTGCATTCGCCGTCGCCTCCAC
GAGAGAACATACGCCACAGCATGCGCTGTCGCCGCCGCGACATGGCCTCCTCGGCTTCCACA
CCTGTTTCGCACACCCAACCTCTGGCTGCCAACCACAGACGTTCAAGGAA
>cloneUL151
CTATCAGAACCGCCGCTATTCTTTATTAACGTCTTAATCCCCCCCGCTTATACACGCA
ACGCTGCATGCAGCTACGCTCACACTCTATCTCTTCACAGCGACATGTTGCTTCGTCTATGCA
CTGCCGCAGCAGACACCAGCGGACACCGCCATCTGCCACCACACATGGCCCATGTGCTCCGA
CGTCCCGCATCCTACGTCGTCTGCTCACAACACGGCGCTTTCTTCCCCGCACGCCATCTCCATC
GAACACCGTCTGCTGCATTCGCCGTCGCCTCCACGAGAGAACAATACGCCACAGCA
>cloneUL139
CC ACTAC AGGTACC AGCTCT AATTCC AGTC A ATCGT ACT AGTGCT ACCGCC A AC ACG 
ACCGT ATCG AC ATGT ATNT A ATGCCTCT AACGGC AGT AGCTGG AC AGT ACC AC AGCTCGCGCT 
GCTTGCCGCTAGCGGCTGGACATTATCTGGACTCCTTCTCTTATTTACCTGCTGCTTTTGCTGCT 
TTTGGCTAGTACGTAAAATCTGCAGCTGCTGCGGCAACTCCTCCGAGTCAGAGAGCAAAACAA 
CCCACGCGTACACCAATGCCGCATTCACTTCTTCCGACGCAACGTTACCA 
>cloneUL147
. g c a a t c g t c a g g a a g t Gc t g g c t a t g t t t a a
AGGACAAGGGAACCAAGTGTGCTCAATCCTAACGCGCAAGCCGTGCGNNCGTCACATCAACC 
GGCTATTTTTTCGGTT AATCTT AG ACG AGG A AC A ACGC ATTT ACG ACGT AGTGTCT ACC A AT A 
TTG AGTTCGGTGCCTGGCC AGTCCCT ACGGCCT AC AAAGCCTTTCTTTGG A A AT ACGCC A AG A 
GACTGAACTACCACCACTTCAGACTGCQCTC 
5cloneUL130
GTTGCGACCGCTCAGATACCAGATCACCTTTNTTCACCCAGGTGGAGCTTCTCTCCACCAAGG
TCTGGCCTTCCCGGTTGTACAGCAGATACAGGGTCTCGTTGCGACACTCGGGACCCGTTAATA
CCCGCTGG AACCCCG AG AATTGC A AGGGGG ACCGTGGGGGCG AGGG AT AG AT AAA AGG AC A
GT AA A ACGTCGCCGCGTC ATGCGGTTTGG A AT ACGTC AGTTT AG ACC ATAGCGGGG ACGG ATT
CTGGTTCGCCGTTAGCGTTGACCACGGAGACGCCAGACAGGGCGTTGCCCAAACCGCGCACG
GAAGCAGGCAGTGAAAGTGGTGACGAAGCAGAAGCCGCA
>cloneUL137
•CACTGCTGCCAGAATGGATGGATGCGGTGCATGTGGCGGTCCAAGCCGCCGTTCAAGCGACC
GTGC A AGT A AGTGGCCCGCGGG AG A ACGCCGT ATCTCCCGCTACGT AAGAGGGTTG AGGGGG
CCGTTCCCGCGCG AGTGCTGT AC AA A AG AG AG AG ACTGGG ACGT AG ATCCGGTC AG AGG ACG
GTCACCATGGACGATCTGCCGCTGAATGTCGGGTTACCCATCATCGGCGTGATGCTCGTGCTG
ATCGTGGCCAT
>cloneUL149
g t a c g c g t g a g t c t c t g t t c g a t g g t c c a c g a c g t c g c g a t c g g c a g Gc g g c c c g g c t a c g g c
GCTTGG AGCTGT AGCCGCT AG AG ACTTGTCT AGCCGCTGCTGCTCCCGCTGCGTGCCTGCTGCT
GCGTAAAGTACATCAGGGCCACCAGACAGACTCCGATGAAGATGACGATAGCAACACTGATC
CACC
